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ABSTRACT 
The main objective of this thesis has been the design and the evaluation of nanocarriers for the 
delivery of natural and semi-synthetic anticancer compounds.  
The limitations of conventional therapies have resulted in a great interest for the use of nanocarriers 
for anticancer drug delivery. Nanomedicine is an innovative field with immense potential for 
improving the efficacy of cancer therapeutics. Numerous natural products have been studied to 
determine the molecular pathways for cancer prevention and treatment. Though it has been proven 
that many natural products have a strong therapeutic value, their poor solubility and bioavailability 
have severely limited their use. The use of nanocarriers enable us to overcome many of the inherent 
problems (stability, solubility, toxicity) associated with natural products, and also provide a 
platform for targeted delivery to tumor sites. 
The aim of the work has been the development and characterization of three different nanocarriers: 
solid lipid nanoparticles, polymeric nanocapsules and liposomes.  
The feasibility of the inclusion of the water-insoluble drug curcumin in solid lipid nanoparticles for 
oral delivery has been investigated. In fact despite multiple medicinal benefits its therapeutical 
utility is strongly limited by its poor aqueous solubility and low oral bioavailability. 
Polymeric nanocapsules were selected for their positive features for drug delivery in anticancer 
therapy: the oily core of polymeric nanocapsules is an ideal environment to encapsulate most 
antitumor drugs at high payloads, with good encapsulation efficacies and in a stable environment; 
on the other hand, the polymeric shell can be chosen to improve the biodistribution and the 
pharmacokinetic profile of the nanocarrier and to increase the intracellular penetration. Taking this 
information in account, we evaluated the potential of innovative nanocapsules as vehicles for 
docetaxel as model drug. 
Conventional and stealth liposomes were designed for the delivery of dihydroartemisinin, a semi-
synthetic derivative of artemisinin. This compound, well know as a treatment for malaria, also has a 
cytotoxic effect on cancer cells but it is characterized by poor water-solubility and low 
bioavailability. 
Formulations developed were fully characterized in terms of size, zeta potential, encapsulation 
efficiency and morphological analysis. Stability was evaluated during time and different in vitro 
studies were carried out. 
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1.1 Nanocarriers and cancer therapy 
Cancer remains one of the world’s most devastating diseases,  reaching 7.6 million deaths (13% of 
all deaths) in 2008. Moreover, deaths from cancer worldwide are projected to continue rising to 
over 11 million in 2030 (World Health Organization, 2011).  
Cancer is a lethal disorder characterised by the development of abnormalities in cells causing 
uncontrollable and fast growth and division due to a combination of mutagenic stages. As a 
consequence of these mutations, cancer cells obtain a battery of specific properties such as limitless 
proliferation potential, self-sufficiency in growth signals and resistance to growth inhibitory signals, 
as well as evasion from apoptotic cues, which would, in a normal situation, contain their growth 
(Luo, 2009). Besides, tumours have developed diverse methods to attain further support through 
interactions with surrounding stromal cells, promoting their angiogenesis, tissue invasion and 
metastasis to distant organs, along with evasion from immune detection (Hanahan, 2000).  
Current cancer treatments include surgical intervention, radiation and chemotherapeutic drugs, 
which often also kill healthy cells and cause toxicity to the patient. Frequent challenges encountered 
by current cancer therapies include non specific systemic distribution of antitumor agents, 
inadequate drug concentrations reaching the tumor site, intolerable cytotoxicity, limited ability to 
monitor therapeutic responses and development of multiple drug resistance (Das, 2009; Parven, 
2006; Parven, 2008). For this reason, important progress has been achieved in the field of 
nanotechnology to solve these problems and offer a promising and effective alternative for cancer 
treatment.  Recent years have witnessed unprecedented use of nanocarriers (particularly in the size 
range from 10 nm to 100 nm) as an emerging class of therapeutics for cancer treatment. To address 
the challenges of targeting tumours with nanotechnology, it is necessary to combine the rational 
design of nanocarriers (Table 1) with the fundamental understanding of tumour biology.  
 
Rational design of nanocarriers for cancer therapy 
 
Nanocarriers can offer many advantages 
over free drugs. They: 
 
• protect the drug from premature degradation 
• prevent drugs from prematurely interacting 
with the biological environment 
• enhance absorption of the drugs into a 
selected tissue (for example, solid tumour) 
• control the pharmacokinetic and drug tissue 
distribution profile 
• improve intracellular penetration 
 
For rapid and effective clinical translation, the 
nanocarrier should: 
 
• be made from a material that is biocompatible, 
well characterized, and easily functionalized 
• exhibit high differential uptake efficiency in the 
target  cells over normal cells (or tissue) 
• be either soluble or colloidal under aqueous 
conditions for increased effectiveness 
• have an extended circulating half-life, a low 
rate of aggregation, and a long shelf life 
Table 1: Rational design of nanocarriers for cancer therapy (Peer, 2007).
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1.2 Physiopathological characteristics of tumour tissues  
The potential of nanotechnology is to overcome the shortcomings of conventional anticancer 
therapy. To achieve this goal is important to know the specific features of tumour cells. 
1.2.1 Leaky vasculature 
Angiogenesis is a crucial step for cell function and survival, involving the creation of new blood 
vessels, from pre-existing ones, to provide oxygen and essential nutrients to the newly forming 
tissue. In this way, tumours are able to obtain their own blood supply. Tumour cells divide at a 
rapid and uncontrollable rate, notably faster than other cells. This excessive growth soon leads to 
hypoxic conditions, due to restrictions of oxygen and nutrients on the tumour environment. 
Consequently, a sequence of steps for the formation of the capillary tube takes place, in order to 
produce new vessels. This process is mediated by the effect of proangiogenic growth factors 
overexpressed at the tumour site (Kohandel, 2007) i.e., vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), bradykinins, nitric oxide, prostaglandins and so on (Maeda, 
2000). The abnormal proliferation of endothelial cells has some consequences for the newly formed 
microvascular network, giving rise to a defective architecture in these novel vessels, in contrast to 
the neovasculature in normal tissues. Thus, the new tumour blood vessels present a disorganised 
and tortuous structure, with large spaces between the endothelial cells, creating a leaky and porous 
vasculature, resulting in an increased vascular permeability to macromolecules (Jain, 2010). 
1.2.2 Impaired lymphatic drainage 
In addition to the previous alteration, proliferating cancer cells are capable of collapsing 
intratumour lymphatic vessels by compression, limiting functional lymphatic vessels to the outlying 
tumour (Padera, 2002). Furthermore, the active lymphatic vessels manage tumour metastasis 
through the lymphatic system. This impaired lymphatic drainage, together with the chaotic 
leakiness of the newly formed tumour blood vessels, is recognised as a phenomenon denominated 
enhanced permeability and retention (EPR) effect (Maeda, 2001). The EPR effect is one of the most 
important mechanisms whereby nanoparticles and other macromolecules over 50 KDa can be 
accumulated within the tumour interstitium (Cho, 2008). 
 
1.2.3 Acidic tumour microenvironment 
Besides the EPR effect, highly proliferative cancer cells exhibit an increased metabolic rate. To 
support their needs and, as the supply of oxygen and nutrients is never enough, tumour cells must 
obtain additional energy by glycolysis, producing an acidic environment (Pelicano, 2006). 
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1.3 Drug targeting 
Ideally, for anticancer drugs to be effective in cancer treatment, they should first be able to reach 
the desired tumor tissues through the penetration of barriers in the body with minimal loss of 
volume or activity in the blood circulation. Second, after reaching the tumor tissue, drugs should 
have the ability to selectively kill tumor cells without affecting normal cells with a controlled 
release mechanism of the active form. These two basic strategies are also associated with 
improvements in patient survival and quality of life, by simultaneously increasing the intracellular 
concentration of drugs and reducing dose-limiting toxicities. To efficiently achieve these goals, 
three mechanisms of drug targeting to tumours have been described and are detailed below. 
1.3.1 Passive Targeting  
General features of tumours include leaky blood vessels and poor lymphatic drainage such as 
previously explained. Whereas free drugs may diffuse non specifically, a nanocarrier can 
extravasate (escape) into the tumour tissues via the leaky vessels by the EPR effect (Enhanced 
permeability and retention effect) (Matsumura, 1986; Figure 1). The increased permeability and the 
dysfunctional lymphatic drainage in tumours retains the accumulated nanocarriers and allows them 
to release drugs into the vicinity of the tumour cells. Very high local concentrations of drug-loaded 
nanocarriers can be achieved at the tumor site, for instance 10–50-fold higher than in normal tissue 
within 1–2 days (Iyer, 2006). Some properties of nanocarriers are particularly important:  
(i) The ideal nanocarrier size should be somewhere between 10 and 100 nm. Indeed, for efficient 
extravasation from the fenestrations in leaky vasculature, nanocarriers should be much less than 400 
nm. On the other hand, to avoid the filtration by the kidneys, nanocarriers need to be larger than 10 
nm; and to avoid the aspecific capture by the liver, nanocarriers need to be smaller than 100 nm.  
(ii) The charge of the particles should be neutral or anionic for efficient evasion of the renal 
elimination. 
(iii) The nanocarriers must be hidden from the reticulo–endothelial system, which destroys any 
foreign material through opsonization followed by phagocytosis (Malam, 2009; Gullotti, 2009). 
Neverthless, to reach passively the tumor, some limitation exist. Certain tumours do not exhibit the 
EPR effect, and the permeability of vessels may not be the same throughout a single tumour (Jain, 
1994). In addition targeting cells within a tumour is not always feasible because some drugs cannot 
diffuse efficiently and the random nature of the approach makes it difficult to control the process. 
This lack of control may induce multi-drug resistance (MDR) that occurs because transporter 
proteins that expel drugs from cells are overexpressed on the surface of cancer cells (Ferrari, 2005; 
Gottesman, 2002; Peer, 2006). 
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Figure 1: Passive targeting of nanocarriers. (1) Nanocarriers reach tumors selectively through the 
leaky vasculature surrounding the tumors. (2) Schematic representation of the influence of the size 
for retention in the tumor tissue. Drugs alone diffuse freely in and out the tumor blood vessels 
because of their small size and thus their effective concentrations in the tumor decrease rapidly. By 
contrast, drug-loaded nanocarriers cannot diffuse back into the blood stream because of their large 
size, resulting in progressive accumulation: the EPR effect. 
 
1.3.2 Active targeting 
One way to overcome limitations of passive targeting is to programme the nanocarriers so they 
actively bind to specific cells after extravasation (Figure 2). This binding may be achieved by 
attaching targeting agents such as ligands˗molecules, that bind to specific receptors on the cell 
surface, to the surface of the nanocarrier by a variety of conjugation chemistries (Torchilin, 2005). 
Nanocarriers will recognize and bind to target cells through ligand˗receptor interactions, and bound 
carriers are internalized before the drug is released inside the cell. In general, when using a targeting 
agent to deliver nanocarriers to cancer cells, it is imperative that the agent binds with high 
selectivity to molecules that are uniquely expressed on the cell surface. To maximize specificity, a 
surface marker (antigen or receptor) should be overexpressed on target cells relative to normal cells. 
The binding of certain ligands to their receptors may cause receptor˗mediated internalization, which 
is often necessary if nanocarriers are to release drugs inside the cell (Allen, 2002; Peer, 2007). In 
contrast, targeting nanocarriers to non-internalizing receptors may sometimes be advantageous in 
solid tumours owing to the bystander effect, where cells lacking the target receptor can be killed 
through drug release at the surface of the neighbouring cells, where carriers can bind (Allen, 1994). 
Targeting agents can be broadly classified as proteins (mainly antibodies and their fragments), 
nucleic acids (aptamers), or other receptor ligands (peptides, vitamins, and carbohydrates). 
Growth factor or vitamin interactions with cancer cells represent a commonly used targeting 
strategy, as cancer cells often overexpress the receptors for nutrition to maintain their fast-growing 
metabolism. Epidermal growth factor (EGF) has been shown to block and reduce tumour expression 
of the EGF receptor, which is overexpressed in a variety of tumour cells such as breast and tongue
Chapter 1 
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cancer (Sanfilippo, 1996). Additionally, based on the same idea, the vitamin folic acid (folate) has 
also been used for cancer targeting because folate receptors (FRs) are frequently overexpressed in a 
range of tumour cells including ovarian, endometrial and kidney cancer (Antony, 1992). Transferrin 
(Tf) interacts with Tf receptors (TfRs), which are overexpressed on a variety of tumour cells 
(including pancreatic, colon, lung, and bladder cancer) owing to increased metabolic rates (Prost, 
1998). Direct coupling of these targeting agents to nanocarriers containing chemotherapies such as 
drugs has improved intracellular delivery and therapeutic out come in animal tumour models 
(Kukowska-Latallo, 2005; Ishida, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Active targeting strategies. Ligands grafted at the surface of nanocarriers bind to 
receptors (over)expressed by (1) cancer cells or (2) angiogenic endothelial cells. 
 
1.3.3 Triggered drug targeting 
Another promising mechanism of drug targeting to tumours is triggered targeting, where the 
nanoparticles release their payloads by exposing them to an external stimulus, such as an electric or 
magnetic field, ultrasound, hyperthermia or light (Lammers, 2012). The main disadvantage of these 
kinds of nanoformulations is that they are not easy to prepare. Moreover, they can release amounts 
of drug without being triggered or even fail to release their load at the conditions required to induce 
drug release. However, much effort is being made to solve these limiting shortcomings (Tagami, 
2011a; Tagami 2011b). 
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1.4 Investigated nanocarriers for cancer therapy 
The main limitations in cancer therapies are related to their lack of specificity and subsequent 
toxicity. Moreover, in many cancers, there are specific biological barriers, such as the MDR (multi 
drug resistance) mechanisms, which limit the efficacy of the treatments (Gottesman, 2002;  Ehdaie, 
2007). Finally, from the formulation point of view, most of the anticancer drugs suffer from poor 
water solubility and instability. Over recent decades, different nanoparticle delivery systems 
(liposomes, polymeric nanoparticles, polymeric micelles, polymer-drug conjugate nanoparticles or 
lipid-drug conjugate nanoparticles) have been developed. Some of them are already on the market 
and others are still under clinical and preclinical research. Our work was focused on three different 
formulations applicable to cancer therapy: liposomes, solid lipid nanoparticles and nanocapsules. 
1.4.1 Liposomes 
Liposomes are spherical, self-closed structures formed by one or several concentric lipid bilayers 
with an aqueous phase inside and between the lipid bilayers. They have been widely used since 
Bargham discovered them 40 years ago (Bangham, 1964) for their attractive properties:  
• Liposomes are biocompatible. 
• Liposomes can entrap water-soluble (hydrophilic) pharmaceutical agents in their internal water 
compartment and water-insoluble (hydrophobic) pharmaceuticals into the membrane. 
• Liposome-incorporated pharmaceuticals are protected from the inactivating effect of external 
conditions, yet do not cause undesirable side reactions. 
• Liposomes provide a unique opportunity to deliver pharmaceuticals into cells or even inside 
individual cellular compartments. 
• Size, charge and surface properties of liposomes can be easily changed simply by adding new 
ingredients to the lipid mixture before liposome preparation and/or by variation of preparation 
methods. 
Research on liposome technology has progressed from conventional vescicles (“first-generation 
liposomes”) to “second-generation liposomes”, in wich long-circulating liposomes are obtained by 
modulating the lipid composition, size and charge of the vesicle. A significant step in the 
development of long circulating liposomes came with inclusion of the synthetic polymer poly-
ethylene glycol (PEG) in liposome composition (stealth liposomes). The mechanism whereby 
steric stabilization of liposomes increases their longevity in circulation has been extensively 
discussed (Drummond, 1999). The basic concept is that a hydrophilic polymers such as PEG, 
possessing a flexible chain that occupies the space immediately adjacent to the liposome surface 
(“periliposomal layer”), tends to exclude other macromolecules from this space. Consequently, 
access and binding of blood plasma opsonins to the liposome surface are hindered, and thus 
interactions of MPS (mononuclear phagocyte system) macrophages with such liposomes are 
inhibited. The most evidentcharacteristic of PEGylated  liposomes is their circulation longevity 
determined by pharmacokinetic evaluation as reported by Immordino et al. (Immordino, 2003)
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for liposomes containing docetaxel. By reducing MPS uptake long-circulating liposomes can 
passively accumulate inside other tissues or organs. This technology has resulted in a large number 
of liposome formulations encapsulating active molecules, with high target efficiency and activity. 
To increase liposomal drug accumulation in the desired tissues, producing higher and more 
selective therapeutic activity, the use of targeted liposomes has been suggested. This involves the 
coupling of targeting moieties capable of recognizing target cells, binding to them, and inducing the 
internalization of liposomes or encapsulated drugs. Targeting moieties include monoclonal 
antibodies (MAb) or fragments, peptides, growth factors, glycoproteins, carbohydrates, or receptor 
ligands (Lopes De Menezes, 1999; Sapra, 1999; Medina , 2004). Targeted liposomes offer various 
advantages over individual drugs targeted by means of polymers or antibodies. One of the most 
compelling advantages is the dramatic increase in drug amount that can be delivered to the target. 
Furthermore, the number of ligand molecules exposed on the liposome surface can be increased, 
improving ligand avidity and degree of uptake. Immunoliposomes also provide a “bystander 
killing” effect, because the drug molecules can diffuse into adjoining tumor cells (Immordino, 
2006). 
Thus far, just four formulations based on liposomes have been clinically approved: Doxil® 
(Caelyx® in Europe), Myocet®, DaunoXome® and DepoCyt® (Hofheinz, 2005). The first two 
formulations include doxorubicin, which has dangerous side effects related to its cardiotoxicity at 
therapeutic concentrations when administered in a standard formulation, which limits its dosage 
(Singal, 1998). DaunoXome® is a non-PEGylated liposomal daunorubicin. It was demonstrated to 
be a safe and effective in therapy for advanced AIDS-related Kaposi’s sarcoma (Gill, 1996). To 
date, the last liposomal formulation on the market is DepoCyt®, the commercial name of a non-
PEGylated liposomal cytarabine, a hydrophilic chemotherapeutic drug. In addition to the previous 
formulations on the market, a huge variety of antineoplastic liposomes are still under clinical 
research and many of them have been elaborated with PEG. As reported in Table 2 also targeted 
liposomes are under clinical studies. The first formulation (MBP-426) incorporates oxaliplatin in a 
liposome consisting of transferrin conjugated to N-glutarylphosphatidylethanolamine (NGPE). 
MBP-426 is currently in a phase II clinical trial after demonstrating a favourable safety profile, with 
thrombocytopenia as the main side effect, together with improved efficacy (Sankhala, 2009). MCC-
465, an immunoliposome encapsulating doxorubicin, was compared to Doxil® in a phase I trial, 
indicating similar pharmacokinetic results, however the adverse events related to Doxil® were 
reduced. The novelty of this promising formulation is that it is tagged with PEG and a fragment of 
the human monoclonal antibody, able to identify cell surface molecules of different cancer cell lines 
(Matsumura, 2004). A stimuli-responsive promising liposomal formulation is Thermodox™; this 
novel formulation is a thermally sensitive PEGylated liposome entrapping doxorubicin, activated by 
the application of localised hyperthermia. Thus, it releases its payload when reaching temperatures  
between 39 and 42°C. Therefore, this delivery system enables higher concentrations of the 
chemotherapeutic agent at the tumour site. Thermodox™ is currently being tested in a phase II  
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study to evaluate its efficacy in combination with radiofrequency ablation (RFA) in patients with 
hepatocellular carcinoma, compared to those receiving RFA alone (www.clinicaltrials.gov).  
 
Name Formulation Drug Indication Status 
Doxil® 
(Caelyx® ) 
PEGylated liposome Doxorubicin Breast cancer, ovarian 
cancer, multiple 
myeloma, Kaposi’s 
sarcoma 
 
Market 
Myocet® Non-PEGylated liposome Doxorubicin Breast cancer Market 
DaunoXome® Non-PEGylated liposome Daunorubicin Kaposi’s sarcoma Market 
 
DepoCyt® Non-PEGylated liposome Cytarabine Lymphomatus meningitis, 
leukemia, glioblastoma 
 
Market 
Lipoplatin PEGylated liposome Cisplatin Various malignancies Phase III 
 
S-CKD602 PEGylated liposome CKD-602 Various malignancies Phase I/II 
NL CPT-11 PEGylated liposome Irinotecan 
(CPT-11) 
Glioma Phase I 
CPX-1 Liposome Irinotecan Colorectal cancer Phase II 
LE-SN38 Liposome SN-38 Colorectal cancer Phase II 
MBP-426 Tf-NGPE-liposome Oxaliplatin Various malignancies Phase II 
MCC-465 Human antibody fragment 
(GAH)-PEG-liposome 
Doxorubicin Gastric cancer Phase I 
Thermodox™ Heat-activated PEGylated 
liposome 
Doxorubicin Liver cancer, breast cancer Phase III 
 
CPX-351 Liposome Cytarabine+ 
daunorubicin 
Acute myeloid leukaemia Phase II 
SGT-53 Transferrin-targeted DNA 
plasmid liposome 
P53 gene Various solid malignancies Phase I 
Table 2: Liposomes on the market and in clinical development (Egusquiaguirre, 2012). 
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1.4.2 Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) were  introduced in 1991 and represent an alternative carrier system 
to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro- and nano- 
particles (Muller, 1995). SLN have been designed to overcome the main problems of membrane 
stability and drug leakage associated with liposomes and conventional emulsions (Ruckmani, 
2006). SLN are characterized as being colloidal particles made of lipid that remain in solid state at 
room and body temperature, wich are generally recognized as safe (GRAS) or have a regulatory 
accepted status. They present sizes from 50 to 500 nm, depending on the method and materials 
employed for the manufacturing process (Figure 3). 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic representation of solid lipid nanoparticles. 
 
General ingredients include solid lipid(s), emulsifier(s) and water. The term lipid is used here in a 
broader sense and includes triglycerides (e.g. tristearin), partial glycerides (e.g. Imwitor), fatty acids 
(e.g. stearic acid), steroids (e.g. cholesterol) and waxes (e.g. cetyl palmitate). All classes of 
emulsifiers (with respect to charge and molecular weight) have been used to stabilize the lipid 
dispersion. The lipid matrix is made from physiological lipids which decreases the danger of acute 
and chronic toxicity. The choice of the emulsifier depends on the administration route and is more 
limited for parenteral administrations.  
Clear advantages of SLN include the possibility of controlled drug release and drug targeting, 
increased drug stability, absence of biotoxicity of the carrier, avoidance of organic solvents, no 
problems with respect to large scale production and sterilization (Mehenert, 2012).  
There are two main production techniques for SLN: the high pressure homogenization (HPH) 
(Muller, 1995) and the microemulsion technique (Gasco, 1993). Alternatively, several other 
processes have been used for the production of these systems, in order to attempt cheaper and easier 
ways of production, e.g., ultrasound technique (US), solvent-based techniques or cold 
homogenization (Sarmento, 2007; Kristl, 2003; Gokce, 2008; Wang, 2005; Zhang, 2006). 
Since early 1990's, a number of SLN-based systems for the delivery of cytotoxic drugs have been 
successfully formulated and tested. Compared to many other drug delivery systems, the history of 
SLN is relatively short: there is still a lack of clinical studies of the use of SLN for cancer 
management and to date there is no SLN product for cancer therapy on the market. Nevertheless, 
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the findings in the preclinical studies using cell culture systems or animal models have so far been 
very promising. Table 3 provides a list of drugs formulated in these systems.  
 
Group Examples 
Alkaloids Mitotic inhibitor: Vinorelbine 
Topoisomerase I inhibitor: Camptothecin 
Alkylating agents Nitrogen mustard: Chlorambucil 
Alkyl Lysophospholipids Edelfosine 
Anthracyclines Doxorubicin, Idarubicin 
Antimetabolites Folic acid analog: Methotrexate 
Pyrimidine analog: 5-Fluorouracil 
Hormonal agents Estrogen receptor antagonist: Tamoxifen 
Podophyllotoxin derivatives Etoposide 
Taxanes Paclitaxel, Docetaxel 
Others All trans retinoic acid 
Beta-elemene 
Cholesteryl butirate 
Cisplatin 
Topoisomerase II inhibitor: Mitoxantrone 
Table 3: Classification of antineoplastic agents vectorized in SLN (Hestella-Ermoso, 2009). 
 
In vivo studies with Ehrlich ascite carcinoma (EAC) were carried out by Ruckmany et al. They 
administered methotrexate-loaded SLN made of stearic acid intraperitoneally for 9 days. After 9 
days, mean survival time for the mice treated with SLN was nearly 30% higher than that of the mice 
treatedwith methotrexate solution (Ruckmany, 2006). In another study, mitoxantrone-loaded SLN 
also showed efficacy lymph node metastases. The treatment with SLN gave a mean size of lymph 
node three times smaller than that of the mitoxantrone solution (Lu, 2006). In addition many in vitro 
studies performed with doxorubicin loaded SLN have clearly show the efficacy of the system. In all 
tested tumor cell lines, doxorubicin-loaded SLN inhibited cell growth more strongly than the free 
solution. Cytotoxicity of paclitaxel-loaded SLN has also been widely assayed (Serpe, 2004; Yuan, 
2008; Chen, 2001). Different authors have discovered that the cellular uptakes of different types of 
SLN are time-dependent, concentration-dependent and that the intracellular accumulation of drugs 
may be further optimized though receptor-mediates endocytosis of the drug-loaded SLN.  
 
1.4.3 Nanocapsules  
Nanocapsules, first developed by Couvreur et al. (Couvreur, 1977), offer unique opportunities with 
the pourpose of improving the biological profile of drugs in terms of transport across biological 
barriers, biodistribution and cellular uptake. They have a vesicular organization whose internal 
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reservoir can be composed of aqueous or oily components, and they are surrounded by a polymeric 
coating (Legrand, 1999; Couvreur, 2002). This reservoir system offers the possibility of great 
loadings of either lipophilic or hydrophilic drugs, depending on the nature of the liquid core (Figure 
4). Additionally, the core has the role of protecting the drug from the physiological environment. 
Finally, the liquid nature of nanocapsules and, thus, their elasticity, may facilitate the contact of the 
nanostructures with the ephithelia and further internalization. 
 
Figure 4: Schematic diagram of nanocapsules containing an aqueous or oily core. 
 
Moreover, nanocapsules have shown to be capable of inhibiting multidrug resistance cellular 
mechanisms, especially important in cancer therapy. Several methods have been developed to date 
for the production of nanocapsules and the encapsulation of drugs. These methods are based on 
different physicochemical principles including (i) interfacial polymerization (Couvreur, 1977), (ii) 
interfacial deposition or solvent displacement (Fessi, 1989), (iii) phase inversion temperature 
(Heurtault, 2002) and (iv) polymer adsorption onto a preformed emulsion (Prego, 2006; Lozano, 
2008).  
The choice of the most appropriate materials and methods for the preparation of the nanocapsules is 
critical. The size and large surface-to-volume ratios of the nanocapsules facilitate their 
accumulation in the tumor by the well-known enhanced permeability and retention effect (EPR) 
(Iyer, 2006; Greish 2007) and their capacity to be internalized by the tumor cells. Moreover, it has 
been shown that lipid nanocapsules behave as a MDR-inhibiting system (Brigger, 2002; Garcion, 
2006).  
There are a number of reports showing the advantages of nanocapsules for specific anticancer 
drugs. For example, Lenaerts et al. (Lenaerts, 1995) encapsulated phtalocyanines, important agents 
in photodynamic tumor therapy, in poloxamer surface modified-PACA nanocapsules. They found 
that the presence of some types of poloxamer significantly decreased the uptake of nanocapsules by 
organs rich in phagocytic cells and increased the accumulation of phtalocyanines in primary tumors 
The concentration of photosensitizers in the tumor was maximal 12 h post-administration, these 
carriers allowing a 200-fold higher accumulation in the tumor.  
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In different reports it has been shown that lipid nanocapsules are adequate vehicles for the delivery 
of taxanes. More specifically, the encapsulation of paclitaxel into lipid nanocapsules led to a 
significant concentration increase in the tumoral tissue, and significantly reduced the tumor mass 
compared to the commercial product (Taxol ®) (Garcion, 2006). Additionally, in vivo studies in rats 
have shown that lipid nanocapsules enhanced around 3-fold the oral bioavailability of the anticancer 
drug, in comparison with the commercial product (Peltier, 2006; Lacoeuille, 2007). Docetaxel is 
another taxane that has been encapsulated into lipid nanocapsules; these nanocapsules showed an 
enhanced drug deposition in mice tumors which was characterized by a 5-fold increase in the area 
under the curve of the tumor (AUCtumor) when compared to the control formulation (Taxotere®) 
(Khalid, 2006). 
An alternative carrier for the intracellular delivery of docetaxel consisting of oligomer chitosan 
nanocapsules (Lozano, 2008) has been proposed. The results have shown that chitosan 
nanocapsules are able to facilitate the rapid internalization of the drug into the cancer cells, leading 
to a significant increase of the antiproliferative effect of the drug.  
Overall, the results presented here indicate that nanocapsules represent an alternative for the 
intracellular delivery of hydrophobic anticancer drugs. This potential is related to their capacity to 
be internalized by the cells and inhibit the MDR mechanisms, thus maximizing the antitumoral drug 
effects.  
A new generation of nanocapsules, named lipid nanocapsules, were first prepared by the group of 
Benoit (Heurtault, 2002). These systems consist of an oil core surrounded by a thick polymeric 
shell, made of PEG-hydroxystearate and phosphatidylcholine. These nanocapsules can be prepared 
via a solvent-free, phase inversion process. In this process, all the components of the system are 
mixed together with the aqueous phase and, then, exposed to several cycles of heating and cooling 
(usually between temperatures around 65 and 85ºC). The size and polydispersity of the 
nanocapsules decrease as a function of the number and temperature cycles and a thick interfacial 
layer is created with this cycling process, since the surfactant is forced to overconcentrate at the 
interface of the oily droplets (Anton, 2007). Finally, the process is quenched at a temperature below 
the phase inversion temperature (o/w emulsion), followed by addition of cold water. This fast 
cooling-dilution process led to the formation of lipid nanocapsules with particle sizes between 20 
and 100 nm (Heurtault, 2003).  
1.4.3.1 Polyaminoacids as coating materials for nanocarriers 
Polyaminoacids are biodegradable materials composed of long chains of amino acids. They can be 
obtained by natural or synthetic route and have raised great expectancy in the development of 
nanocarriers for anticancer drugs. Polyaminoacids have been  found to render nanocarriers surface 
more hydrophilic and flexible to prevent the uptake by the mononuclear phagocytic system (MPS) 
(Danhier, 2010; Huynh, 2010; Yoshizawa, 2011). An interesting property of polyaminoacids relies
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on the possibility to conjugate them with poly(ethylene glycol) (PEG). Among them, the anionic 
polymer poly-L-glutamic acid (PGA) is a promising candidate because of its properties. 
Polyglutamic acid (PGA) is a highly anionic polyaminoacid composed of naturally occurring L-
glutamic acid linked by peptide bonds. Two different isoforms of this polyaminoacid exist: α and γ 
isoforms. Isoform γ is obtained by bacterial fermentation and it is made up of L-glutamic acid 
monomers linked via amino bonds between γ-carboxyl and α-amino groups of adjacent monomer. 
This isoform is rarely used in pharmaceutical technology due to their limited availability. Isoform α, 
structurally different and obtained by synthesis, consists of L-glutamic acid units linked through 
amide bonds (Figure 5).  free carboxyl groups are negatively charged favoring its solubility in 
water. Furthermore,  carboxyl groups can be used to bind other polymers, such as PEG, in order to 
obtain diblock or grafted structures. PGA is highly biocompatible and readily biodegradable by 
digestion with lysosomal enzymes. It is a suitable material for drug delivery designed not only 
owing to its safety profile but also because it renders the surface of the nanocarriers more 
hydrophilic avoiding the uptake by the mononuclear phagocytic system. This enhanced circulation 
times are important to achieve enhanced accumulation of the anticancer drug at the tumor site by 
the EPR effect, as it has been observed for PGA-paclitaxel® conjugates.  
 
 
 
 
 
 
 
 
 
 
Figure 5: Chemical structure of isoform α of poly-L-glutamic acid. 
PGA has been already included in carrier system relevant to cancer therapy. Xyotax® (PGA-
conjugated paclitaxel) has become the first polymer-drug conjugated for the delivery of cytotoxic 
chemotherapeutic agent to advance to clinical Phase III trials (Jack, 2005). 
Also in 2008 Phase I and II studies of PGA derivate, polyglutammate-camptothecine conjugated 
(CT 2106) were successfully carried out (Homsi, 2007).
 
 
1.5 Selected model drugs 
The role of natural products as a source for remedies has been recognized since ancient times 
(Farnsworth, 1985; Cragg, 1997). An analysis of the number of chemotherapeutic agents and their 
sources indicates that over 60% of approved drugs are derived from natural compounds (Cragg, 
1997). Numerous natural products have been studied to determine the molecular pathways for 
cancer prevention and treatment (Bachrach, 2002; Narayan, 2004; Jagtap, 2009; Lee, 2011).  
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The development of novel agents from natural sources presents obstacles that are not usually met 
when one deals with synthetic compounds. For instance, there may be difficulties in accessing the 
source of the samples, obtaining appropriate amounts of the sample, in the identification and 
isolation of the active compound in the sample, and problems in synthesizing the necessary amounts 
of the compound of interest. In addition their poor solubility and bioavailability have severely 
limited their use. Our work was focused on formulation of different natural (curcumin and 
artemisinin) and semisynthetic (docetaxel and dihydroartemisinin) compounds for cancer therapy, 
to overcome the shortcomings described. 
 
1.5.1 Docetaxel 
 
 
 
 
 
 
 
Figure 6: Chemical structure of docetaxel. 
 
Docetaxel (Figure 6) is one of the most important cytotoxic chemotherapeutic agents used today in 
the treatment of breast, lung, ovarian, gastric, and prostate cancer. Phase III clinical trials in other 
solid tumours, such as squamous-cell head and neck cancers and transitional-cell carcinoma of the 
urothelium, are further defining the role of docetaxel in these cancers (Montero, 2005).  
Docetaxel is a semisynthetic taxane, a class of anticancer agents that bind to β tubulin, thereby 
stabilizing microtubules and inducing cell-cycle arrest and apoptosis. Taxanes (paclitaxel and 
docetaxel) have a different mechanism of action from that of any other class of anticancer. 
Paclitaxel was originally isolated from the bark of the yew tree Taxus brevifolia (Wani, 1971), a 
finite source of the compound. It took some years to develop a semi-synthetic analog (docetaxel) 
which is derived from a renewable source, the leaves of Taxus baccata (Cortes, 1995). Currently, 
total synthesis has been achieved for both agents and drug supply is no longer a problem. 
Although these novel chemotherapeutics have led to improvements in survival, they are associated 
with numerous drug-related toxicities. Docetaxel has been associated with a significant increase in 
neutropenia, febrile neutropenia, leucopenia, stomatitis, edema, fatigue and/or asthenia, and 
diarrhea (Montero, 2005). These effects are due in part to the high doses used to achieve the desired 
anti-tumor effect, which are necessary because of the non-specific distribution of both novel and 
traditional chemotherapies, with only a small fraction of drugs reaching the tumor. The drugs can 
accumulate in healthy organs, and there is a fine line between tolerability and severe morbidity, e.g., 
in the case of doxorubicin, a DNA intercalator that produces cardiotoxicity (Olson, 1990).
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These drugs are characterized by their hydrophobic character and a resulting necessity to use 
solubilizer for their intravenous administration. So far, Cremophor EL and Tween80®, both of wich 
combined with ethanol, have been the only pharmaceutical formulation vehicles used for 
administration of paclitaxel and docetaxel, respectively. These veicles, however are responsible for 
severe side effects wich limit the amount of drug that can be safely administered (Van Zuylen, 
2001; Engels, 2006).  
The commercial formulation of docetaxel, Taxotere®, is formulated with a high concentration of 
Tween 80® (40 g/L), which has been found to have severe side effects, including hypersensitivity 
reactions, cumulative fluid retention, and nausea and which has shown incompatibility with 
commonly used polyvinyl chloride intravenous administration sets (Ma, 2011). Taken together, 
these factors compromise the curative potential of anticancer drugs, and more effective methods for 
their delivery to tumors are required (Blanko, 2011). To overcome these problems, alternative 
nanotechnology-based formulation, which do not require solubilization, have recently been 
proposed. These formulation consist of nanostructures, such as polymer conjugates, polymeric 
micelles, liposomes or nanoparticles (Heath, 2008; Peer, 2007). 
 
1.5.2 Curcumin 
 
 
 
 
Figure 7: Chemical structure of curcumin. 
The polyphenol curcumin (Figure 7) is the active ingredient in the herbal remedy and dietary spice 
turmeric Curcuma longa Linn. This yellow spice, derived from the rhizome of the plant, has a long 
history of use in traditional medicines of China and India (Ammon, 1991). Research has revealed 
that curcumin has a surprisingly wide range of beneficial properties, including anti-inflammatory, 
antioxidant, chemopreventive and chemotherapeutic activity. These activities have been 
demonstrated both in cultured cells and in animal models, and have paved the way for ongoing 
human clinical trials (Hatcher, 2008). The pleiotropic activities of curcumin derive from its 
complex chemistry as well as its ability to influence multiple signaling pathways. Curcumin inhibits 
cancer development and progression, targeting multiple steps in the pathway to malignancy (Figure 
8). Curcumin has activity as both a blocking agent, inhibiting the initiation step of cancer pressing  
agent, inhibiting malignant cell proliferation during promotion and progression of carcinogenesis 
(Duvoix, 2005).  
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Figure 8: Stages in tumor progression inhibited by curcumin (Arbiser, 1998). 
 
Curcumin has been shown to interfere with many of the processes involved in angiogenesis 
(Arbiser, 1998). Early studies demonstrated that curcumin inhibits fibroblast growth factor (FGF)-
induced neovascularization (Gururaj, 2002). Additional effects of curcumin on angiogenesis and 
metastasis may be mediated by its ability to regulate cell adhesion molecules such as intracellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial 
leukocyte adhesion molecule-1 (ELAM-1), cell surface proteins involved in tumor metastasis 
(Bhandarkar, 2007). Curcumin is a potent inhibitor of ligand-induced activation of epidermal 
growth factor receptor (EGFR), suggesting the potential to block the cascade of intracellular signals 
associated with mutagenesis and cell proliferation (Korutla, 1995). Among signaling pathways 
affected by curcumin are key survival pathways regulated by NF-kB and Akt, as well as 
cytoprotective pathways dependent on Nrf2.  
Owing to its valuable properties, almost 100 pharmaceutical and chemical companies are producing 
various curcumin products in the form of tablets, capsules, coloring agents, creams, drinks, extracts, 
gels, nasal sprays, and so on for daily and medical needs (Goel, 2008). Various clinical trials are 
underway or have been completed to judge the efficacy of curcumin as a therapeutic molecule in 
medicine (www.clinicaltrials.gov/curcumin).  
A major limiting factor of curcumin is its low solubility in water (i.e. 0.4x10
-3
 mg/ml at pH 7.3). 
Many preclinical and clinical studies in mice, rats and humans revealed a low bioavailability of 
curcumin (Goel, 2008; Aggarwal, 2007). Although 10 or 12 g/ml of curcumin administered orally 
in humans showed curcumin levels in serum to be approximately 50 ng/ml, this resulted in a 
minimum availability of curcumin in the blood circulation to achieve its therapeutic effects (Lao, 
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2007). A simple way of solving the limiting factors of curcumin is to improve its bioavailability, 
protect it from degradation and metabolism, and increase its targeting capacity toward cancer 
tumor(s).  
Various types of nanocarriers are suitable and have been investigated for the delivery of an active 
form of curcumin to tumors (Muqbil, 2011). Stable self-emulsifying liquid formulations of 
curcumin with particles size of approximately 30 nm and approximately 99% curcumin loading 
have successfully been developed (Setthacheewakul, 2010). These formulations have a 10–14-fold 
greater absorption rate in male Wistar-strain rats given an oral treatment of 50 mg/kg of curcumin, 
compared with the same oral dose of free curcumin. 
D-a tocopheryl polyethylene glycol 1000 succinate (TPGS) stabilized curcumin nanosuspension 
(CUR-NS) crystal formulation has been evaluated for the pharmacokinetics and biodistribution of 
curcumin after intravenous administration in rabbits and mice (Gao, 2010). The area under the 
plasma concentration (AUC; 0–1) of CUR-NS (700.43±281.53 mg/ml min) was 3.8-fold greater 
than for a curcumin solution (145.4±9.29 mg/ml min). The mean residence time was 11.2-fold 
longer with CUR-NS compared with a curcumin solution (194.57±32.18 min versus 15.88±3.56 
min). 
Co-administration of curcumin and paclitaxel nanoemulsion formulations are capable of 
overcoming MDR in SKOV-3 (TR) human ovarian adenocarcinoma cells by inhibiting NF-kB 
activity, downregulating P-gp and promoting apoptotic responses (Ganta, 2009). Additionally, 
curcumin nanoemulsion increases the bioavailability of paclitaxel up to 5.2-fold, and there is a 3.2-
fold increase in its accumulation at the tumor site in an oral administration to SKOV-3 tumor-
bearing xenograft mice models. This resulted from downregulation of intestinal P-gp and 
cytochrome P450 3A2 (CYP3A2) protein levels (Ganta, 2010).  
A combined glycerol monooleate and pluronic F-127 polymer nanocarrier is also well suited to the 
delivery of curcumin to various types of cancer cell (i.e. PANC-1, MiaPaCa-2, K-562, MCF-7, 
A549 and HCT-16) (Mohanty, 2010). This formulation has shown significant anticancer properties 
at all concentrations (5–30 mM) compared with free curcumin. These improved effects are 
correlated with the inhibition of phosphorylation and activation of the Akt pathway, which 
inactivates NF-kB and inhibits the proliferation and induction of apoptosis. 
Safe toxicological profiles of the various curcumin nanoformulations and their efficacy in the cell-
line models highlight their potential for evaluation in in vivo models. Human trials need to be 
conducted to establish their effectiveness in clinical applications as an improved therapeutic 
modality for cancer treatment. 
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1.5.3 Artemisinin and Dihydroartemisinin  
 
 
 
 
 
 
 
 
 
 
Figure 9:Chemical structure of artemisinin (A) and dihydroartemisinin (B). 
 
Artemisinin (Figure 9) a sesquiterpene lactone derived from the sweet wormwood plant Artemisia 
annua is widely used as an antimalarial drug (Hsu, 2006; Miller, 2011; Tu, 2011). Recently, more 
and more evidences have emerged to elucidate that artemisinin and its derivatives show potent 
anticancer activities in a variety of human cancer cells (Hou, 2008; Chen, 2009; Morrisey, 2010; 
O’Neill, 2010). Molecular, cellular and physiological studies have demonstrated that, depending on 
the tissue type and experimental system, artemisinin and its derivatives arrest the growth, induce an 
apoptotic response, alter hormone responsive properties and/or inhibit angiogenesis of human 
cancer cells. One proposed mechanism by which artemisinin targets cancer cells is cleavage of the 
endoperoxide bridge by the relatively high concentrations of iron in cancer cells, resulting in free 
radicals such as ROS and subsequent oxidative damage as well as iron depletion in the cells. This 
mechanism resembles the action of artemisinin in malarial parasites (Bustos, 1994).  In addition to 
possessing higher iron influx via transferrin receptors, cancer cells are also sensitive to oxygen 
radicals because of a relative deficiency in antioxidant. In details it has been postulated that 
bioactivation of artemisinin occurs in the endosome after pH-induced release of iron from 
internalized transferrin. Iron activated-artemisinin generates carbon-centered radicals which may 
mediate lysosomal disruption and generation of ROS resulting in mitochondrial damage, activation 
of caspases, and cell death. Alternatively, it has been suggested that only specific activation of 
artemisinin by heme or heme-bound protein generates cytotoxic carbon-centered radicals. In the 
mitochondrion, these adducts interfere with the electron transfer chain (ETC) by interacting with 
heme or heme-bound proteins leading to generation of ROS and apoptosis. ROS harboring may 
induce ER stress and genotoxicity (Crespo-Ortiz, 2012) (Figure 10). 
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Figure 13: Postulated anticancer mechanisms of action of artemisinins (Crespo-Ortiz, 2012) 
 
Despite its efficacy artemisinin has pharmacokinetic limitations. Artemisinin has low solubility in 
water or oil, making it difficult to administrate through intravenous injection, it has poor 
bioavailability, and a short half-life in vivo (~2.5 h) (Ashton, 1998; Li, 2007). To overcome some of 
these problems, generations of artemisinin-like endoperoxides including semisynthetic derivatives 
and fully synthetic compounds have been developed. Semisynthetic artemisinins are obtained from 
dihydroartemisinin (DHA), the main active metabolite of artemisinin (Haynes, 2002; Klayman, 
1985).   
Dihydroartemisinin (Figure 9) is an artemisinin derivative with the C-10 lactone group replaced by 
hemiacetal.  DHA has been widely used as an antimalarial drug due to its efficacy and easy 
production with less synthetic steps and a lower cost (Wilairatana, 1998). In recent years, DHA has 
also been shown to be effective in killing cancer cells (Lai, 1995; Efferth, 2001; Efferth, 2004; Sing, 
2001; Golenser, 2006; Nakase, 2008). One study that tested 55 cell lines from the Developmental 
Therapeutics Program of the National Cancer Institute (NCI) showed that dihydroartemisinin has 
remarkable antineoplastic activity against pancreatic, leukemic, osteosarcoma, and lung cancer cells 
(Lu, 2009). Studies have shown that DHA inhibits cell proliferation, and/or induces apoptosis in 
various human cancer cell lines via downregulating cyclin (D1,E), Bcl-2, Bcl-xL, caspase (3,9), and 
VEGF, while upregulating P21, P27, and Bax (Chen 2003; Mu, 2008; Fujita, 2008; Hou, 2008). 
Recent studies also indicate that DHA inhibits cell growth, induces cell cycle arrest, and promotes 
apoptosis in pancreatic cancer cells both in vitro and in vivo (Chen, 2009).
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However, DHA has poor water-solubility and low bioavailability for oral administration due to slow 
drug dissolution and decomposition in the stomach and intestine (Gabriels, 2004). Furthermore, the 
half-life of DHA is very short (34–90 min) (Batty, 1996). It has been demonstrated that intravenous 
delivery of DHA results in the highest availability to body as compared to all other routes (Li, 
1998). Therefore, the development of the new formulation of DHA that enables quickavailability to 
the body is in great need. 
A novel N/O/W submicron emulsion with high drug loading capacity was prepared for intravenous 
administration of DHA. The pharmacokinetics of N/O/W emulsion is characterized by the 
significantly prolonged half-life and slow plasma clearance compared with conventional O/W 
emulsion and DHA solution. Presumably due to the improved PK profiles, the toxic effect of DHA 
was greatly reduced. Furthermore, the antitumor efficacy was demonstrated in vivo studies using a 
hepatic H22 tumor transplanted mouse model. (Wang, 2012).  
A solvent diffusion method in an aqueous system was employed to prepare DHA-NLC; the 
formulation was optimized using response surface methodology central and the drug release in vitro 
exhibited a sustained release over 48 h (Zhang, 2010a). 
The pharmacokinetics and tissue distribution after intravenous administration of DHA in 
nanostructured lipid carrier (NLC) and in solution were then compared. The mean residence times 
(MRT) of the DHA-NLC was much longer than that of the DHA solution. In the tested organs, the 
AUC values of the DHA-NLC were higher than that of the DHA solution in liver, spleen, lung, 
brain and muscle, and lower than the DHA solution in heart and kidney. DHA-NLC prepared in this 
study is a promising sustained-release and drug-targeting system for antitumor drugs. It may also 
allow a reduction in dosage and a decrease in systemic toxicity (Zhang, 2010b).
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2.1 INTRODUCTION 
Curcumin is a yellow-colored phenolic natural constituent derived from the rhizome of the spice 
herb Curcuma longa widely known as turmeric. It has a broad spectrum of biological and 
pharmacological activity. Clinical trials have shown that curcumin has antioxidant (Sharma, 1976; 
Selvam, 1995; Ruby, 1995) anti-inflammatory (Menon, 2007; Rao, 1982), antibacterial (Negri, 
1997), antifungal (Sharma, 2010) and anticarcinogenic activity (Devasena, 2003; Park, 2010). In 
particular it has been received considerable attention because of its putative cancer prevention and 
anti-cancer activities which are mediated through influencing multiple signaling pathways. 
Curcumin helps modulate 33 different proteins, including thioredoxin reductase, cyclooxygenase-2 
(COX-2), protein kinase C (PKC), 5-lipoxygenase, and tubulin. Other molecular targets modulated 
by this agent include transcription factors, growth factors and their receptors, cytokines, enzymes, 
and genes regulating cell proliferation and apoptosis (Aggarwal, 2003; 2007; 2009). The most 
compelling and key rationale for the therapeutic use of curcumin is its good safety profile. To date, 
no studies in either animals or humans have demonstrated any toxicity associated with the use of 
curcumin, even at high doses (Shankar 1980; Lao; 2006). Despite multiple medicinal benefits its 
therapeutical utility is strongly limited by its poor aqueous solubility and low oral bioavailability. 
The latter is attributed to poor absorption, extensive intestinal and hepatic metabolism, rapid 
elimination and clearance from the body (Pan, 1999; Anand, 2007). Formulating curcumin for 
clinical efficacy has presented many challenges due to its poor physicochemical properties. Inspite 
of the numerous formulation challenges, several strategies such as nanoparticles, liposomes, 
complexation with phospholipids and cyclodextrins and solid dispersions have been developed to 
improve the bioavailability of curcumin (Bisht, 2007; Maiti, 2007; Tiyaboonchai, 2007).  
Our work was focused on the development and characterization of SLN for the encapsulation of 
curcumin for oral administration used as antitumoral treatment. Oral curcumin administration has 
been found to inhibit the development of chemically-induced cancer in animal models of oral 
(Krishnaswamy, 1998; Li, 2002), stomach (Ikezaki, 2001; Huang, 1994), liver (Chuang, 2000), and 
colon (Pereira, 1996; Rao, 1995; Kawamori, 1995) cancer. Phase II clinical trials of curcumin in 
patients with colorectal cancer are currently under way. A phase II clinical trial in patients with 
advanced pancreatic cancer found that curcumin exhibited some anticancer activity in two out of 21 
patients; however, bioavailability of curcumin was extremely poor (Dhillon, 2008). Oral route is the 
most common and preferred for drug administration. This choice is mainly related with its non-
invasiveness and ease of administration, which increases patient’s compliance and therapeutic 
success. However, the hydrophilic environment of the gastrointestinal tract (GIT) can limit the 
bioavailability of lipophilic and/or other poorly water-soluble compounds. The trend in drug 
discovery toward lipophilic molecules has increased the need to develop alternative oral delivery 
systems for poorly soluble compounds. Lipid-based drug delivery systems are promising, since 
lipids are known oral drug absorption enhancers (Porter, 2008; Chakraborty, 2009) and can be 
prepared with low particle size (Jia, 2005; Pouton, 2006). Solid lipid nanoparticles (SLN) combine 
these two features: they are colloidal carriers of submicron sizes, composed of lipids that are solid 
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at body and room temperature. These carriers can be made of physiologic or inert substances 
generally recognized as safe (GRAS), which means that they have low or total absence of toxicity 
in humans (Müller, 1995). Moreover, they retain the advantages of traditional colloidal systems, 
while circumventing some of their disadvantages (Müller, 2000): this includes enhanced physical 
stability; protection of drug molecules from degradation in the body; controlled drug release; organ 
or tissue specific targeting; biocompatibility; laboratory to industrial-scalability. Due to the 
characteristic configuration of SLNs, that consists of a biocompatible lipid core and an amphiphilic 
surfactant as an outer shell, the amount of drug in the outer shell and on the particle surface is 
released in the form of a burst and thus rapid onset of action is firstly observed. On the other hand, 
the drug incorporated into the particle core is released in a prolonged way. This makes the 
controlled release from these carriers possible which becomes an important tool when it is 
necessary to supply the drug over a prolonged period of time (Muller, 2000; Reddy, 2005). The aim 
of the present study was to investigate the feasibility of the inclusion of the water-insoluble drug 
curcumin into SLNs. Ultrasound technique was employed to prepare SLNs and formulation 
parameters as sonication time and drug concentration were evaluated. The physicochemical 
characterization of curcumin-loaded SLNs, in terms of particle size, drug loading capacity, drug 
entrapment efficiency, and in vitro drug release, was carried out. Transcellular permeability by the 
non-cell based assay PAMPA was also evaluated.  
 
2.2 MATERIALS AND METHOD 
2.2.1 Materials 
Compritol® 888 ATO (glyceryl behenate, tribehenin), a mixture of mono-, di- and triglycerides of 
behenic acid (C22), was a gift of Gattefossè (Milan, Italy). Curcumin, Pluronic F68 and 1,7 
octadiene were purchased from Sigma Aldrich corporation (St. Louis, MO, USA). All the solvents 
used were HPLC grade from Merck (Darmstadt, Germany); 85% formic acid was provided by 
Carlo Erba (Milan, Italy). Water was purified by a Milli-Qplus system from Millipore (Milford, MA). 
Lecithin was kindly provided by Galeno (Comeana, Italy). Cholesterol was analytical grade from 
Sigma Aldrich (Milan, Italy). 96-well MultiScreen PAMPA filter plate were purchased from 
Millipore corporation. 
2.2.2 Ultrasonication method 
Blank and drug loaded SLN were prepared using hot homogenization process followed by 
ultrasonication (Castelli, 2005). Table 1 show the three different formulations investigated. Briefly 
different amounts of curcumin, (respectively 75, 150 and 225 mg) were weighted accurately and 
added to Compritol® 888 ATO (7.5 g) previously melted at 80ºC. Pluronic F 68 was dissolved in 
double distilled water (2.7 % w/w) and heated up to 80ºC in a beaker. When a clear homogenous 
lipid phase was obtained, the hot aqueous surfactant solution was added to hot lipid phase and 
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homogenization was carried out at 12.000 rpm, by using a high-speed stirrer (Ultra Turrax 
T25,IKA-WerkeGmbH&Co. KG, Staufen, Germany) for five minutes. The temperature was 
maintained at 80ºC during the homogenization step. The coarse emulsion was then subjected to 
probe sonication (Bandelin, Berlin, Germany) by TT13 probe for different times in amplitude of 70 
% and potence of 100 W. To prevent temperature increase, the probe sonicator was inactive in 2-s 
intervals. Sonication was applied maximum for 15 minutes to avoid metal contamination. To 
prevent recrystallization during homogenization and ultrasonication, production temperature was 
kept at least 5ºC above the lipid melting point. After ultrasonication the obtained emulsion (O/W) 
was cooled in an ice bath in order to solidify the lipid matrix and to form SLN. Blank and drug 
loaded SLN were prepared and characterized as well. SLN dispersions were stored at 4ºC for 
further analyses. 
 
Table 1: Composition of different solid lipid nanoparticles formulations. SLN-1: solid lipid 
nanoparticles loaded with 1% of curcumin. SLN-2: solid lipid nanoparticles loaded with 2% of 
curcumin. SLN-3: solid lipid nanoparticles loaded with 3% of curcumin. 
 
2.2.3 Particle size analysis and zeta potential measurements 
Mean diameter of the main population and polydispersity index (P.I.) as a measure of the width of 
particle size distribution were assessed by photon correlation spectroscopy (PCS) using a Zetasizer 
Nano ZS (Malvern Instruments, UK). Samples were prepared diluting 10µl of SLN suspension with 
2 ml of deionized water. All measurements were done in triplicate. The surface charge was 
determined by measuring the zeta potential of SLN based on the Smoluchowski equation: 
   
   
 
  
 
where ν is the measured electrophoretic velocity, η is the viscosity, ε is the electrical permittivity of 
the electrolytic solution, and E is the electric field.  
2.2.4 Determination of encapsulation efficiency 
The percentage of curcumin entrapped in the lipid matrix was determined as follows: a fixed 
amount of SLN dispersion was submitted to exhaustive dialysis using a membrane (MW=12.400). 
An amount of retained material was then freeze-dried at −40ºC for 24 h. The pre-freezing and 
freeze drying time were optimized to recover completely dried nanoparticles. Sample obtained were
Formulation Curcumin 
(g) 
Compritol® 888 ATO 
(g) 
Pluronic F 68 
(g) 
Water 
(g) 
SLN-1 0.075 7.5 3.75 138 
SLN-2 0.150 7.5 3.75 138 
SLN-3 0.225 7.5 3.75 138 
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dissolved in MeOH under sonication, centrifuged for 30 minutes at 14.000 rpm and the supernatant 
obtained was analyzed by HPLC/DAD analysis using curcumin as external standard. Calibration 
curves for the validated method were performed on six solutions in the concentration range 1.38–
138 µg/ml. The correlation coefficient was >0.99. Curcumin encapsulation efficiency was 
expressed as drug recovery and calculated from:  
 
                    
                                
                                
       
 
The drug loading content was the ratio of incorporated drug to lipid (w/w): 
 
                 
                                
               
       
 
Possible lipid interferences during UV determination of curcumin were also investigated: no lipid 
interference occurred (data not show). Curcumin loaded concentration was assayed by HPLC/DAD 
analysis performed using a HP 1100 Liquid Chromatograph (Agilent Technologies, Palo Alto, CA, 
USA) equipped with a HP 1040 Diode Array Detector (DAD), an automatic injector, an auto 
sampler and a column oven and managed by a HP 9000 workstation (Agilent Technologies, Palo 
Alto, CA, USA). The UV-Vis spectra were recorded between 220–500 nm and the chromatographic 
profiles was registered at 420 nm. Separations were performed on a reversed phase column Luna 
C18 (150 x 4.6 mm, 5 μm, Phenomenex) maintained at 27°C. The eluents were H2O at pH 3.2 by 
formic acid ( Solvent A) and acetonitrile ( Solvent B). The multi-step linear gradient applied is 
described on Table 2. 
 
Time (min.) Solvent A Solvent B 
0.10 72 18 
10 56 44 
13 56 44 
27 52 48 
32 20 80 
35 72 18 
Table 2: HPLC method for curcumin quantification 
 
2.2.5 Differential scanning calorimetry (DSC)  
DSC was carried out using a Mettler TA4000 apparatus equipped with a DSC 25 cell. A mass of 10 
mg samples were accurately weighted (Mettler M3 Microbalance) directly in pierced aluminium 
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pans and scanned between 30 and 250°C at a heating rate of 10 K min-
1
 under static air. DSC 
thermograms of pure curcumin, Compritol® ATO 888, and curcumin-loaded SLN were compared.   
2.2.6 Wide angle X-ray scattering (WAXS) 
X-ray diffraction patterns were obtained using the wide-angle X-ray scattering (WAXS, 2θ= 4-40º) 
on a Philips PW 1830 X-ray generator (Philips, Amedo, The Netherlands) with a copper anode (Cu-
Kαradiation, λ = 1.5418 nm) using a Goniometer PW18120 as a detector. Data of the scattered 
radiation were recorded with a blend local-sensible detector using an anode voltage of 40 kV, a 
current of 25mA and a scan rate of 0.5º per minute. 
2.2.7 Transmission electron microscopy (TEM) 
The morphological characterization of the systems was performed using the transmission electron 
microscopy technique (TEM, CM12 Philips, Netherlands). Samples were stained with 2% (w/v) 
phosphotungstic acid solution and placed on copper grids with Formvar films for viewing by TEM.  
2.2.8 In vitro release studies 
Dialysis bag method was performed to study the drug release using a mixture of PBS and EtOH 
(50:50 v/v), pH 6.8, as the dissolution medium. Release was monitored for 24. The dialysis bags 
were hydrated in PBS before use. Two milliliter of SLN dispersion was poured into the dialysis 
bag. The bag was placed in a beaker containing 200 mL of dissolution medium maintained at 37ºC 
and stirred at a rate of 100 rpm. Aliquots of the dissolution medium were withdrawn at different 
time intervals and were replaced with the same volume of fresh medium to maintain the sink 
conditions. The samples were suitably diluted and analyzed for curcumin spectrophotometrically. 
All the operations were carried out in triplicate. 
2.2.9 Stability studies 
Stability of curcumin solid lipid nanoparticles was studied over 1 month. Solid lipid nanoparticles 
were kept at 4±1°C and at fixed time intervals they were assayed for their physical stability. 
Physical stability was checked by monitoring of size, zeta potential and polidispersity in time, by 
DLS.  
2.2.10 Parallel artificial membrane permeability assay (PAMPA) 
The PAMPA assay is a method for predicting passive intestinal absorption. The assay is carried out 
in a 96-well, MultiScreen-IP PAMPA (Millipore corporation) filter plate. The ability of compounds 
to diffuse from a donor compartment, through a PVDF membrane filter pretreated with a lipid-
containing organic solvent, into an acceptor compartment is evaluated. A mixture of lecithin (1% 
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w/v) and cholesterol (0.8 w/v) in 1,7 octadiene was prepared and sonicate to ensure complete 
dissolution. 5 μL of the lipidic mixture were added to the filter of each well. Immediately after the 
application of the artificial membrane, 150 μL of drug containing donor solutions (free drug or 
curcumin SLNs diluted in 5% DMSO, PBS) were added to each well of the donor plate. 300 μL of 
buffer (5% DMSO in PBS, pH 7.4) were added to each well of the acceptor plate. The acceptor 
plate was then placed into the donor plate (Figure 1) , ensuring that the underside of the membrane 
was in contact with buffer. The plate was covered and incubated at room temperature under shaking 
for 24 hours and permeation was evaluated at fixed time interval of 1, 2, 4, 6, 19, 24 hours.  
 
 
 
 
 
 
 
 
 
 
Figure 1: PAMPA model in a 96-well plate and detail of a well 
 
2.3 RESULTS AND DISCUSSION 
Due to the increasing life expectancy, majority of people in the older age dwell with multiple 
disorders, thus creating a need to look upon molecules with multiple targets. Curcumin obtained 
from the rhizome of C. longa Linn. is a lipid-soluble antioxidant constituent. Curcumin targets 
multiple chemotherapeutic and inflammatory pathways and has demonstrated safety and tolerability 
in humans; however, the clinical literature lacks conclusive evidence supporting its use as a 
therapeutic agent due to its low bioavailability (Kakkar, 2011). Its insolubility in most 
biocompatible solvents has made curcumin very difficult to deliver into the body through 
conventional routes, including orally or by an intravenous or intramuscular injection. The aim of 
this study was to develop and characterize lipid nanoparticles wich can circumvent these problems 
for the encapsulation of curcumin for oral administration used for antitumoral treatment.  
2.3.1 Preparation of SLN 
SLN made of Compritol® 888 ATO as the core material were stabilized with Pluronic F68. 
Compritol® ATO 888 was selected because is a mixture of monoglycerides, diglycerides, and 
triglycerides. In the nanoparticle structure, the lipid that results in a highly crystalline structure with 
a perfect lattice would lead to drug expulsion. On the other hand, the imperfections (lattice defects) 
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of the lipid structure could offer more loading space to accommodate drugs. As a result, the 
structure of less ordered arrangement in the nanoparticles would be beneficial to the drug loading 
capacity. Pluronics® are class of non-ionic surfactants that are well known for their very low 
toxicity. Pluronic F68 has been used also for development of injectables and ophthalmic solutions. 
The emulsification-ultrasonication method was found to be efficient and quick to produce SLNs; a 
great advantage of this method is the fact that the equipment is common in every lab and the 
production can easily be done. Three different formulations with increasing amount of curcumin (1, 
2 and 3% w/w respect to the lipid phase) were prepared and fully characterized.  Effect of different 
process variables on size, P.I, zeta potential and encapsulation efficiency are discussed in the 
following section and presented on Table 3. Homogenization time was fixed at ten minutes, in fact 
as already reported (Das, 2011), this variable did not show any effect on particle size. This should 
be expected as homogenization step is only for emulsification of lipid in aqueus phase; it is an 
intermediate step and did not produce final particles.  
Sonication time showed huge influence on particle size. Size significantly decreased with 
increasing sonication time and we obtained a decreasing of P.I. values in the formulations SLN-1 
and SLN-2. These observations are reasonable as sonication was responsable for final particle size 
of SLNs, which broke the coarse emulsion drops to nanoemulsion droplets. Longer sonication time 
put more sonication energy to the SLN dispersions, which reduced size of the nanoemulsion 
droplets and decreased size distribution. The zeta potential indicates the degree of repulsion 
between close and similarly charged particles in the nanodispersion. High zeta potential indicates 
highly charged particles. Generally, high zeta potential negative or positive prevents aggregation of 
the particles due to electric repulsion and electrically stabilizes the nanoparticle dispersion. Zeta 
potential more than |30| mV indicates stable nanodispersion. The negative zeta potential of SLNs 
was attributed to the presence of behenic acid onto the lipid matrix surface; values were around -
30/-40 mV indicating a stable system, however a small decreasing of zeta potentials values was 
found with increasing sonication time. Encapsulation efficiency was not significantly different 
among the groups. We can observe higher values of zeta potential in the case of loaded 
nanoparticles that confirm the incapsulation of curcumin in the carrier.  
Particle size slightly increased with higher drug concentration (2 and 3% of curcumin); this is 
probably due to the presence of curcumin on the lipidic core. Zeta potential were comparable in all 
cases which suggests good stability of the SLN dispersions. In general we obtained good values of 
encapsulation efficiency around 70 %; such values may be due to the highly lipophilic nature of the 
drug and good solubility in glyceryl behenate.   
As lipid has certain drug loading capacity, addition of excess drug led to increase of unencapsulated 
drug; it was observed for formulation loaded with 3% w/w of curcumin that showed a macroscopic 
precipitate after only few hours after preparation. The formulation selected for the best properties in 
terms of size, P.I. and zeta potential was SLN-2-15; it showed also good values of encapsulation 
efficiency (80%) and was selected for further investigation 
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Table 3: Characterization of developed blank and curcumin loaded SLNs; effect of sonication time 
and amount of curcumin on size, P.I., encapsulation efficiency and drug loading. SLN-1, SLN-2 and 
SLN-3 are solid lipid nanoparticles loaded respectively with 1, 2 and 3% of curcumin. 5, 10 and 15 
indicates  sonication time. 
 
2.3.2 TEM analysis 
The morphology of solid lipid nanoparticles determined by TEM was shown in Figure 2. The TEM 
study demonstrated that the particles had almost spherical and uniform shapes and did not stick to 
each other. The mean diameter was in the range of  250-300 nm.    
Formulation Time of 
sonication 
(min) 
Curcumin 
 
(% w/w) 
Size 
 
(nm) 
P.I. ζ 
Potential 
(mV) 
Encapsulation 
efficiency 
(%) 
Drug 
loading 
(%) 
Blank SLN 5 - 333±1 0.28±0.02 -36±3 - - 
 10 - 254±6 0.25±0.01 -24±2 - - 
 15 - 241±9 0.33±0.03 -10±1 - - 
        
SLN-1-5 5 1 320±18 0.31±0.03 -45±2 76.4±4.9 0.76 
SLN-1-10 10 1 238±4 0.31±0.04 -34±4 74.2±16 0.74 
SLN-1-15 15 1 199±23 0.26±0.02 -39±4 76.4±4.6 0.76 
        
SLN-2-5 5 2 415±6 0.31±0.08 -39±3 70.7±2 1.41 
SLN-2-10 10 2 313±13 0.33±0.01 -29±4 77.8±8 1.56 
SLN-2-15 15 2 270±15 0.29±0.01 -33±3 80.2±2 1.60 
        
SLN-3-5 5 3 345±20 0.31±0.02 -40±4 66.3±6.4 1.99 
SLN-3-10 10 3 278±19 0.33±0.05 -39±2 82.5±11.6 2.48 
SLN-3-15 15 3 227±11 0.32±0.04 -28±7 86.5±8.2 2.60 
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Figure 2: TEM morphology of curcumin solid lipid nanoparticles with details  of single SLNs. 
 
2.3.3 DSC and X-ray diffractometry assays 
Lipid nanoparticles were analysed by DSC and X-ray diffractometry to investigate the crystal 
pattern of both curcumin and lipids, because this aspect could influence the in vitro and in vivo 
release of the drug from the systems. To investigate this effect, analysis was performed on the 
following samples: curcumin, Compritol
®
888 ATO; unloaded solid lipid nanoparticle and loaded 
solid lipid nanoparticles. Figure 3 depicts the DSC thermograms obtained. As Compritol
®
888 ATO 
is not composed of pure triacylglycerols, the observed melting peak at 72.1ºC might be due to a 
mixture of metastable polymorphic β and β' forms. The heating run showed also a relatively small 
endothermic shoulder at around 55ºC; this small shoulder corresponds to the melting of a very 
unstable modification of Compritol
®888 ATO which is the α modification (Souto, 2006), that 
clearly disappears after the treatment for nanoparticle preparation. DSC analysis of curcumin 
showed the drug melting peak at 173.17ºC. In the DSC thermograms of blank SLN (unloaded) and 
loaded SLNs, a small endothermic peak was observed at 50ºC. This peak indicates the presence of 
Pluronic either in the form of coating surrounding the nanoparticles or as residue after dyalisis and 
lyophilization. X-ray diffraction studies showed that diffraction pattern of bulk Compritol
®
888 
ATO (Figure 4) has two main typical signals at 21.5 (2θ) and 23.5 (2θ) that are significantly 
modified when formulated into nanoparticles. Besides, when nanoparticles are formulated, another 
signal arises at 19.4 (2θ) which corresponds to the most stable polymorphic form of triacylglycerols 
β (Souto, 2006). These results might indicate that the final formulation is composed of the most 
stable polymorphic state of Compritol
®
888 ATO: solid lipid nanoparticles seem to lose part of their 
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crystalline state transforming from a mixture of β and β' polymorphs to the most stable β 
polymorph, permitting curcumin to fit in the molecular gaps.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: DSC thermographs of  Compritol®888 ATO; pure curcumin; blank and loade solid lipid 
nanoparticles. 
 
Figure 4: X-ray diffraction pattern of Compritol®888 ATO; pure curcumin; blank and loaded solid 
lipid nanoparticles. 
2.3.4 In vitro release studies 
The prepared particles were further evaluate for in vitro release of curcumin. The choice of 
dissolution medium and the sink condition have always been a problem for the low solubility drugs 
such as curcumin. For these compounds, an aqueus solution containing a surfactant or solvent in
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which the drug is soluble may be used to enhance its solubility. In the present case solubility of 
curcumin in water and simulated gastric fluid at room temperature has been determined to be 3x10
-3
 
and 5.7x10
-3
 µg/ml (Kakkar, 2011). Thus, to provide sink condition, 50% v/v ethanol in which the 
solubility of curcumin is 0.693±0.13 mg/ml was chosen as the receptor medium. The use of this 
receptor medium has been already described in literature (Kakkar, 2011; Mulik, 2010). Drug 
released from the SLNs and diffused through the dialysis membrane into the release media, while 
the dialysis bag retained the SLN. Hence, drug released from the SLN were measured by 
determining drug concentration in the release media. Percent cumulative drug release versus time 
was plotted to demonstrate the drug release pattern (Figure 5). A rapid release was observed in the 
first 6 hours that reached about 30% of the overall curcumin released from the formulation, which 
could be due to the drug-enriched shell around the particles and the consequence short diffusion 
distance for the drug. Although the release rate of SLN could be influenced by complex factors, it 
was reported that among the factors that contribute to a fast release are the large surface area, a high 
diffusion coefficient due to small molecular size or low viscosity in the matrix. The subsequent 
phase of delayed release may be attribute to the fact that the curcumin dispersed within the core is 
being released slowly from the lipidic solid matrices through diffusion and dissolution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: In vitro release profile of curcumin from solid lipid nanoparticles by dialysis method, 
50% ethanol was used as the release medium. Each data represent the mean ± standard deviation 
of three experiments. 
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2.3.5 Stability studies 
Stability of curcumin solid lipid nanoparticles was studied over 1 month. Physical stability was 
checked by monitoring of size, zeta potential and P.I. in time, by DLS measurements. There was no 
modification on the particle size neither on the zeta potential of the solid lipid nanoparticles, which 
maintained their original values throughout the study (Figure 6). Furthermore, polydispersity was 
stable over time. That means that no vesicle size alterations occurred over the whole period. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Particle size and P.I (a) and zeta potential (b) evolution of curcumin solid lipid 
nanoparticles at storage condition (1 month, 4ºC). (Mean±S.D.; n=3). 
 
2.3.6 Parallel artificial membrane permeability assay (PAMPA) 
An approach for rapid assessment of absorption potential include the parallel artificial membrane 
permeability assay (PAMPA) (Kansy, 2004).  Pampa is based on a 96-well microplate technology 
and allows reasonable throughput, although it lacks similarity to natural membranes in that it does 
not posses pores or active transport mechanism. It enables fast determination of the trends in the 
ability of the compounds to permeate membrane by passive diffusion and is thus suited for the 
screening of large libraries. A caveat of the PAMPA approaches is to remember that they will 
underestimate the absorption of compound subject to active or paracellular transport in vivo and 
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overestimate the absorption of compound subject to efflux pump transport. The experiment was 
carried out measuring the ability of curcumin to diffuse from our SLN suspension to a donor 
compartment through a PVDF membrane. Solid lipid nanoparticles suspension was diluted to a 
final concentration of 160 μg of curcumin in each donor compartment. A saturated solution of 
curcumin in DMSO 5%/PBS (0.2 μg of curcumin solubilized in each donor compartment) was used 
as control. Results obtained (Figure 7) showed a strong increasing of the amount of curcumin 
permeated in the case of SLN suspension if compared with the saturated solution of curcumin used 
as control. We can observe that in the case of solid lipid nanoparticles after 6h, 19h and 24h 
respectively 2.6%, 4.9% and 5.8% of curcumin present in the donor compartment permeated to the 
acceptor compartment. In the case of saturated solution after 6h, 19h and 24h respectively 10%, 
10% and 14% of curcumin present in the donor compartment permeated to the acceptor 
compartment.  We can observe also that the amount of free curcumin permeated is constant during 
all the time while in SLNs the amount of curcumin permeated increase in time. This confirm the 
sustained release of our nanocarriers and it is also in accordance with the results obtained by 
releasing profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:Permeation profile of  free curcumin and curcumin loaded SLNs by Parallel artificial 
membrane permeability assay (PAMPA). Each data represent the mean of three experiments. 
Amount of curcumin is referred to each well. 
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2.4 CONCLUSIONS 
In this study the poorly-soluble drug curcumin was incorporated into SLN by homogenization and 
ultrasound technique. Compritol® 888 ATO demonstrated good curcumin solubilization and the 
effect on the formulation of variables like amount of drug and time of sonication were evaluated. 
Selected formulation showed good values of encapsulation efficiency, size, P.I., zeta potential and 
stability was confirmed over one month on storage condition. The presence of round shape SLN 
with homogeneus size distribution was confimed by TEM analysis. In particular the average particle 
size of nanoparticles was maintained below 300 nm, it helps bypassing the liver first pass 
metabolism that has been reported to be the major site of curcumin degradation. Like other 
formulations, such as microemulsions or submicron emulsions, reduction in the particles size is a 
key factor for improving the peroral performance of poorly soluble drugs. In SLN formulations the 
particle size range was reduced resulting in an increase in surface area and saturation solubility. An 
increase in saturation solubility and, consequently, an increase in the release rate of the drug allows 
it to reach high concentrations in the gastrointestinal tract. In addition, use of surfactants such 
Pluronic F68 in the preparation of SLNs may contribute toward an increase in the permeability of 
the intestinal membrane or affinity between lipid particles and intestinal membrane, and may also 
exhibit bioadhesion to the GI tract wall. It was confirmed by Parallel artificial membrane 
permeability assay (PAMPA) that showed a considerable increasing in curcumin permeation by 
SLN. Also, by incorporation into SLN, curcumin is embedded into a solid lipid matrix that reduce 
the exposure to enzymatic degradation during the process of absorption. We observe also a 
prolonged release profile that suggest that curcumin molecules are solubilized throught the solid 
lipid matrix. Advantages of SLN is the fact that they can be freeze-dried and  converted into solid 
dosage forms, such as tablets, capsules, pellets or powders in sachets, and they can also be 
transferred to a powder (by spray-drying or lyophilization) and added to the tabletting powder 
mixture. The obtained powders can be used to produce classic solid dosage forms, can be 
redispersed in water or juice prior to administration, and can also be used for the filling of hard 
gelatine capsules. Further investigations will be carried out to optimize freeze-dried process for oral 
delivery of developed SLNs. We can conclude that SLNs offer a promising delivery system for 
enhancing the oral absorption of poorly soluble drugs like curcumin.   
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3.1 INTRODUCTION 
The clinical use of most anticancer drugs is associated to severe side effects and decreased quality 
of life for the patients. These effects are related to the biodistribution of large fractions of the drugs 
to non-target tissues, where they result in toxic effects to normal cells (Park, 2008). Interestingly, 
the side effects of many anticancer treatments are not only related to the active ingredient, but also 
to the excipients used for formulating them for parenteral administration. This is due to the extreme 
water insolubility of many anticancer drugs that requires the use of organic solvents to prepare 
conventional parenteral formulations. Typical organic solvents used in these formulations are 
Cremophor® EL/ethanol mixtures that have been deemed responsible of serious adverse effects 
including acute hypersensitivity reactions characterised by dyspnoea, flushing, rash, chest pain, 
tachycardia, hypotension, angio-edema and generalised urticarial (Gelderblom, 2001).  
The limitations of conventional therapies have resulted in a great interest for the use of nanocarriers 
for anticancer drug delivery. From a technological perspective, the ideal nanocarrier should be well 
tolerated and capable of encapsulating highly hydrophobic drugs. Among the different delivery 
strategies, polymeric nanocapsules present many positive features for this application (Mora-
Huertas, 2010; Couvreur, 2002; Garcion, 2006).  
The oily core of polymeric nanocapsules is an ideal environment to encapsulate most antitumor 
drugs at high payloads, with good encapsulation efficacies and in a stable environment. On the 
other hand, the polymeric shell can be chosen to improve the biodistribution and the 
pharmacokinetic profile of the nanocarrier and to increase the intracellular penetration. 
Polyglutamic acid (PGA) is a highly anionic polyaminoacid composed of naturally occurring L-
glutamic acid linked by peptide bonds. PGA is highly biocompatible and readily biodegradable by 
digestion with lysosomal enzymes. It is a suitable material for drug delivery design not only owing 
to its safety profile but also because it renders the surface of the nanocarriers more hydrophilic 
avoiding the uptake by the mononuclear phagocytic system (Dash, 2010).  
The research group of Prof. M.J. Alonso has developed in previous studies highly efficient 
polymeric nanocapsulese to deliver docetaxel into tumor cells; these nanocarriers are characterized 
by the presence of soybean lecithin and cationic surfactant that drive the interaction between 
nanoemulsion and polymer. Natural surfactant like lecithin present significant variability of content 
and purity with risk of poor reproducibility of results. Moreover it has been established that ionic 
surfactants show higher toxicity value that non-ionic ones, and that cationic surfactants are more 
potent than their anionic counterparts as demonstrated by cytotoxicity test on HeLa cells (Vlachy, 
2009).  
Taking into account this information, the aim of this work was to evaluate the potential of 
innovative PGA nanocapsules as vehicles for docetaxel as model drug (I) avoiding use of lecithin as 
surfactant to overcome stability and variability problems (II) decreasing the amount of cationic 
surfactants to reduce the toxicity of the formulation. The disadvantage with the use of surfactants in 
drug delivery system is their potential toxicity at higher concentration. Surfactants are capable of 
causing distruption in biological membranes and display significant interaction with certain proteins 
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and a high concentration of surfactant over a long period of time may disturb some bodily processes 
(Buckton, 1995).  
Tween80® and PEG40-stearate were selected as non ionic surfactants (Figure 1). Tween 80® is a 
polyethylene sorbitol ester, with a calculated molecular weight of 1310 Da, assuming 20 ethylene 
oxide units, one sorbitol, and one oleic acid as the primary fatty acid. It is widely used as 
pharmaceutical surfactants in various oral and parenteral delivery system. Its application 
intravenously is also approved by the US Food and Drug Administration as well as the European 
Medicine Agency. Alternatively, we have also explored the possibility of modulating the surface 
properties of the nanocapsules by using PEG-stearate on the shell composition. The presence of 
PEG40-stearate as stabilizer reduced significantly the surface hydrophobicity and prolonging 
circulation time in vivo. Mononuclear phagocyte system can opsonize colloidal drug carriers and so 
rapid clearance of drug may cause reduction of its effectiveness. To enhance the plasma half-life 
and circulation of nanoparticles, many researchers have recommended PEG modification of 
nanoparticles (Kajiwara, 2007; Han, 2007).  
Two different cationic surfactants were selected for nanocapsules preparation: stearylamine and 
hexadecyltrimethylammonium bromide (CTAB), already used in the formulations previously 
developed. Stearylamine has been reported to have lower toxicity after oral administration if 
compared with CTAB (CTAB in rat LD 50 oral 410 mg/Kg and SA 1395mg/Kg) (Ramadan, 2011).  
Docetaxel has demonstrated anticancer effects both in vitro and in vivo against a variety of tumors 
including lung, ovaries, breast, leukemia, malignant melanoma (Saloustros, 2008; Haas, 2008). It 
was selected as model drug. It is characterized by hydrophobic character and result necessary the of 
use solubilizer (i.e. Cremophor®EL and ethanol) for its intravenous administration with severe side 
effects.  
In this work different innovative PGA nanocapsules were designed for the delivery of docetaxel; 
blank and DCX-loaded nanocapsules were prepared and physicochemically characterized. An in 
vitro release study was carried out and a qualitative uptake study in A549 cells confirmed the 
possibility to use the two selected formulation as efficient carriers to deliver docetaxel to cancer 
cells. 
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Figure  1:Molecular structure of the components used for the preparation of the nanoparticles. Non 
ionic surfactants: (a) Tween®80 and (b) PEG40-stearate. Cationic surfactants: (c) 
hexadecyltrimethylammonium bromide (CTAB) and (d) octadecylamine (stearylamine). 
 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
Poly-L-glutamic acid (PGA) (Mw 15-50 KDa), docetaxel (DCX), Tween80®, 
hexadecyltrimethylammonium bromide (CTAB), octadecylamine (stearylamine) were purchased 
from Sigma, Spain. Miglyol 812®, a neutral oil formed by esters of caprylic and capric fatty acids 
and glycerol, was a kind gift from Sasol Germany GmbH (Germany). Poly(ethyethyleneglycol)-
stearate of a degree of polymerization of 40 henceforth designated as PEG40-stearate (Simulsol M 
52) was provided by Seppic, France; DAPI (4’-6-diamidino-2-phenylindole) and 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD) (DiD Em 644 nm; Ex 664 nm) were 
obtained from Molecular Probes-Invitrogen (USA). All other reagents used were HPLC grade. 
3.2.2 Preparation of nanocapsules  
The preparation of PGA nanocapsules was based on a modification of the solvent displacement 
technique as previously reported (Calvo, 1997). The method involved a polymer ionic interaction 
after solvent diffusion. Blank nanocapsules were obtained by two different methods: one-step and 
two step-techniques. 
One step technique:  Briefly, an organic phase was formed by dissolving 12 mg of anionic 
surfactant (Tween 80® or PEG40-stearate) in 0.250 ml of ethanol, followed by 62.5 μl of 
Mygliol®812 and different amounts of cationic surfactant (0.9 mg of CTAB or 0.5 mg of 
stearylamine) in 4.75 ml of acetone solution. This organic phase was immediately poured over 5ml 
a b 
d c 
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of a water solution of PGA (0.5 mg/ml). Finally, solvents were evaporated under vacuum  from the 
suspension to a final constant volume of 5 ml. 
Nanoemulsions were also obtained by the method previously described. Unlike nanocapsules, 
nanoemulsions are only formed by the hydrophobic cores without the polymer cover. We prepare 
anionic and cationic nanoemulsions which differ for the presence of the cationic surfactants 
stearylamine or CTAB. 
Two step technique: The primary nanoemulsion obtained as previously described was incubated 
with PGA solution (1-2 mg/ml) in 5:1 ratio under magnetic stirring for 30 min, obtaining the PGA 
coated nanocapsules. 
3.2.3 Characterization of PGA nanocapsules  
Particle size and polydispersion index were determined by photon correlation spectroscopy (PCS). 
Samples were diluted to an appropriate concentration with filtered water (60 μl of sample in 2 ml of 
water) and each analysis was carried out at 25ºC with an angle detection of 173º. Zeta potential 
values were calculated from the mean electrophoretic mobility values, which were determined by 
laser Doppler anemometry. Samples were diluted with KCl 0.1 mM. Analyses were performed in 
triplicate using a zetasizer NanoZS® (Malvern Instruments, Malvern, UK). The morphological 
characterization of the systems was performed using the transmission electron microscopy 
technique (TEM, CM12 Philips, Netherlands). Samples were stained with 2% (w/v) 
phosphotungstic acid solution and placed on copper grids with Formvar films for viewing by TEM. 
3.2.4 Docetaxel encapsulation into nanocapsules  
In order to achieve the incorporation of DCX into PGA nanocapsules, 50 µl of the DCX stock 
ethanol solution (conc. 1 mg/ml) were added to the organic phase and the process was continued as 
described previously. PGA nanocapsules were concentrated up to a final volume of 5 ml in order to 
obtain a final drug concentration of 10 µg/µl. 
The encapsulation efficiency of DCX in PGA nanocapsules was determined indirectly by the 
difference between the total amount of DCX in the formulation and the free drug measured in the 
subnatant of the nanocapsules. Therefore, the total amount of drug was estimated by dissolving an 
aliquot of non-isolated DCX loaded PGA nanocapsules with acetonitrile. This sample was 
centrifuged during 20 min at 4000g and the supernatant was measured with a high-performance 
liquid chromatography (HPLC) system. The non-encapsulated drug was determined by the same 
method following separation of PGA nanocapsules from the aqueous medium by ultracentrifugation 
at 30000 rpm, 15°C, 1h.  
DCX was assayed by a slightly modified version of the method proposed by Lee et al. (Lee, 1999). 
The HPLC system consisted of an Agilent 1100 Series instrument equipped with a UV detector set 
at 227 nm and a reverse phase Zorbax Eclipse® XDB-C8 column (4.6 x 150 mm i.d., pore size 5 
μm Agilent USA). The mobile phase consisted of a mixture of acetonitrile and 0.1% v/v 
Chapter 3  
 
63 
ortophosphoric acid (55:45 v/v) and the flow rate was 1 ml/min. The standard calibration curves of 
docetaxel were linear (r
2 
= 0.999) in the range of concentrations between 10-0.5 µg/ml 
The encapsulation efficiency (E.E.) was calculated as follows: 
E.E.%=[(A-B)/A]×100 
Where A is the experimental total drug concentration and B is the drug concentration measured in 
the external aqueous medium, corresponding to unloaded drug. 
3.2.5 Fluorescent DiD encapsulation  
Fluorescent labeled formulations were obtained replacing 0.5 ml of ethanol of the organic phase 
with 0.250 ml of DiD stock solution in ethanol (2.5 mg/ml). The final concentration of DiD in the 
nanocarriers was approximately 125 μg/ml. DiD encapsulation efficiency in all the systems was 
determined indirectly by the difference between the total amount of fluorescent probe in the 
formulations and the free dye measured in the subnatant of the nanocapsules after 
ultracentrifugation (30000 rpm, 15°C, 1h). At the end of the ultracentrifugation aliquots of 
subnatant were diluted with acetonitrile and analyzed by UV spectrophotometry (646 nm). To 
determinate the total amount of the probe present in the systems aliquots of nanocapsules 
suspension were diluted with acetonitrile and analyzed at λ=646 nm. 
3.2.6 In vitro release study  
The release of DCX from PGA nanocapsules was performed by incubating a sample of each 
formulation with phosphate buffer at an appropriate concentration to assure sink conditions (4.9 
µg/ml). The vials were placed in an incubator at 37º C with horizontal shaking. An aliquot of 4 ml 
of the suspension was collected at different time intervals (1, 4, 8, 24, 48 h), and ultracentrifuged in 
Herolab® tubes (Herolab GmbH, Germany). The amount of drug released was calculated indirectly 
by determining the amount of free drug in the aqueous phase as described above. As a control, the 
total amount of drug in the suspension was also determined. 
3.2.7 Stability studies  
The stability of loaded PGA nanocapsules suspension at 37°C in phosphate buffer under stirring 
was followed for a period of 7 days by measuring the particle size and polidispersity index of the 
colloidal system. Stability of two selected formulations was also evaluated for 48h in two different 
cell culture media: Opti-MEM® (Reduced Serum Medium) and DMEM supplemented with 10% 
FBS. 
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3.2.8 Cell culture 
The human lung carcinoma derived A549 cell line was cultured on 80 cm
2
 flasks (Nunc, Denmark) 
using Dulbecco’s modified Eagle medium-high glucose (DMEM) supplemented with 10% FBS, 1% 
L-glutamine, 1% non-essential amino acids (x100), penicillin (100U/ml) and streptomycin (100 
μg/ml) (all obtained from Sigma-Aldrich). Cells were maintained at 37ºC in a humidified 
atmosphere with 5% CO2. The culture medium was changed every two days for approximately 5-6 
days until cells reached approximately 80-90% confluence. Then, cells were trypsinized, 
subcultured and seeded at 2.5x10
5
 cells per flask.  
3.2.9 Qualitative uptake studies  
A549 cells were seeded at a density of 5 x 10
4
 cells/cm
2
 on sterile coverslips placed in 6-well plates; 
after this, the apical culture medium was removed and cells were incubated with the fluorescent 
nanosystems. After incubation for 4 hours, cells were washed three times with PBS (Sigma-Aldrich, 
Spain). Then, the cells were fixed for 10 min with 4% p-formaldehyde in PBS at room temperature, 
rinsed twice with fresh PBS and nuclei was staided with DAPI. Living cells were analyzed by 
confocal microscopy (Leica).  
3.2.10 Statistical analysis 
The design of experiments was formulated using the statistical software NEMRODW. Particle size, 
P.I. and zeta potential were statistically analyzed by the analysis of variance (ANOVA). Differences 
were considered to be significant at level of p ˂ 0.05. 
 
3.3 RESULTS AND DISCUSSION 
As indicated in the introduction, the purpose of this work was to optimize innovative nanocapsules 
that overcome stability problems due to the use of lecithin and characterized by a lower amount of 
cationic surfactant. The rationale for selecting PGA as the coating polymer was its biocompatibility 
and its potential ability to provide stealth properties to the carrier . Four different formulations were 
optimized to load the anticancer molecule docetaxel. We discuss the preparation of these 
nanocarriers, their physicochemical characterization, their capacity to load and release docetaxel 
and a qualitative cell uptake study. 
3.3.1 Optimization of non ionic nanoemulsion by solvent displacement technique 
Non ionic nanoemulsions were obtained according to a modified solvent displacement technique; 
different amounts of non ionic surfactant (Tween80® and Peg40-stearate), referred to 5 ml of 
formulation, were tested. Blank nanoemulsions (Table 1) formed a homogeneous population of a 
mean particle size around the 200 nm with a  narrow size distribution (polydispersity index = 0.1 or 
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0.2). The two nanoemulsions with smaller amount of non ionic surfactant (12 mg of Tween80® and 
12 mg of PEG40-stearate) were selected to develop relative cationic nanoemulsions. 
 
Tween80® (mg) Size (nm) P.I. ζ Potential (mV) 
12 172±7 0.1 -15±1 
24 179±4 0.1 -17±1 
48 185±4 0.1 -20±1 
 1A 
PEG40-St (mg) Size (nm) P.I. ζ Potential (mV) 
12 226±3 0.2 -2±1 
24 237±12 0.2 -6±1 
48 266±6 0.2 -6±2 
1B 
Table 1: Characterization of blank non ionic nanoemulsions developed using Tween80® (A) or PEG40-
stearate (B) as non ionic surfactants. P.I.: polydispersity index, Values are given as mean ± SD; n=3. 
  
 
3.3.2 Development of blank nanocapsules by two step technique: optimization of polymer and 
cationic surfactant amounts 
Nanocapsules were obtained according to a modified solvent displacement technique where the 
coating polymer is deposited onto the oily core by electrostatic interaction. A similar approach had 
successfully been used before by the group to prepare chitosan and polyarginine nanocapsules 
(Lozano, submitted; Calvo, 1997). In this case, the inclusion of a cationic surfactant (CTAB or 
stearylamine) was required to drive the interaction between PGA and the nanoemulsion (Figure 2): 
the PGA coating around the positive surface was formed due to the ionic-polar interactions between 
the positively amine groups of surfactant agent and the lateral chain of PGA. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Illustration of the structure and preparation method of PGA nanocapsule 
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In the first step of our work several cationic nanoemulsion were developed and characterized in 
terms of size, P.I and zeta potential in order to optimize the amount of cationic surfactant used. 
Cationic nanoemulsions were then incubated with water solution of PGA at two different 
concentrations: 1 mg/ml and 2 mg/ml in order to optimize the amount of polymer used. The mean 
particle size of PGA nanocapsules was approximately 200 nm, corresponding to a monomodal and 
narrow size distribution (polydispersity index=0.1). The zeta potential was indicative of the 
different composition of these systems. PGA nanocapsules exhibited a polyanionic charge, whereas 
nanoemulsion have net positive charge. Considering that nanoemulsion has the same composition 
as compared to PGA nanocapsules except for the polymer coating, this charge inversion suggests 
that the electrostatically driven coating process is successful.  
Cationic nanoemulsions prepared using Tween80® as non ionic surfactant and CTAB as cationic 
surfactant showed good values of size, P.I and zeta potential (Table 2); relative nanocapsules, 
obtained after incubation with a water solution of PGA, showed an inversion of zeta potential 
values that confirm the process coating. We observe a strong decreasing of zeta potential values 
comparing nanocapsules prepared with 0.9 mg of CTAB (-30 mV) with nanocapsules prepared with 
0.5 mg of CTAB (-8 mV). The amount of PGA hasn’t been so influent for the physical 
characteristics of the preparation (Figure 3). We obtained a similar profile also for nanocapsules 
prepared with the same method using PEG40-stearate as non ionic surfactant (Table 3, Figure 4). 
Thaking into account these results 0.9 mg of CTAB was the minimum amount of cationic surfactant 
selected to obtain a stable system by one step technique. Cationic nanoemulsions prepared using 
Tween80® as non ionic surfactant and stearylamine as cationic surfactant showed higher values of 
zeta potential (Table 4); relative nanocapsules obtained by two step technique showed good values 
of zeta potential also using 0.5 mg of stearylamine (-20 mv) (Figure 5). We obtained a similar 
profile also for nanocapsules prepared with PEG40-stearate and stearylamine as cationic surfactant 
(Table 5; Figure 6): nanocapsules with 0.5 mg of stearylamine and 1 mg/ml PGA showed a zeta 
potential of -25 mV that assure good stability of the system. 0.5 mg of stearylamine was the amount 
selected for nanocapsules preparation by one step technique. 
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Cationic Nanoemulsion Size 
(nm) 
P.I. ζ Potential 
(mV) 
1. Tween80®/0.9 mg CTAB  203±3 0.1 +34±2 
2. Tween80®/0.5 mg CTAB  203±4 0.1 +25±1 
3. Tween80®/0.3 mg CTAB  193±1 0.1 +17±1 
Table 2: Characterization of blank cationic nanoemulsion prepared using Tween80® as non ionic 
surfactant and CTAB as cationic surfactant. P.I.: polydispersity index, Values are given as mean ± 
SD; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Characterization of blank cationic nanocapsules  prepared by two step technique with 
different amount of PGA (1 mg/ml and 2 mg/ml) using Tween80® as non ionic surfactant and 
CTAB as cationic surfactant. Values are given as mean ± SD; n=3. 
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Cationic Nanoemulsion Size 
(nm) 
P.I. ζ Potential 
(mV) 
4. PEG40-St/0.9 mg CTAB  215±4 0.1 +44±1 
5. PEG40-St/ 0.5 mg CTAB  216±4 0.1 +35±2 
6. PEG40-St/0.3 mg CTAB 218±6 0.2 +28±2 
Table 3: Characterization of blank cationic nanoemulsion prepared using Peg-40 stearate as non 
ionic surfactant and CTAB as cationic surfactant. P.I.: polydispersity index, Values are given as 
mean ± SD; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Characterization of blank cationic nanocapsules  prepared by two step technique with 
different amount of PGA (1 mg/ml and 2 mg/ml) using Peg-40 stearate as non ionic surfactant and 
CTAB as cationic surfactant. Values are given as mean ± SD; n=3. 
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Cationic Nanoemulsion Size 
(nm) 
P.I. ζ Potential   
(mV) 
7. Tween80®/0.9 mg Stearylamine 236±11 0.1 +49±1 
8. Tween80®/0.5 mg Stearylamine 209±9 0.1 +39±2 
9. Tween80®/0.3 mg Stearylamine 208±2 0.1 +26±1 
Table 4: Characterization of blank cationic nanoemulsion prepared using Tween80® as non ionic 
surfactant and Stearylamine as cationic surfactant. P.I.: polydispersity index, Values are given as 
mean ± SD; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Characterization of blank cationic nanocapsules  prepared by two step technique with 
different amount of PGA (1 mg/ml and 2 mg/ml) using Tween80® as non ionic surfactant and 
Stearylamine as cationic surfactant. Values are given as mean ± SD; n=3. 
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Cationic Nanoemulsion Size 
(nm) 
P.I. ζ Potential   
(mV) 
10. PEG40-St/0.9 mg Stearylamine  253±13 0.2 +52±2 
11. PEG40-St/0.5 mg Stearylamine  246±10 0.2 +48±1 
12. PEG40-St/0.3 mg Stearylamine  241±4 0.2 +40±2 
Table 5: Characterization of blank cationic nanoemulsion prepared using Peg40-stearate as non 
ionic surfactant and Stearylamine as cationic surfactant. P.I.: polydispersity index, Values are 
given as mean ± SD; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Characterization of blank cationic nanocapsules  prepared by two step technique with 
different amount of PGA (1 mg/ml and 2 mg/ml) using Peg-40 stearate as non ionic surfactant and 
Stearylamine as cationic surfactant. Values are given as mean ± SD; n=3. 
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3.3.3 Preparation and characterization of blank PGA nanocapsules by one step technique 
Blank nanocapsules, using the amounts of cationic surfactants selected, were prepared by solvent 
displacement techniques in one step as previously described. 
Considering the results obtained during the preliminary studies (section 3.3.2) and confirmed by  
experimental designed (section 3.3.11), we decided to test two concentration of PGA in water: 1 
mg/ml and 0.5 mg/ml. Nanocapsules obtained were fully characterized as reported in Table 6. As 
can be noted, the use of adequate concentrations of polymer and cationic surfactant results in the 
formation of homogenous populations of nanocapsules between 170-215 nm.  
The results showed that the different amount of PGA did not affect markedly size and zeta potential 
values of the systems so we select 0.5 mg/ml as concentration of PGA to obtain a stable system 
reducing the cost of the formulation. Formulations number 1, 3, 5, and 7 were selected for further 
investigations. 
 
Formulation PGA  conc. 
(mg/ml) 
Size 
(nm) 
P.I. ζ Potential 
(mV) 
1. NCs Tween80®/CTAB 0.5 171±2 0.2 -25±1 
2. NCs Tween80®/CTAB  1 198±6 0.1 -24±4 
3. NCs PEG40-St/CTAB 0.5 179±5 0.1 -20±1 
4. NCs PEG40-St/CTAB 1 193±4 0.1 -25±2 
5. NCs Tween80®/Stearylamine 0.5 190±3 0.1 -19±3 
6. NCs Tween80®/Stearylamine 1 186±3 0.1 -15±2 
7. NCs PEG40-St/Stearylamine 0.5 217±6 0.1 -18±5 
8. NCs PEG40-St/Stearylamine 1 215±15 0.1 -22±1 
Table 6: Physic characteristics of blank PGA nanocapsules (Mean ± S.D.; n=3). NCs: 
nanocapsules. PEG40-St: PEG40-Stearate 
 
3.3.4 Preparation and characterization of docetaxel-loaded PGA nanocapsules 
The four formulations selected were loaded with DCX at concentration of 10 µg/ml and fully 
characterized. The Table 7 summarized the characterization of loaded and blank nanocapsules. The 
mean particle size of PGA nanocapsules was approximately 200 nm, corresponding to a 
monomodal and narrow size distribution (polydispersity index=0.1 or 0.2). PGA nanocapsules 
exhibited a negative zeta potential between -20 and -25 mV. Docetaxel-loaded nanocarriers showed 
similar physicochemical properties than unloaded ones. This might be related to an efficient 
incorporation of the drug in the oily core of the nanocarriers (Teixera, 2005). Values of 
encapsulation efficiency are between 40-50 % with slightly higer values in the case of stearylamina. 
Values of encapsulation efficiency compared with systems previously developed (Lozano, 2008) 
were lower probably due to the absence of a lipophilic surfactant like lecithin. 
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Formulation Size  
(nm) 
P.I. ζ Potential (mV) EE 
 (%) 
NCs Tween80®/CTAB 171±2 0.2 -25±1  
NCs Tween80®/CTAB-DCX 200±6 0.1 -23±1 41.1±1.5 
NCs PEG40-St/CTAB 179±5 0.1 -20±1  
NCs PEG40-St/CTAB-DCX 185±4 0.2 -19±1 45.9±4.2 
NCs Tween80®/Stearylamine 190±3 0.1 -19±3  
NCs Tween80®/Stearylamine-DCX 186±2 0.1 -19±1 51.3±1.8 
NCs PEG40-St/Stearylamine 217±6 0.1 -18±5  
NCs PEG40-St/Stearylamine-DCX 205±9 0.1 -18±2 45.2±2.5 
 
Table 7: Physicochemical characteristics of blank and  DXC-loaded PGA nanocapsules. P.I.: polydispersity 
index, Values are given as mean ± SD; n=3. NCs: nanocapsules and PEG40-St: PEG40-stearate 
 
3.3.5 Stability of docetaxel-loaded PGA nanocapsules   
For assessing the stability of the different formulations in in vitro conditions PGA nanocapsules 
preparations were incubated at 37ºC in phosphate buffere for one week (Figure 7). Different 
parameters were assessed at different time point: macroscopic aspect; particle size, polydispersity 
and zeta potential. The macroscopic aspect is important to exclude dramatic aggregation or phase 
separation processes, including drug precipitation. The preservation of the nanocapsules particle 
size and polydispersity is critical to ensure that system is suitable for administration, but also that it 
will maintain its pharmacokinetic properties that can change with nanocarrier size. The macroscopic 
analysis showed evidence of aggregation and sedimentation in the samples prepared with PEG40-
stearate as non ionic surfactant after only one day. The precipitate was observed both in the 
unloaded and loaded formulations, probably not due to the presence of DCX. 
Instead the two formulations with Tween80® as non ionic surfactant showed a good stability, no 
significant differences on the mean particles size were observed during 7 days. Polydispersity 
determinations confirm chemical and physicochemical stability of the system (data not shown). The 
two stable formulations prepared with Tween80® as non ionic surfactant were selected for further 
studies. 
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Figure 7: Stability of blank and loaded nanocapsules at 37ºC in phosphate buffer. Data represents 
means ±SD, n=3 
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3.3.6 Transmission electron micrograph of  PGA nanocapsules 
TEM images confirmed the approximate values of particle size for PGA nanocapsules as measured 
by PCS, and supported the homogeneity of the particle size distribution (Figure 8). TEM images 
indicated also that nanocapsules have a rounded and regular morphology, with the presence of a 
polymeric outer layer. 
 
 
                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: TEM images of PGA nanocapsules loaded with docetaxel. PGA nanocapsules with 
stearylamine (A, B, C) or CTAB (D, E, F)  as cationic surfactant and Tween80® as non ionic 
surfactant. 
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3.3.7 In vitro release studies 
The release pattern of docetaxel from PGA nanocapsules was studied upon incubation in phosphate 
buffer (Figure 9). After one hour nanocapsules with CTAB as cationic surfactant were shown to 
release around 45% of their cargo and nanocapsules with stearylamine around 60%. Afterwards, no 
further release could be observed for the remaining time of the experiment (48 h). This in vitro 
release profile presents the typical biphasic release characterized by an initial burst until partition 
equilibrium is reached with the external aqueous phase. The fact that a significant fraction of the 
drug remained in the nanocapsules despite the high dilution is a further indication of the high 
affinity of docetaxel for the oily core of the nanocapsules (Lozano, 2008; Calvo, 1997). Stability of 
free drug in the same condition was confirmed (data not shown). 
 
 
 
Figure 9: In vitro drug release from docetaxel-loaded nanocapsule formulations in phosphate 
buffer, pH=7, 37 ºC. PGA nanocapsules with stearylamine as cationic surfactant (□); PGA 
nanocapsules with CTAB as cationic surfactant (♦). Data represents the mean ±SD, n=3. 
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3.3.8 Stability in cell culture media 
Stability studies were performed in two different cell culture media (Opti-MEM®: Reduced Serum 
Medium and DMEM supplemented with 10% FBS) in order to carry out a preliminary cellular 
uptake study. The two selected formulations showed a good stability in both cells culture media 
until 24 h, with an increasing in size at 48 h in NCs loaded with docetaxel and Tween80® as non 
ionic surfactant (Figure 10). 
 
 
 
 
 
 
Figure 10: Evolution of the particle size of PGA nanocapsules measured after incubation at 37ºC 
in cell culture media A) Opti-MEM® and B) DMEM supplemented with 10% FBS. PGA 
nanocapsules with CTAB as cationic surfactant (♦) PGA nanocapsules with stearylamine as 
cationic surfactant (□). Values are presented as mean ±SD, n=3. 
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3.3.9 Fluorescent DiD encapsulation into nanocapsules  
The results obtained indicate that the fluorescent probe was efficiently encapsulated (59-76 %) 
without altering the original characteristics of nanocapsules (Table 8). Values of encapsulation 
efficiency were higher in nanocapsules prepared using stearylamine as surfactant; it was probably 
due to the more lipophilic properties of this surfactant in comparison with CTAB. 
 
Formulation Size P.I. ζ Potential   
 (mV) 
EE 
(%) 
NCs Tween80®/CTAB-DiD 187±5 0.1 -24±2 59±6 
NCs Tween80®/Stearylamine-DiD 170±6 0.1 -18±2 76±3 
Table 8: Physicochemical characteristics of DiD-loaded PGA nanocapsules. P.I.: polydispersity 
index. EE: encapsulation efficiency. Values are given as mean ± SD; n=3.  
 
3.3.10 Uptake analysis 
Fluorescence microscopy studies were conducted to test the intensity of uptake by A549 cells of the 
encapsulated fluorescent probe DiD. The uptake was significantly fast and after only 4 hours 
nanocapsules showed cellular uptake. Uptake didn’t increase with longer incubation time: after 24 
hours cells showed the same amount of fluorescence and no differences among the two types of 
nanocapsules could be detected (data not shown). Fluorescence microscopy showed that the dye 
localization inside the cell was in the cytoplasm (Figure 11). 
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Figure 11: Confocal microscopy of  A549 cells after incubation with DiD-loaded carriers. Cells 
were incubated for 4 h with 0.5 µg/ml of incapsulated fluorescent probe. They were subsequently 
processed by staining nuclear DNA (DAPI). A, C, E: NCs Tween80®/CTAB-DiD; B, D, F: NCs 
Tween80®/Stearylamine-DiD. Red label corresponds to fluorescent carriers loaded with DiD. 
Nuclei stained with DAPI (blue). Merged imagine of nuclei stained with DAPI (blue) and 
fluorescent nanocapsules (red).  
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3.3.11 Study of formulation variables by experimental designed 
Statistical experimental design methodologies are powerful, efficient and systematic tools in the 
design of pharmaceutical dosage forms, allowing a rational study of the influence of formulation 
and/or processing parameters on the selected responses with a shortening of the experiment time 
and an improvement in the research and development work (Schwartz, 1997; Lewis, 1999; 
Gabrielsson, 2002). The main objective of the experimental design strategies is to plan experiments 
in order to obtain the maximum information regarding the considered experimental domain with the 
lowest number of experiments (Lunsted, 1998). Moreover, the multi-varied strategy of experimental 
design enables the simultaneous evaluation of the influence of the different variables involved in 
any process, being therefore particularly useful when, as in the case of pre-formulation studies, 
multiple factors have to be evaluated contemporaneously. The aim of the present section was to 
evaluate, by means of a multi-varied experimental design methodology, the influence of both the 
amount and type of cationic surfactant and the amount of polymer on the physical characteristics of 
nanocapsules prepared by two steps technique. Tween80® and PEG40-stearate were selected as 
non ionicic surfactants. The selected response variables were size, P.I. and zeta potential of 
nanocapsules. The software NEMRODW was used for generation and evaluation of the statistical 
experimental design (Mathieu, 2000). Blank nanocapsules were prepared by two step-technique and 
fully characterized as previously described (Section 4.2). 
The parameters selected as response variables to describe and optimize characteristics of 
nanocapsules were: 
Y1: size 
Y2: zeta potential 
Y3: P.I. 
The effect of different levels of each independent variable on the considered responses was studied. 
The variables evaluated for each examined cationic surfactant (CTAB, stearylamine) and for each 
considered non ionic surfactant (Tween80® and PEG40-stearate) and their respective levels were:  
U1: amount of PGA (mg/ml) 
U2: amount of cationic surfactant (mg) (referred to 5 ml of formulation). 
A qualitative model (Broudiscou, 1996) was hypothesized among response and factors under study 
that contained one constant plus, for each factor, a number of terms equal to its number of levels 
minus one: 
y=b0+A1x1+B1x2+B2x2 
In particular, A1 is the coefficient relative to the effect on the response of the level change of the 
factor U1 and B1-B2 are the coefficients relative to the changes of level of the factor U2. In order to 
evaluate the effects on the response of variations in the factor levels, an asymmetric screening 
design was used (Lewis, 1999; Addelman, 1962). The asymmetric screening design allows a rapid 
examination of factors at different numbers of levels, thus it can be used when the number of levels 
of each factor is different. In the present case, the D-optimal design contained six experiments 
(Table 9). Four independent studies were performed, according to the same general experimental 
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plan (Table 9).The experimental plans and the obtained responses for the two examined non ionic 
surfactants are reported in Tables 10 and 11. Effect on the response statistically significative were 
evaluated by analysis of variance (Table 12). Statistical evaluation of the experimental results 
processed with the NEMRODW software made it possible to obtain the desired information about 
the weight of each level of each factor on the considered responses. In particular, the graphic 
analysis of the effects (Mathieu, 1996) was used to evaluate the different effect of factor levels and 
determine the suitable level of the variable to be selected for optimising the considered response. 
The results of the graphic analysis of the investigated are presented in Figure 12-15. It must be 
pointed out that for the statistic treatment of the data zeta potential values was expressed in absolute 
values. Graphic analysis of effects is a simple experimental design tool in which the changes of 
levels that are active on the response correspond to the bars that exceed the dotted vertical lines, 
which represent the experimental error (Figure 12-15 a). In particular, coefficient A1 indicates the 
effect on the response moving from level 1 to level 2 of factor U1. Coefficient B1 indicates the 
effect on the response moving from level 1 to level 2 of factor U2; B2 indicates for the same factor 
the effect on the response moving from level 1 to the level 3; B3 refers to the 2–3 level change. 
Once the active level changes are pointed out, it is possible to individuate the suitable levels with 
another graph in which the effects of each tested level on the response are reported (Figure 12-15 
b). In this graph the length of the bars is correlated with the effect of the level on the response: the 
bars with maximum length are those relative to the levels that determine a maximization of the 
response. Bars with similar length indicate that the change in the factor levels is not statistically 
significant for the observed response (Mathieu, 2006). Starting from these figures, it is possible to 
select, for each drug, the best level of each factor for each considered response. In particular, for 
each variable, the level to select is indicated by the highest or lowest bar, depending on the 
considered response have to be maximized (zeta potential) or minimized (size), respectively. 
 
Trials Variable U1 
(mg PGA) 
Variable U2 
(mg of cationic surfactant) 
1 1 0.3 
2 2 0.3 
3 1 0.5 
4 2 0.5 
5 1 0.9 
6 2 0.9 
Table 9: Six run asymmetric screening matrix 
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Table 10: Experimental plan and observed responses for Tween80®/CTAB and  
Tween80®/stearylamine nanocapsules with cationic surfactant and polymer at different 
concentrations. 
Trials U1(mg) U2(mg) Cationic surfactant: CTAB Cationic surfactant: stearylamine 
   Size 
(nm) 
Zeta potential 
(mv) 
P.I. Size 
(nm) 
Zeta potential 
(mv) 
P.I. 
1 1 0.3 179 -19 0.1 226 -19 0.1 
2 2 0.3 180 -17 0.2 225 -20 0.1 
3 1 0.5 198 -20 0.1 196 -25 0.2 
4 2 0.5 188 -27 0.1 194 -30 0.2 
5 1 0.9 194 -30 0.2 178 -28 0.2 
6 2 0.9 206 -38 0.2 193 -31 0.2 
 
Table 11: Experimental plan and observed responses for PEG40-Stearate/CTAB and  PEG40-
Stearate/stearylamine nanocapsules with cationic surfactant and polymer at different 
concentrations. 
Formulation Surfactant concentration PGA concentration 
 Size Zp P.I. Size Zp P.I. 
1.NCs Tween80®/CTAB ◙ ◙     
2.NCs Tween80®/Stearylamine ◙ ◙   ◙  
3.NCs Peg40-St/CTAB  ◙     
4.NCs Peg40-St/Stearylamine  ◙ ◙     
Table 12: Results of analysis of variance. Variables: surfactant concentration and PGA 
concentration. Response of interest : Size, zeta potential and P.I. Differences were considered to be 
significant at a level of p< 0.05.                                                                           
Trials U1 (mg) U2 (mg) Cationic surfactant: CTAB Cationic surfactant: stearylamine 
   Size 
(nm) 
Zeta potential 
(mv) 
P.I. Size 
(nm) 
Zeta potential 
(mv) 
P.I. 
1 1 0.3 189 -9 0.1 205 -14 0.1 
2 2 0.3 178 -13 0.1 205 -13 0.1 
3 1 0.5 190 -8 0.1 190 -20 0.1 
4 2 0.5 182 -16 0.1 193 -26 0.1 
5 1 0.9 205 -30 0.1 200 -24 0.1 
6 2 0.9 208 -33 0.1 198 -39 0.1 
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Figure 12: NCs Tween80®/CTAB. (a) Graphic analysis of effects: A1 coefficient relative to the 
change of level of the factor U1 (amount of polymer); B1–B3 coefficients relative to the change of 
levels of the factor U2 (amount of cationic surfactan). (b) Response trend due to the different factor 
levels. 
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Figure 13: NCs Tween80®/Stearylamine. (a) Graphic analysis of effects: A1 coefficient relative to 
the change of level of the factor U1 (amount of polymer); B1–B3 coefficients relative to the change 
of levels of the factor U2 (amount of cationic surfactan). (b) Response trend due to the different 
factor levels. 
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Figure 14: NCs PEG40-St/CTAB nanocapsules (a) Graphic analysis of effects: A1 coefficient 
relative to the change of level of the factor U1 (amount of polymer); B1–B3 coefficients relative to 
the change of levels of the factor U2 (amount of cationic surfactan). (b) Response trend due to the 
different factor levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: PEG40-St/stearylamine  nanocapsules. (a) Graphic analysis of effects: A1 coefficient 
relative to the change of level of the factor U1 (amount of polymer); B1–B3 coefficients relative to 
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the change of levels of the factor U2 (amount of cationic surfactan). (b) Response trend due to the 
different factor levels. 
 
In the case of nanocapsules of Tween80® and CTAB (figure 12) we can observe that the effect of 
two level of factor U1 on the considered responses (size and zeta potential) is not statistically 
important. In contrast, the change in level of the other factor (amount of cationic surfactant) was 
statistically significant, and the results indicated that for minimizing size an amount of 0.3 mg 
should be used. The results indicate that for maximizing zeta potential values an amount of 0.9 mg 
of CTAB should be used. The change of P.I values wasn’t statistically significative. 
In the case of nanocapsules of PEG40-Stearate and CTAB (figure 14) we observed that the change 
of size wasn’t statistically significative (data not showed). The effect of the factor U1 wasn’t 
statistically significative. In contrast for maximizing zeta potential values an amount of 0.9 mg 
should be used. 
With regard to the nanocapsules of Tween80® and stearylamine (Figure 13) the graphic analysis of 
the effects showed that the amount of PGA on size is not statistically important. The change in level 
of the  second factor (amount of cationic surfactant) was statistically significant, and the results 
indicated that for minimizing size an amount of 0.5 mg should be used. In addition for maximizing 
zeta potential values an amount of 0.9 mg of  stearylamine should be used. Also the amount of PGA 
was important and to maximizing zeta potential value an amount of 2 mg/ml should be used. The 
change of P.I values wasn’t statistically significative. 
In the case of nanocapsules of PEG40-stearate and stearylamine (figure 15) we observe that for 
minimizing size an amount of 0.9 mg of stearylamine is necessary.  In addition for maximizing zeta 
potential values an amount of 0.9 mg of stearylamine should be used as well. The change of P.I 
values wasn’t statistically significative. We can also observe a slight difference between B2 and B3 
coefficients relative to the change of levels of the factor U2 (amount of cationic surfactant) in both 
size and zeta potential. 
In conclusion the results obtained underlined that the amount of polymer was statistically 
important only in one case (size of NCs of Tween80® and stearylamine). In general increasing the 
amount of polymer we didn’t observe any significative change in size, zeta potential or P.I. It can be 
reasonably hypothesized that the polymeric coating of nanoemulsion is complete with PGA 
concentration of 1 mg/ml.  
In the case of NCs Tween80®/CTAB and NCs PEG40-Stearate/CTAB for maximizing zeta 
potential values an amount of 0.9 mg of CTAB should be used. The presence of bigger amount of 
cationic surfactant promote the electrostatic interaction with the chain of polymer, this can explain 
the decreasing of zeta potential values. This amount of cationic surfactant was selected to get stable 
formulation by one step technique for further investigation.  
In the case of stearylamine as cationic surfactant an amount of 0.5 mg was selected. This 
formulation optimizes the size for NCs of Tween80®/stearylamine and it has a very similar 
behavior to that obtained with 0.9 mg of cationic surfactant. Graphic analysis of the effect for NCs 
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of PEG40-stearate/stearylamine showed only slight differences between B2 and B3 coefficients in 
size and zeta potential so the reduced amount of cationic surfactant was priority. Nanocapsules 
obtained with selected amounts of polymer and cationic surfactant have been previously described 
on section 3.3.3. 
 
3.4 CONCLUSIONS 
In conclusion two different nanocapsules for doceaxel delivery were developed and fully 
characterized. The formulations were developed avoiding use of lecithin as surfactant and show 
good characteristics for parenteral delivery: have nanometric size (about 200 nm), low 
polydispersity and good values of zeta potential. A decrease in the amount of cationic surfactant 
used was possible in the case of stearylamine without any alteration in stability of NCs. Docetaxel, 
used as model drug, was incorporated in the formulations without modification in their properties. 
Encapsulation efficiency was  between 40-50 %. The formulations selected showed good stability in 
phosphate buffer and in cell culture medium and preliminary cellular uptake studies support 
nanocapsules internalization. Further in vitro studies need to be performed in order to compare the 
toxicity of these new formulation with the nanocapsules previously developed and to show the 
advantage in reduction of cationic surfactant. 
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CHAPTER 4 
 
Liposomes for dihydroartemisinin delivery to cancer cells: 
development, characterization and in vitro studies 
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4.1 INTRODUCTION 
Poor solubility of a chemical entity is a major obstacle affecting its drugability (Fahr, 2007). It is 
estimated that more than 40% of the new chemical entities generated in drug discovery programs 
are poorly soluble (Lipinski, 2001). With growing interest in the role of modern pharmaceutics in 
early stage of drug discovery and development, rationale design of drug delivery systems for poorly 
soluble drugs has been widely explored, such as emulsions (Bansal, 2008; Chen, 2008), solid lipid 
nanoparticles (Hanafy, 2007; Ye, 2008), micelles, and liposomes (Pastorino, 2003; Harvey, 2007). 
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, is isolated from Artemisia 
annua. Artemisinin and its derivatives are well known as a treatment for malaria (Klayman, 1985),  
but more recent studies have revealed that it also has a preferentially cytotoxic effect on cancer 
cells, including leukemia cells, fibrosarcoma cells, ovarian cells, breast cancer cells and cervical 
cancer cells (Lu, 2009; Kim, 2006; Colm, 2010). Moreover, some studies have indicated that 
artemisinin derivatives have anti-cancer activities in vitro and in vivo. The fact that 
dihydroartemisinin induces cytotoxicity and apoptosis in cancerous cells has been reported by 
several groups. Lai and others treated molt-4 lymphoblastoid cells with dihydroartemisinin and 
showed that their survival was less than 50% after incubation (Efferth, 2002). However, DHA has 
poor water-solubility and low bioavailability for oral administration due to slow drug dissolution 
(Gabriëls, 2004). Furthermore, the half-life of DHA is very short (34–90 min) (Batty, 1996). It has 
been demonstrated that intravenous delivery of DHA results in the highest availability to body as 
compared to all other routes and can lead to quick eradication of the malarial infection (Li, 1998). 
Therefore, the development of the new formulation of DHA that enables quick availability to the 
body is in great need. Our work was focused on development and characterization of conventional 
and stealth liposomes for dihydroartemisinin delivery to cancer cells. 
To further advance biomedical application, it is important to characterize the interactions between 
liposomes and blood components, particularly with serum proteins that play an important role in the 
stability and properties of liposomes in blood e.g. in their circulation lifetimes (Panagi, 1999; 
Chonn, 1992). The amount of serum proteins associated on the liposomes used was inversely 
related to their circulation half-lives (Chonn, 1992). The serum proteins associated onto the surface 
of liposomes systematically administered have been suggested to be one of the most important 
factors to determine their in vivo fate (Drummond, 1999; Cattel, 2003). The amount of blood 
protein associated with liposomes in the circulation dramatically affects liposome clearance 
behaviour in vivo (Chonn, 1992). Specific bounded proteins can have a direct effect on particle 
internalization and biodistribution. Certain proteins allow macrophages of the reticulo endothelial 
system (RES) to more easily recognize nanoparticles (Owens, 2006). On  the other hand, 
dysopsonins such as albumin are said to promote prolonged circulation times in the blood (Goppert, 
2005; Moghimi, 1993; Ogawara, 2004). It has been found that proteins partially penetrate (Juliano, 
1971; Sabin, 2009) and modify the lipid bilayer (Lis, 1976; Hoekstra, 1979) when they are in 
contact with the membrane surface. This protein penetration into the liposomal membrane can 
change the properties of the bilayer with drastic consequences in their use as drug delivery systems 
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(Sabin, 2009). Increase in the rate of efflux of different liposomal contents in contact with serum 
albumin has been reported (Sweet, 1969,1970; Zborowski, 1977), but the role of albumin in 
phospholipid transfer, leading to loss of bilayer integrity and release of liposomal contents, is 
controversial. Near-physiological concentration (30 mg/mL) albumin dissolved more then 50% of 
liposomes (Michnik, 1997).  
The addition of PEG can add protein/opsonization resistance properties by preventing interactions 
between the particle surface and the plasma proteins (Owens, 2006; Jeon, 1991). Often water-
soluble polymers like polyethylene glycol (PEG) are attached to the surface of long-circulating 
liposomes to reduce adhesion of opsonic plasma proteins that would otherwise induce recognition 
and rapid removal from the circulation by macrophages in the liver and spleen (Woodle, 1994; Oku, 
1994; Aggarwal, 2009). Using this approach, PEG-coated long-circulating liposomes can remain in 
the circulation with a half-life as long as 50 hours (Gabizon, 1994; Hong, 2001).  
In this work, conventional and stealth liposomes were designed for the delivery of 
dihydroartemisinin. Loaded DHA liposomes were prepared and studied physicochemically. Their 
capacity to encapsulate the drug and the stability of the formulations in storage condition and in 
vitro in presence of albumin were evaluated. Flow cytometry analysis was used also for this aim 
and like alternative technique for rapid size determination of liposomes. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
All the solvents used were HPLC grade from Merck (Darmstadt, Germany); 85% formic acid was 
provided by Carlo Erba (Milan, Italy). Water was purified by a Milli-Qplus system from Millipore 
(Milford, MA). Dihydroartemisinin (DHA) was provided by Sigma-Tau (Pomezia, Roma). PEG 
2000 (18:0/18:0) was purchased from Spectra2000 srl (Rome, Italy). Egg phosphatidylcholine 
(Phospholipon90G, P90G) was gently provided from Natterman Phospholipids, GmbH, 
Hermersberg, Rhineland-Palatinate, Germany. Cholesterol was analytical grade from Aldrich 
(Milan, Italy). Dihydroartemisinin reference standard (ST3105, batch no. C005641) was kindly 
provided by Sigma-Tau (Pomezia, Rome, Italy). NBD-PE (N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
1,2-dihexadecanoyl-snglycero-3-phosphoethanolamine, triethylammonium salt; λex= 463 nm; λem= 
536 nm) were purchased from Molecular Probes, Invitrogen, Breda, The Netherlands. 
4.2.2 Preparation of conventional and PEGylated liposomes 
Conventional and PEGylated liposomes were prepared according to the film hydration method 
(Bangham, 1965), according to the optimised molar ratios reported in Table 1. 
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Constituent L-C-DHA L-P-DHA 
P90G 5 5 
Cholesterol 0.6 0.6 
PE 18:0/18:0 PEG 2000 - 0.25 
DHA 2 2 
Table 1: Molar ratios between the constituents of dihydroartemisinin-loaded conventional 
liposomes (L-C-DHA) and dihydroartemisinin-loaded PEGylated liposomes (L-P-DHA). 
Briefly, in the case of loaded conventional liposomes P90G, cholesterol and DHA were dissolved in 
dichloromethane. The organic solvent were vacuum evaporated and the dry lipid film was hydrated 
by addition of phosphate buffered saline solution. The dispersion was stirred with a mechanical 
stirrer for 30 minutes in a waterbath at the constant temperature of 38°C. In order to reduce the 
dimensions of the vesicles from MLV to LUV, a sonication probe was used at power delivery of 50 
% for different intervals of time (5’-15’ with pulsed duty cycle of 5 s on and 2 s off) with sample in 
ice bath to overcome lipid degradation. In order to obtain loaded PEGylated liposomes, PE 
18:0/18:0 PEG 2000 was weighted together with P90G, cholesterol and DHA and then the vesicles 
were prepared as describe above. Fluorescent liposomes were prepared by the addition of the 
fluorescence label NBD-PE at the concentration of 1% mol of the total lipid concentration. NBD-
PE’s stock solution had a concentration of 1 mg/mL in CHCl3 and it could be saved in freezer. 
4.2.3 Characterization of liposomes  
Liposomes size, polydispersity and zeta potential were measured by photon correlation 
spectroscopy. For these measurements, 20 µL of each liposomal dispersion was diluted 100-folds 
with aqueous solution. Measurements were carried out at the setted temperature of +25°C using a 
Zetasizer® Nano ZS3600 (Malvern Instruments, Malvern, UK). The morphological characterization 
of the systems was performed using the transmission electron microscopy technique (TEM, CM12 
Philips, Netherlands). Samples were stained with 2% (w/v) phosphotungstic acid solution and 
placed on copper grids with Formvar films for viewing by TEM. 
The encapsulation efficiency (EE) is defined as the percentual amount of drug entrapped in the 
vesicles in relation to the total amount of drug present during the vesicle formation and entrapment 
procedure. Free DHA was removed by means of dialysis. Liposomal formulation was transferred in 
a dialysis bag. This dialysis bag was stirred in 2 L of PBS at room temperature for 2 hours. The 
aqueous medium was refreshed once. The content of DHA into the liposomes was quantified by 
HPLC/DAD analysis using DHA as external standard. 
Dihydroartemisinin loaded concentration was assayed by HPLC/DAD analysis performed HP 1100 
Liquid Chromatograph (Agilent Technologies, Palo Alto, CA, USA) equipped with a HP 1040 
Chapter 4  
 
94 
Diode Array Detector (DAD), an automatic injector, an autosampler and a column oven and 
managed by a HP 9000 workstation (Agilent Technologies, Palo Alto, CA, USA). The UV-Vis 
spectra were recorded between 220–500 nm and the chromatographic profiles was registered at 210 
nm. Separations were performed on a reversed phase column Luna C18 (250 x 4.6 mm, 5 μm, 
Phenomenex) maintained at 27°C. The eluents were H2O at pH 3.2 by formic acid (A) and 
acetonitrile (B). The multi-step linear gradient applied is described on Table 2. The injection 
volume was 20 µl. The content of fluorescent probes into the liposomes was quantified by HPLC 
with fluorometric detection. Detector was set to excitation and emission of 460 nm and 535 nm  
respectively. In order to quantified the amount of fluorescence, a calibration curve was prepared 
using increasing amount of not dialyzed distrupted liposomes. The formulations were stored at 
+4°C and physicochemical characterisation was carried out according to the techniques described 
above. All the measurements were performed in triplicate.  
 
 
 
 
 
 
 
. 
 
 
Table 2: HPLC method for dihydroartemisinin quantification. 
4.2.4 Stability studies 
4.2.4.1 Stability in storage condition 
Stability of dihydroartemisinin-loaded vesicles dispersion was studied over 20 days. Vesicles 
dispersions were kept at 4±1°C and at fixed time intervals they were assayed for their physical and 
chemical stability. Physical stability was checked by monitoring of size and polidispersity in time. 
Chemical stability was checked by quantification of drug content after disruption of purified 
vesicles by HPLC-DAD analysis. 
4.2.4.2 Stability in presence of albumin 
I. Flow cytometry for rapid size determination 
Flow cytometry analysis
Time 
(min) 
Eluent A 
(%) 
 
Eluent B 
(%) 
0.10 50 50 
15 50 50 
20 0 100 
23 0 100 
28 50 50 
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Flow cytometry was performed using a FACSCanto II (Becton and Dickinson, Mountain View, 
CA, USA) equipped with three air-cooled lasers at 488 and 633 nm. Side scatter outcome was set to 
logarithmic and detected at a scattering angle of 90° with a threshold set on FL-1 (set to logarithmic 
amplification) to exclude side scatter values from non-fluorescent particulate matter. Flow rates 
and/or dilutions were chosen such that less than 2000 events/s were recorded to prevent 
coincidence. For each measurement a total number of 10000 events were recorded. Results were 
analyzed by software WinMDI 2.9. 
FACS data processing 
For calibration, histograms of SSC values were plotted and the geometric means of each peak 
corresponding to a bead size were derived. Bead sizes (y) and geometric means of SSC values (x) 
were then plotted in Graphpad Prism and fitted with non linear regression using: y=a+bxc as 
described previously (Vorauer-Uhl, 2000). 
Calibration curves by labeled beads 
The size distribution of the liposomes was determined by correlating the side scattered signals of 
the vesicles and the side scattered signals of the calibration beads. For the calibration of the size 
distribution, fluorescence labeled latex beads FluoSpheres Size Kit #2, carboxylate-modified 
microspheres of 0.1-0.2-0.5-0.7-1.0–, yellow-green fluorescent (505/515) were used. Diameters of 
the fluorescent beads were confirmed by Dynamic Light Scattering  (100, 200, 500, 700 and 1000 
nm bead). The standard beads were analized by FACS and a calibration curve based on 
measurements of the labeled beads was calculated. 
II. Incubation with albumin and FACS analysis 
Conventional and PEGylated liposomes loaded with DHA were incubated with a solution of 
albumin (40 mg/mL in PBS) at the body temperature in a shaking waterbath to mimic the in vivo 
condition. They were labeled with NBD-PE 1% mol and analysed by FACS experiment. 200 µL of 
fluorescent liposomes were exposed to 2.2 mL of albumin solution (40 mg/mL). This volume of 
albumin was choosen because for in vivo mouse studies, the total blood volume of a mouse of 
approx. 25 grams is 2 mL, which equals approx 1.1 ml of serum (55% of 2 mL) and the maximum 
injection volume of 100 µL is used. Fluorescent liposomes were sampled (150 µL) at 20, 40, 60, 90 
and 120 minutes. Conventional and PEGylated DHA-liposomes were diluted 4x10
3 
times in PBS. 
Conventional and PEGylated DHA-liposomes after incubation with albumin were diluted 4x10
2
 
times in PBS. They were subsequently analyzed by FACS for particle size and number of 
fluorescent events. The experiment and the measurements were repeated in triplo. 
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4.2.5 Cell lines 
The MCF-7 human breast cancer cell line was obtained from the American Type Culture Collection 
(Rockville, MD). This line was grown in Dulbecco’s modified Eagle medium-high glucose 
(DMEM) (GIBCO, European Division, San Giuliano Milanese, MI, Italy), supplemented with 10% 
FBS, 1% L-glutamine (Euroclone Company, Celbio s.r.l Italy). Cells were maintained at 37ºC in a 
humidified atmosphere with 5% CO2. The culture medium was changed every two days for 
approximately 5-6 days until cells reached approximately 80-90% confluence.  
4.2.6 Sulforhodamine B cytotoxicity assay 
This assay is based on a method described by Skehan et al. (Skehan, 1990) for measuring cellular 
protein content. Briefly, MCF-7 cells were seeded onto Greiner 96-well microplates (International 
pbi, Milan, Italy). After 24 h, culture medium was replaced with fresh medium and either liposomes 
formulation at final drug concentrations varying from 1µM to 1000 µM or medium (controls) was 
added. After 72 hours of incubation a 96-well microplate was processed by using the 
sulforhodamine B (SRB) method to determine cell growth inhibition. Cells were  fixed, air-dried, 
and stained for 30 min with 0.4% SRB (Sulforhodamine B) (Sigma–Aldrich, St. Louis, MO, USA) 
dissolved in 1% acetic acid. At the end of the staining period, SRB was removed and protein-bound 
dye was extracted with 10 mM unbuffered Tris base (Hidroxymethylaminomethan, pH 10.5, Merk, 
Germany) for 10 min on a shaker. Optical density was read in a computer-interfaced, 96-well 
microplate reader (Bio-Rad Laboratories, Milano, Italy) at 540 nm. 
4.2.7 Cellular uptake of liposomes by flow cytometry analysis 
Flow cytometry analysis was conducted on conventional and PEGylated liposomes labeled with 
NBD-PE 1% mol and on no labeled  liposomes (negative controls). Fluorescent liposomes were 
fully characterized as previously described. Cells (10
5
/ml) were treated for 1h with blank liposomes, 
and conventional or PEGylated liposomes incapsulating NBD-PE (400 µM). After incubation at 
37ºC, cells were washed twice with PBS and dissociated with 0.05% trypsin/EDTA. After a 
centrifugation step at 1200 rpm for 5 min at 4ºC, supernatants were discarded and cell pellets were 
washed with cold PBS. Cells were then resuspended in 1 ml of cold PBS and kept on ice in the 
dark. Analyses were performed using the flow cytometer FACS Canto (Becton Dickinson, San 
Jose, CA, USA). The autofluorescence of cell line was determined and a total of 20000 events were 
recorded. 
4.2.8 Fluorescence microscopy analysis 
MCF-7 cells were seeded (2 x 10
4
 cells/well) onto 2-well chamber slides and cultured overnight 
prior to the experiment. Cells were washed with PBS and 400 µM NBD-PE labeled liposomes in 
serum-free medium was added. After 1 hour, unbound liposomes were removed and the cells were 
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washed with PBS. The cells were either fixed with EtOH for 10 minutes before visualization. 
Fluorescence microscopy analysis was performed with a Leica TCS-SP confocal laser scanning 
microscope equipped with a 488 nm Argon, 568 nm Krypton and 647 nm HeNe laser.  
4.3 RESULTS AND DISCUSSION 
4.3.1 Characterization of liposomes 
Conventional and PEGylated liposomes were prepared according to the film hydration method as 
previously described and dimensions of the vesicles were reduced from MLV to LUV by 
sonication. Sonication time was affected  the liposomal particle size and P.I. as reported in Table 3. 
By increasing the sonication time from 5 min to 15 min, the particle size decreases from 218 nm to 
111 nm in conventional liposomes loaded with DHA. Only five minutes of sonication were 
necessary to decrease P.I and size of PEGylated liposomes respectively to 0.19 and 99 nm. 
Formulation Sonication time 
(min) 
Size 
(nm) 
P.I. 
L-C-DHA 0 218 ± 3 0.29 
 5’ 181 ± 2 0.33 
 10’ 125 ± 2 0.27 
 15’ 111 ± 7 0.28 
    
L-P-DHA 0 112 ± 1 0.31 
 5’ 99 ± 9 0.19 
Table 3: Optimization of sonication time during liposomes preparation. L-C-DHA: 
dihydroartemisinin-loaded conventional liposomes; L-P-DHA: dihydroartemisinin-loaded 
PEGylated liposomes. Data were shown as mean ± S.D. (n=3). 
All liposomal dispersions were analyzed in terms of size (nm), polydispersity (P.I.) and zeta 
potential by photon correlation spectroscopy. The correlation coefficient is superior to 0.9 that 
means that the signal to noise ratio is good (noise is 10%). The mean diameters of all the 
artemisinin-based vesicles was ≤200 nm and resulted suitable for the parenteral administration. The 
measurements performed three-times for each formulation were nicely reproducible. ζ-potential is 
around -32 mV for conventional liposomes and -25 mV for PEGylated liposomes. This change is a 
first indication of the presence of PEG shielding liposomes as observed before for other 
nanocarriers (Garcia-Fuentes, 2004). The DHA loading efficiencies were about 71% and 69% for 
both conventional liposomes and PEGylated liposomes, respectively, evaluated by HPLC/DAD 
analysis (Table 4). DHA loading efficiency for L-P-DHA was slightly lower than in the case of L-
C-DHA. This fact could be related to the smaller size of PEGylated liposomes which decreases  the 
bilayer capacity of solubilising lipophilic drugs (Isacchi, 2012).   
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The morphological appearance of the systems was observed by transmission electron microscopy 
(Figure 1). Both formulations had a round shape and results were in good agreement with the ones 
obtained from dynamic light scattering analyses. In particular stealth liposomes exhibit a rounded 
shape and corona, which might be attributed to the PEG polymer shell (Figure 1D, E, F).  
 
Table 4: Size, polydispersity index (P.I.), ζ-potential and encapsulation efficiency  of L-C-DHA: 
dihydroartemisinin-loaded conventional liposomes and L-P-DHA: dihydroartemisinin-loaded 
PEGylated liposomes. Data were shown as mean ± S.D. (n=3). 
 
 
Figure 1: TEM images revealing shape, structure, and sizes of conventional (A, B, C) and 
PEGylated (D, E, F) liposomes encapsulating dihydroartemisinin. 
4.3.2 Stability in drug storage conditions  
Stability of dihydroartemisinin-loaded conventional and PEGylated vesicles was studied over 20 
days. Physical stability was checked by monitoring of size and zeta potential in time, by DLS 
measurements. There was no modification on the particle size neither on the zeta potential of the 
liposomes, which maintained their original values throughout the study (Figure 2). Furthermore, 
Formulation Size 
(nm) 
P.I. ζ potential 
(mV) 
Encapsulation efficiency 
(%) 
L-C-DHA 111±7 0.28 -32.7±5.4 71±8.8 
L-P-DHA 99±9 0.19 -25±8 69±5.5 
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polydispersity of all the liposomal formulations was stable over time (data not showed). That means 
that no vesicle size alterations occurred over the whole period. Moreover, chemical stability was 
checked by quantification of drug content after disruption of purified vesicles. As described in the 
experimental section, the content of dihydroartemisinin into the liposomes was quantified by 
HPLC/DAD analysis. We found that  dihydroartemisinin maintained a residual percentage of 82% 
and 77%  after  20 days respectively in conventional and PEGylated liposomes (Figure 3). 
 
 
 
 
 
 
 
 
 
 
Figure 2: Particle size and zeta potential evolution of conventional DHA-liposomes and PEGylated 
DHA-liposomes at storage conditions (20 days, 4°C). (Mean ± S.D.; n=3). 
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Figure 3: Chemical stability of conventional and PEGylated DHA liposomes in terms of DHA 
content (Mean ± S.D; n=3). 
4.3.3 Characterization of fluorescent liposomes 
Liposomes were prepared as previously described and NBD-PE (1 mol%) was added during lipidic 
film preparation; the resulting liposomes, containing NBD-PE only in the outer monolayer, were 
fully characterized as reported in Table 5. The fluorescent probe with lipophilic characteristics was 
efficiently encapsulated (80-85%) without altering the original structure of liposomes. Size of 
conventional and stealth DHA-fluorescent liposomes were slightly higher than DHA-liposomes but 
in any case under 200 nm; this fact could be related to the presence of both compound (DHA and 
NBD-PE) in the bilayer. Fluorescent liposomes obtained were used to investigate cellular uptake 
and stability in presence of albumin. 
 
Table 5: Size, polydispersity index (P.I.), ζ-potential and encapsulation efficiency of L-C-DHA-F: 
dihydroartemisinin-loaded fluorescent conventional liposomes and L-P-DHA-F: 
dihydroartemisinin-loaded fluorescent PEGylated liposomes. Data were shown as mean ± S.D. 
(n=3). 
4.3.4 Cell uptake of conventional and PEGylated liposomes 
Fluorescence microscopy study allowed evaluating the intracellular fate of liposomes themselves 
and of their encapsulated material as a function of time and in various cell lines. Fluorescence 
microscopy is frequently associated with Fluorescence Activated Cell Sorting (FACS) to provide 
Formulation Size 
(nm) 
P.I. ζ potential 
(mV) 
Encapsulation efficiency 
(%) 
L-C-DHA-F 198±2 0.35 -13.4±5 85±2.3 
L-P-DHA-F 116±5 0.24 -12.4±1 80±5.2 
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quantitative results related to the uptake of nanocarriers in cells. FACS produces simultaneously 
multiple optical measurements on individual cells at high rates. Herein, FACS study was conducted 
on MCF-7 cell lines to compare the internalization of conventional and stealth liposomes. 
I) Fluorescence microscopy: Fluorescence microscopy showed that the dye localization inside the 
cell was in the cytoplasm without staining the nucleus (Figure 4). Moreover we can observe a 
stronger localization in the case of conventional liposomes. Although the application of PEG 
molecules has provided enhanced stability and relatively long circulation time for improved 
therapeutic effects, the steric hindrance of PEG molecules interfered with the cellular uptake of the 
drug systems (Raucher, 2001). 
II) Flow cytometry analysis: To investigate the cellular uptake of prepared liposomes and to 
confirm results obtained by fluorescence microscopy, we measured fluorescence levels accumulated 
in MCF-7 cells by using flow cytometry. Each group was treated respectively with conventional 
and stealth fluorescent liposomes for 1 hour. As shown in Figure 5 the mean fluorescence intensity 
from conventional liposomes was 7.5 fold higher than that of stealth liposomes. Data confirm the 
possibility that hydrophilic steric barrier of PEG molecules reduce cellular uptake and the reduction 
of the cell-repellent property in conventional liposomes may have induced the affinity to cells, 
thereby resulting in higher cellular uptake (Raucher, 2001). 
 
 
 
 
 
 
Figure 4: Fluorescence microscopy image of MCF7 cells treated with fluorescent liposomes after 
1h of incubation. On the left, the image corresponds to cells treated with fluorescent conventional 
liposomes. On the right the image corresponds to cells treated with fluorescent stealth liposomes. 
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Figure 5: Cellular uptake of liposomes detected by a flow cytometry assay: (black) control, (blue) 
conventional liposomes, (green) PEG-liposomes. The control corresponds to cells incubated in 
culture media without liposomes. Cells incubated with conventional or stealth empty liposomes 
showed values of fluorescence comparable with autofluorescence (data not showed). 
4.3.5 Stability in presence of albumin 
4.3.5.1 Flow cytometry for rapid size determination 
One of the essential quality parameters of liposome formulations is the mean size and size 
distribution of liposome vesicles. In particular, applications in therapeutic treatment and in vivo 
diagnostics require safe and well-defined products. The specification of liposome size ranges is 
therefore important. Methods currently available to measure particle size do not allow reliable 
measurements in the presence of small particulate contaminations present in biological fluids (e.g. 
serum) (Hsu, 2008). Serum is a complex fluid containing (among other) serum albumin, 
lipoproteins (HDL & LDL), immuno-, γ- and macrogobulins, and oleic acid. This heterogeneous 
nature can give rise to significant background signals, whereas sizing techniques based on 
conventional light scattering require minimum levels of background noise for generation of accurate 
results. With imaging techniques such as electron microscopy and atomic force microscopy 
individual particles can be studied, however, these techniques are laborious and have poor statistical 
power. Imaging is particularly valuable to obtain information regarding particle morphology, but 
the risk of artefacts must be taken into account. In this case we have used a method already reported 
(Gaal, 2009) based on flow cytometry that allows high-resolution size distribution analysis directly 
in biological in the submicron range. Flow cytometry is a well established technique that integrates 
light scattering and fluorescence measurements to gather information regarding size, shape, 
morphology of cells and presence and intensity of diverse fluorescent signals (indicative of 
molecular expression based on immunocytochemistry). Flow cytometry was originally developed as 
a tool to study cells, which have typical sizes of 2–120 μm (with a majority being 10–20 μm). 
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Recently this technique was exploited to study submicron matter, including unilamellar synthetic 
vesicles (Fuller, 1996), liposomes (Vorauer-Uhl, 2000) and viral particles (Hercher, 1979; Steen, 
2004). Each single particle is measured in a continuous flow system, which is in contrast to the 
well-established light scattering systems, where a suspension is measured in a closed containment. 
By FACS, the detection of particles may be performed at an angle of 10° forward scatter and at 90° 
side scatter (Vorauer-Uhl, 2000). For a representative measurement, 10000 particles per sample 
were analyzed (Vorauer-Uhl K, 2000). 
4.3.5.2 Calculation of the size ranges 
The correlation between mean diameter of the latex beads and their side scatter signals was 
determined according to equation y = a+bx
c
. Based on this equation, the side scatter signals of 
different samples may be classified in several relative size ranges to allow for better comparability 
between different samples. The results are represented either in frequency curves or in histogram 
form. 
4.3.5.3 Size determination of nanoparticles with flow cytometry 
First, we examined whether side scattering (SSC) values measured by flow cytometry could be 
correlated to sizes within the range of 100–1000 nm using fluorescently labelled polystyrene beads 
of distinct sizes. Sizes of the beads used for calibration were analyzed by Dynamic Light Scattering 
as shown in Table 6.  
Beads (nm)                                                                   Experimental beads values 
 Size (nm) P.I. 
100 99.98±1.6 0.025±0.012 
200 185±0.8 0.099±0.020 
500 518±8.2 0.078±0.039 
700 748±20 0.038±0.004 
1000 1038±18 0.123±0.008 
Table 6: Diameters of fluorescein-labelled calibration beads as determined by dynamic light 
scattering (100–1000 nm). 
In the case of flow cytometry, scattering intensities detected at 90° were recorded for each batch of 
the calibration beads. Flow cytometry parameter settings were adjusted such that background noise 
is negligible and detected fluorescence and SSC are within scale. Flow speed and dilution of beads 
were adjusted until <2000 events/s and they were recorded in order to prevent coincidence 
(simultaneous detection of >1 particle). Geometric mean of SSC-H values and diameters were 
plotted and a calibration curve was fitted according to the equation (1) (Vorauer-Uhl, 2000):
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y = a+bx
c
    (1) 
resulting in an R
2
=0.9706 (Figure 6 B). As a second step we applied the method to a conventional 
liposome sample labeled with the fluorescent probe NBD-PE. Conversion of the geometric mean of 
SSC-H (that had a value of 125) to size using equation (1) gives an average diameter of 234 nm 
comparable with Z-average found by DLS (198±2 nm). 
 
 
Figure 6: Determination of liposome distribution by FCM. Histograms of the side scatter values of 
the five chosen calibration bead classes. Latex beads (100–1000 nm) (A). By correlating the 
geometric mean side scatter values with the corresponding standard beads, the calibration curve 
with the equation y = a+bx
c
 (a=20.32; b=25.56; c=0.4940) (B). To estimate the size distribution of 
a real liposome sample, the recorded side scatter values are subdivided into several size classes 
(C). The calculated percentage distribution is illustrated in histogram form (D). 
 
Figure 6 C shows the side scatter histogram of our liposome suspension. By subdividing the bead 
side scatter values into several size classes, according to Table 7, corresponding with the calibrated 
size ranges, the distribution of a liposome suspension may be described. The percentage of 
liposomes can be calculated for each class, as shown in Figure 7 D. Calculation based on defined 
classes was used when dealing with polydisperse liposome suspensions because gives a more 
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realistic image of the actual distribution. Characterizing vesicle populations by relative size classes 
was in good agreement with the result obtained by FACS as described in Table 7. In the case of 
homogeneous narrow distributed vesicle populations, a mean diameter is calculated only based on 
the geometric mean of the side scatter signal. The method used can be applied with liposomal 
formulations and it is valid within the nanoscale range, with a lower limit around 100 nm. Below 
this size, calibration is complicated due to insufficient sensitivity of the SSC detectors currently 
used in flow cytometry equipment. An important advantage of the method here presented compared 
to existing nanoparticle sizing methods such as dynamic light scattering is the potential to measure 
nanoscale particles in the presence of other particulate, matter which is often present in biological 
fluids.  By adding fluorescence intensity as an inclusion criterion, this method can easily distinguish 
particles of interest from equally sized background noise. A disadvantage of introducing 
fluorescence measurements in particle size determination is the inherent requirement for sample 
labeling in fact the presence of fluorescence labels may influence particle characteristics. In our 
case fluorescent liposomes showed similar characteristics to conventional or stealth DHA liposomes 
so the effect of the fluorescent label is expected to be small. In conclusion flow cytometry can be 
used as alternative technique for size distribution evaluation of liposomes. 
 
Table 7: Percentage distribution of conventional fluorescent liposomes obtained by FACS and by 
DLS. 
 
4.3.5.4 Stability studies in presence of albumin 
The stability of the liposomal formulations in presence of blood protein (albumin at physiological 
concentration) was evaluated by FACS analysis using fluorescent liposomes. Liposomes were 
labelled with NBD-PE 1% mol and the incubation with albumin was monitored at different time 
points measuring number of fluorescent events by FACS analysis. This kind of fluorescent label is 
lipophilic and it forms the bilayer together with the other lipid so we expected a decreasing of 
fluorescent events during 30 seconds if the vesicles were disrupted due to the interaction with 
Size 
classes 
SSC-H 
values 
Mean 
diameter 
(nm) 
Liposomes distribution by 
FACS 
(%) 
Liposomes distribution 
by DLS 
(%) 
M1 ≤100 ≤233 48.77 45.8 
M2 100-200 233-334 25.31 24.9 
M3 200-350 334-449 10.87 7.5 
M4 350-500 449-528 4.80 6.5 
M5 500-650 528-606 4.02 5.3 
M6 650-800 606-679 1.70 4.1 
M7 >800 >679 5.70 5.8 
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albumin. Number of events analyzed by flow cytometer doesn’t decrease in time, it confirm that 
vesicles remain stable and intact also in presence of albumin in both formulation (Figure 7). This 
result was expected for stealth liposomes but not for the conventional formulation. Presence of 
DHA in the lipidic bilayer could stabilize vescicles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Number of fluorescent events registered by flow cytometer for conventional and 
PEGylated liposomes after 2 hours of incubation with albumin. 
4.3.5.5 Evaluation of size in presence of albumin 
The dot plots represent the SCC-A (indicative of size) against FITC-A (fluorescence intensity of the 
particles). The size of conventional and stealth DHA liposomes are respectively around 200 and 100 
nm, according with the DLS measurements. Size is not affected in presence of albumin. The 
vesicles remain stable and intact for 2 hours. Conversion of the geometric mean of SSC-H (that had
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 a value of 125 for conventional liposomes and 19.86 for stealth liposomes) to size using equation 
(1) gives an average diameter of 234 nm and 93 nm respectively for conventional and stealth 
liposomes.   
 
 
Figure 8: SSC signals of conventional (A) and PEGylated (B) fluorescents liposomes, after 
incubation with albumin, overlapped to the signal of fluorescents beads. 
4.3.6 Cytotoxicity of DHA conventional and stealth liposomes 
The cytotoxicity of DHA and its relative liposomal formulations was measured in the breast cancer 
cell line MCF-7. Unloaded liposomes were evaluated as well to ensure the absence of toxicity of  
the empty vehicle. As shown in Figure 9, they don’t  exhibit toxicity since  more than 90% of cell 
viability was measured for all cell lines after 72 h exposure even at the highest concentration. 
Encapsulated DHA was less efficient than free DHA for both formulations but conventional 
liposomes showed higher toxicity (1,6-fold drop in IC50) to that of stealth liposomes. The higher 
cytotoxicity of conventional liposomes (IC50=48.2 µM) compared with stealth liposomes (IC50= 77 
µM) is consistent with the notion that pegylated liposomes might not interact directly with the 
tumor cells (Figure 10; Table 8). 
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Figure 9: Cell viability data from sulforhodamine B cytotoxicity assay to evaluate potential 
cytotoxic effects of  empty liposomes in MCF-7 cancer cell line. After 72 h, no toxic effect of empty 
liposomes was evident. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: In vitro cytotoxicity of (A) free DHA, (B) dihydroartemisinin-loaded conventional 
liposomes and (C) dihydroartemisinin-loaded PEGylated liposomes on MCF-7 breast cancer cells 
as a function of  log (drug concentration). Data are expressed as percentage of cellular viability as 
evaluated by sulforhodamine B test. Results are the mean of  three different experiments ±standard 
deviation.  
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Table 8: Free and encapsulated DHA antiproliferative activities. IC50 (mean of three separate 
experiments±SD) was defined as the drug concentration that inhibits cell growth by 50% compared 
to untreated cells. Values represent data extrapolated from curves A, B and C (Figure 10). 
Although it is difficult to extrapolate from  in vitro data in vivo results for a  therapeutic success, it 
is expected that this liposomal formulations could be of clinical interest. It is important to note that 
liposomal DHA and free DHA have very difference kinetic properties, both in terms of in vitro 
cellular uptake, which is diffusion driven for free drug and enocytosis/fusion for liposomes, both in 
vivo plasma residence time, which is determined by the mechanism of clearance. Due to this 
differences, direct comparison of IC50 values for liposomal DHA and free DHA using equal 
exposure time in a cytotoxicity assay is not always realistic, since the comparison would have no 
relevance to in vivo therapeutic efficacy. In our case for example free DHA was the most efficient 
in breast cancer cell line, but since this compound has been reported to be rapidly metabolized in 
vivo following i.v. injection, the advantage of DHA-liposomes results from the preserved biological 
activity of the encapsulated drug. However, it is possible to carry out in vitro comparisons among 
the various liposomal formulations. In this case our data suggest that the mechanism of cellular 
entry is an important determinant for cytotoxicity; for PEGylated liposomes the low cytotoxicity on 
MCF-7 cells could be attributed to low cellular uptake for the presence of the hydrophilic steric 
barrier of PEG molecules that reduce the process of endocytosis. 
4.3.7 Time course experiments 
The cytotoxicity of DHA and  its relative liposomal formulations was evaluated during a time 
course experiment in the same cell line MCF-7. We can observe that IC50 values of free drug are 
constant during all the time considering that the permeation is driven by diffusion and it is complete 
after the first hours of incubation. In conventional and PEGylated liposomes we can observe higher 
IC50 values after 24 hours of incubation and  a decrease of IC50 values after 48 hours of incubation. 
The results confirm that after cellular uptake the release from vescicles is a modified release during 
time. 
Samples IC50 (µM) 
DHA 12.1±0.6 
L-C-DHA 48.2±7.5 
L-P-DHA 77±7 
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Table 9: Free and encapsulated DHA antiproliferative activities evaluate during time (24-120 
hours). Mean of three separate experiments ± SD.  
 
4.4 CONCLUSIONS 
The two liposome formulations developed represent a successful attempt to incorporate 
dihydroartemisinin in liposomes. They have proper physical characteristics as drug carrier for 
parental administration in terms of particle size, polydispersity, encapsulation efficacy and ζ-
potential. Liposomes provide an appropriate solvent for the drugs and because of their well known 
biocompatibility and tolerability (Allen, 1991) can overcome toxic and irritating effects of standard 
DHA vehicles like DMSO sometimes used for i.p. or i.v. administration in animal models. 
Liposome provide also stabilising system for their storage, during a substancial time after 
production, and in presence of blood protein. Finally, the preliminary results obtained with 
liposomal formulations encourage further evaluation of their antitumor activity in appropriate 
animal models. In fact DHA was confirmed to be a compound cytotoxic in cancerous cells and 
could be considered as a molecule of interest in vivo thank to an appropriate delivery system able to 
protect the drug from its fast metabolism occurring after i.v. administration (half life 45 minutes). 
Moreover, such a delivery system should lead to a decrease of the administered doses and to 
diminish their frequency, while preserving DHA antitumor activity. 
 
TIME  
(h) 
 
 
DHA IC50 
(µM) 
 
L-C-DHAIC550 
(µM) 
 
L-P-DHAIC50 
(µM) 
 
24 
 
19.1±0.3 
 
96.4±3.3 
 
 
155.1±7.1 
 
48 
 
16.2±5.2 
 
56.0±-0.5 
 
 
59.8±5.1 
 
72 
 
12.1±0.6 
 
48.2±7.5 
 
 
77±7 
 
96 
 
14.1±1.6 
 
45.0±1.0 
 
 
81.1±3.4 
 
120 
 
14.4±0.0 
 
50.7± 47.7 
 
 
85.4±7.6 
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CONCLUSIONS  
The study developed demonstrated the usefulness of nanoparticulate technology to enhance the 
therapeutic effectiveness of natural and semi-synthetic compounds.  
Curcumin loaded solid lipid nanoparticles have been developed by homogenization and ultrasound 
technique; they showed good features for oral administration with size around 200 nm and mean 
encapsulation efficiency values of 80%. Parallel artificial membrane permeability assay (PAMPA) 
showed a considerable increasing in curcumin permeation by SLNs. SLNs offer a promising 
delivery system for enhancing the oral absorption of poorly soluble drugs like curcumin.   
Two different polymeric nanocapsules were developed avoiding use of lecithin as surfactant; they 
showed good characteristics for parenteral delivery of docetaxel: have nanometric size (about 200 
nm), low polydispersity and good values of zeta potential. Formulations selected showed good 
stability in phosphate buffer and in cell culture medium and preliminary cellular uptake studies 
support nanocapsules internalization. Nanocapsules developed showed positive features for further 
in vitro and in vivo investigations.  
Conventional and PEGylated liposomes represented a successful attempt to delivery of 
dihydroartemisinin. They have proper physical characteristics as drug carrier for parental 
administration in terms of particle size, polydispersity, encapsulation efficacy and ζ-potential. 
Liposomes provide an appropriate solvent for the drugs and a stabilising system for their storage 
and in presence of blood protein. Results obtained with liposomal formulations encourage further 
evaluation of their antitumor activity in appropriate animal models.  
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1. INTRODUCTION  
Artemisia annua L. (Asteraceae) is an annual herbaceous plant well known in the traditional 
Chinese medicine, used as a remedy for chills and fevers for over 2000 years. A.annua is the only 
(commercial) source of the sesquiterpene lactone artemisinin. It also contains characteristic 
compounds such as: flavonoids, coumarins, triterpenoids, steroids, phenolics, purines, lipids and 
aliphatic compounds and monoterpenoids from different plant parts (Bhakuni, 2001). 
Polymethoxyflavonoids and artemisinin are among the most promising natural products for 
antimalarial and anticancer purposes.  
Artemisinin has been an effective drug against malaria, even against the chloroquine and quinine-
resistant Plasmodium falciparum. More recent studies have shown that artemisinin has a positive 
effect against tumor growth of several types of tumors, including: breast cancer, human leukemia, 
colon cancer, and small–cell lung carcinomas (Efferth, 2001). It contains an endoperoxide group 
that reacts with ferrous iron Fe
2+
, to generate short lived radical species, which are linked to its 
antiparasitic and anticancer activity. Although synthesis of artemisinin is possible, it is not a reliable 
source for production due to the low yields and high production costs because of its complex 
structure. Therefore extraction from the plant remains the most economical and reliable resource 
(Baraldi, 2008). 
Other studies have show that the efficacy of the A. annua plant itself derives from a synergistic 
effect and that it is a combination of constituents in the plant which can produce the total 
antiplasmodial and anticancer activity. Several polymethoxylated flavonoids, such as: artemetin, the 
constitutional isomers casticin and chrysosplenetin, chrysosplenol-D and cirsilineol may contribute 
to the in vitro activity of artemisinin (Elford, 1987; Liu, 1992; Phillipson, 1999). Flavonoids can 
serve as artemisinin’s synergists by reacting with iron and converting Fe3+ to Fe2+ (Tsao, 2004), 
which is important in the bioactivity of artemisinin leading to the release of short-lived toxic free 
radicals that may be part of its antimalarial and anticancer mode of action (Efferth, 2004). By 
combining antioxidant flavonoids, tannins, phenolic acids, and coumarins with artemisinin to treat 
malaria and cancer, as well as to prevent the latter, could be an interesting consideration for 
prophylactic or therapeutic reasons (Ferreira, 2010). On the other hand, it has been reported that 
flavonoids themselves can prevent DNA mutation that can appear in oncogenes or tumor suppressor 
genes. Thereby preventing cancer initiation or progression (Nijveldt, 2001). The modes of action of 
flavonoids for anticancer activity vary considerably on different cell lines. Mostly having an 
inhibitory effect on cell growth, proliferation and signal transduction by inhibiting various kinase 
proteins or inducing apoptosis and arresting the cell cycle (Ferreira, 2010).  
The first part of our work was focused on artemisinin and polymethoxylated flavonoids isolation 
from Artemisia annua L. acetone extract with the comparison of three separation methods: 
Sephadex LH-20, silica gel column chromatography and flash chromatography.  
In the second part of the work preliminary results about development and characterization of 
transferrin (Tf) conjugated liposomes for artemisinin delivery to cancer cells are reported. The 
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knowledge of Tf-Receptor-over-expression in tumour tissues had led to a focused targeting of Tf-R 
in anticancer therapy (Maruyama, 1998) and subsequently to a number of small drugs (e.g. 
adriamycin) and colloidal carrier systems (e.g. liposomes and nanoparticles) linked to Tf (Wagner, 
1994; Tros, 2002). Considering that the cytotoxic effect of artemisinin is specific to cancer cells, 
because Tf-receptors are highly expressed on the surfaces of tumour cells and iron content is higher 
than in normal cells (Moore, 1995; Efferth, 2004), the aim of our work was to develop a nanocarrier 
which can enhance the selectivity to tumour cells due to the presence of transferrin and enhance the 
activity of artemisinin by interaction with iron. 
  
2. MATERIALS AND METHODS 
2.1 Isolation 
2.1.1 Plant material 
A crude Artemisia annua L. acetone extract was kindly provided by Centro Tecnológico 
Agroalimentario Extremadura (CTAEX, Badajoz, Spain, 2006). 
2.1.2 Chemicals  
All the solvents used for extraction, chromatography methods and HPLC analysis (n-heptane, 
EtOAc, CH2Cl2, MeOH, EtOH, cyclohexane, acetone and CH3CN) were HPLC grade, provided by 
Sigma Aldrich (Steinheim, Germany); formic acid 85% was provided by Carlo Elba (Milan, Italy). 
The water was purified by a Milli-Qplus system (Milford, MA, USA). Different standards were used, 
in order to make the calibration curves: artemisinin standard (98% purity) (Sigma Aldrich, 
07529BJ, Steinheim, Germany), casticin standard (99,7% purity) (MADAUS, Lot: 
810715/F/MADAUS, Colone, Germany) narigenina (90% purity)(EXTRASYNTHESE, Lotto 
97060217, 69730 Genay, France), scopoletin (99% purity) (SIGMA, Lotto: 37F02891, Steinheim, 
Germania). The chemicals used in the spray reagents: 2-Aminoethylborinate (Sigma Aldrich, 
D9754-25G, Steinheim, Germany) and polyethylene glycol 4000 (PEG 4000) (Sigma Aldrich,  
Steinheim, Germany) were used to reveal the TLC plates. 
2.1.3 Liquid-liquid extraction 
The Artemisia annua L. acetone extract (51.4 g) was dissolved in 500 mL of MeOH, and sonicated 
for 30 minutes, to create a homogenous solution, and defatted at room temperature with n-heptane 
(500 mL, three times). 500 mL of H2O was added to the remaining MeOH phase and extracted with 
dichloromethane (DM) (1.0 L, three times). The same procedure was repeated using EtOAc instead 
of DM. All fractions were concentrated to complete dryness, using a rotary evaporator system.  
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2.1.4 Size exclusion chromatography 
A separation was performed on Sephadex LH-20 (GE Healthcare Bio-Sciences, AB, Uppsala, 
Sweden). An amount of the dried DM fraction was re-suspended in MeOH and applied over 
Sephadex LH-20 (30 cm × 4.6 cm). Different elution systems were tested: MeOH (100%); MeOH: 
H2O (90:10); EtOAc : MeOH (70:30) and MeOH:DM (50:50). The fractions were followed by 
TLC, HPLC-DAD-MS analyses and the fractions concerning the casticin/chrysosplenetin were 
analyzed by 
1
H NMR for monitoring the separation of the pair of isomers. 
2.1.5 Sample preparation for silica gel and flash chromatography 
The extract (25 g) was suspended in 200 ml of acetone and mixed with 113.4 g of Silica gel 100 
(Art. 10184, grain size 0.063 – 0.200 mm, 70 – 230 mesh ATM, Merck, Darmstadt, Germany). The 
acetone was then evaporated in order to form a dry powder and submitted to open column and flash 
chromatography. 
2.1.6 Silica gel chromatography 
The dry powder was applied on a normal phase silica gel column (30 cm x 4.6 cm), a mobile phase 
gradient was used, with solvent of increasing polarity: cyclohexane 100%, cyclohexane/DM (50:50, 
30:70, 15:85, 5:95), DM 100%, DM/EtOAC (95:5, 90:10, 85:15, 75:25), in a volume of 280 ml. 
HPLC-DAD-MS analysis was performed to quantify and qualify the fractions and 
1
H NMR 
analyses were done for monitoring the eventual separation of the isomers casticin and 
chrysosplenetin.  
2.1.7 Flash chromatographic system 
For a more rapid separation method, a flash chromatographic system was used. The Combi Flash 
system (Combi Flash
®
 Rf, Teledyne ISCO Inc., St. Lincoln, NE, USA) was programmed with a 
method composed of two parts, both parts using a mobile phase with gradient of increasing polarity. 
Part I (artemisinin isolation): 5 min. 100% cyclohexane, 5 min. 50:50 cyclohexane/DM, 5 min. 
30:70 cyclohexane/DM, 10 min. 100% DM. Flow rate: 15 ml/min. Part II (polymethoxylated 
flavonoids separation): 5 min 100% DM, 10 min. 5:95 EtAC/DM, 20 min. 10:90 EtAC/ CH2Cl2, 20 
min. 15:85 EtAC/ CH2Cl2, 10 min. 25:75 EtAC/DM. Flow rate: 10 ml/min. The chromatography 
runs were carried out, using a prepacked Silica column stationary phase (RediSep Rf High 
performance GOLD, 24 gram HP Silica, Lot: 191316001W, Teledyne ISCO, St. Lincoln, NE, 
USA). 
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2.1.8 Thin layer chromatography  
Thin layer chromatography (TLC) method was performed, for qualitative purpose, in order to 
follow the separation of the compounds in the fractions, after the preparative chromatography 
methods. Normal phase TLC plates (Silica gel 60 F254, Merck, Darmstadt, Germany), a mobile 
phase of DM/MeOH (95:5) and a spray reagents, with a mixture of 1% 2-Aminoethylborinate in 
MeOH and 5% Polyethylglycol 4000 in EtOH were used to reveal the TLC plates.  
2.1.9 HPLC-DAD-ESI-MS analysis 
The HPLC-DAD-ESI-MS analyses were performed using a HP1100 Liquid Chromatograph system 
(Agilent Technologies, Palo Alto, CA, USA), equipped with a HP1040 diode-array Detector 
(DAD), automatic injector, auto sampler and a column oven, managed by a HP9000 workstation 
(Agilent Technologies, Palo Alto, CA, USA). The UV-Vis spectra were recorded between 200–600 
nm. The HPLC system was interfaced with a HP1100 MSD API-electro spray (Agilent 
Technologies, Palo Alto, CA, USA). The interface geometry, with an orthogonal position of the 
nebulizer with respect to the capillary inlet, allowed the use of analytical conditions similar to those 
of HPLC-DAD analysis. Mass spectrometry operating conditions were optimized in order to 
achieve maximum sensitivity values: gas temperature 350 °C at a flow rate of 10 ml/min, nebulizer 
pressure of 30 psi, quadruple temperature 30 °C, and capillary voltage 3500 V. A full scan spectra 
from m/z 100–800 in the positive ion mode were obtained with scan time of 1 s. The fragmentor 
was set at 80. The column used was a reversed-phase column, Luna C18(2), size 250 × 4.6 mm, 
particle size 4.98 μm, pore diameter 97 Å (Phenomenex, Part. No. 00G-4252-E0, Batch No. 5291-
50, St. Torrence, CA, USA), maintained at 26°C. The used eluents were: (A) acidified water (pH 
3.2) with formic acid, (B) acetonitrile as reported in Table1.  
 
Table 1: Method used for HPLC analysis 
2.1.10 HPLC sample preparation 
5 mg of the dried defatted acetone extracts and fractions were accurately weighed and suspended in 
1 ml of CH3CN. The suspensions (5 mg/ml) were sonicated for 20 minutes and centrifuged for 5 
minutes (14000 rpm) before HPLC analysis. Fractions eluted by the three chromatography methods 
were adjusted to a final concentration of 1 mg/ml. The analyses were done in triplicates. 
Time Eluent A (%) Eluent B (%) Flow (ml/min.) 
0.10 50.0 50.0 1.0 
15.00 50.0 50.0 1.0 
20.00 0.0 100.0 1.0 
23.00 0.0 100.0 1.0 
28.00 50.0 50.0 1.0 
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2.1.11 Calibration curves and quantitative analysis 
To evaluate the content of constituents, a HPLC analysis was performed using a method described 
in the literature (Bilia, 2006), adapted to our experimental necessities. In particular four standards 
were used, to quantify artemisinin, scopoletin and the main polymethoxylated flavonoids presents in 
the acetone extract of A. annua. For artemisinin calibration, HPLC injection volumes in a range 
from 5 to 30 μl of artemisinin standard (C=0.052 mg/ml) were performed and the peak areas were 
recorded by MS instrument. For calibration of polymethoxyflavones, HPLC injection volumes in a 
range from 5 to 40 μl of casticin standard (0.212 mg/ml)  were performed (the chromatograms were 
recorded at 280 nm). For scopoletin quantification, HPLC injection volumes in a range from 5 to 30 
μl of scopoletin standard (C=0.234 mg/ml) were performed (the chromatograms were recorded at 
330 nm) and for quantification of the naringenin methoxylated derivatives, naringenin standard was 
used (C=0.226 mg/ml), with HPLC injection volumes in a range from 5 to 30 μl. Linear regression 
was performed to establish the calibration curves. The analyses were done in duplicates (RSD were 
 0.02). All data obtained by HPLC was inserted into a Spreadsheet (Microsoft® Office Excel 
2007
™
) and calculated by interpolation of the peak areas, with respect to the initial concentration 
and injection volume used.  
2.1.12 NMR analysis 
Final control analysis of purity and identification of the isolated compounds were performed with 
HPLC-DAD-ESI-MS and NMR. The 
1
H NMR spectra were recorded in CD3Cl and DMSO-d6 on a 
Bruker DRX-400 instrument at 295 K (Bruker AG, Ultrashield
™
 NMR Magnet System, 400Mhz/54 
nm, Fällanden, Zwitzerland). 
 
2.2 Transferrin conjugated liposomes: preparation and characterization 
2.2.1 Materials  
All the solvents used were HPLC grade from Merck (Darmstadt, Germany); 85% formic acid was 
provided by Carlo Erba (Milan, Italy). Water was purified by a Milli-Qplus system from Millipore 
(Milford, MA). Artemisinin (ART) was isolated as described in section 3.1. PEG 2000 (18:0/18:0) 
was purchased from Spectra2000 srl (Rome, Italy). Egg phosphatidylcholine (Phospholipon90G, 
P90G) was gently provided from Natterman Phospholipids, GmbH, Hermersberg, Rhineland-
Palatinate, Germany. Cholesterol was analytical grade from Aldrich (Milan, Italy). 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol) 2000] DSPE-PEG2000-COOH 
was purchased from Avanti Polar Lipids (Alabaster, AL). N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC), sulpho-N-hydroxysuccinimide (S-NHS), human holo-
transferrin, Sepharose CL-4B, bicinchoninic acid (BCA) kit for protein determination were from 
Sigma Aldrich (Seelze, Germany). 
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2.2.2 Liposomes preparation 
Multilamellar vesicles were prepared according to the film hydration method from Phospholipon® 
90 G, cholesterol and DSPE-PEG2000-COOH (6:3:0.6 molar ratio). Briefly, a mixture of 
phosphpolipid and cholesterol in CH2Cl2 was dried to a thin lipid film in a rotary evaporator (Büchi, 
Essen, Germany) and loaded with artemisinin (2 mg/ml). Lipids were re-suspended in an 
appropriate amount of 400 mM citrate/5 mM phosphate buffer (pH 4) resulting in a final lipid 
concentration of 10 mg lipid/ml corresponding buffer. After vortexing for 30 minutes at 38°C an 
extruder was used to reduce vesicle size from MLVs to LUVs and to increase size distribution 
homogeneity. Unilamellar liposomes were obtained by extruding the resulting multilamellar 
vescicles trough 400 nm, 200 nm and 100 nm polycarbonate membranes using a Liposofast Basic 
device (Avestin, Mannheim, Germany). 
2.2.3 Coupling of transferrin to the liposomes 
Small unilamellar liposomes obtained were conjugated to transferrin like previously described by 
Anabousi (Anabousi, 2005). The lipids were re-suspended in an appropriate amount of 
citrate/phosphate buffer. Then, 1 ml of PBS (pH 7.4) and 360 ml of both EDC (0.25 M in H2O) and 
S-NHS (0.25 M in H2O) were added per 10 mmol of lipid. The mixture was allowed to incubate for 
10 min at room temperature, before adjusting to pH 7.5 with 1 M of NaOH. 125 mg Tf/mmol of 
phospholipid was added and gently stirred for 8 h at 4ºC. Unbound protein was removed by passing 
the liposome suspension through a Sepharose CL-4B gel column (Ishida, 2001). 
2.2.4 Protein assay and Tf-binding efficacy  
The average amount of transferrin conjugated to the liposomes was quantified as described by 
Derycke et al. (Derycke, 2002). One hundred microlitres of liposome suspension were added to 400 
μl of methanol. The mixture was vortexed and centrifuged (10 s at 9000xg). Then, 200 μl of 
chloroform were added and the sample was vortexed and centrifuged again (10 s at 9000xg). For 
phase separation, 300 μl of water were added and the sample was vortexed again and centrifuged 
for 1 min at 9000xg. The upper phase was carefully removed and discarded. Three hundred 
microlitres of methanol were added to the chloroform phase and the interphase with the precipitated 
protein. The sample was mixed and centrifuged to pellet the protein (2 min at 9000xg). The 
supernatant was removed and the protein pellet was dried under a stream of air. The pellet was then 
dissolved in 20 μl of PBS (pH 7.4) and the concentration was determined with a bicinchonic acid 
(BCA) protein assay using albumin as standard protein. The coupling efficiency was calculated as 
μg Tf/μmol phospolipid.  
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2.2.5 Liposomes characterization   
Size and polydispersity index (P.I.) of liposomes were determined by dynamic light scattering 
(DLS).Vesicle formation and morphology of liposomes were observed by transmission electron 
microscopy (TEM) after negative staining with phosphotungstic acid 1% w/v. Free ART was 
removed by means of dialysis and encapsulation efficacy was evaluated by HPLC-DAD/ESI/MS by 
method described in section 2.1.9, using artemisinin as external standard. For determination of 
liposomes stability size, P.I. and encapsulation efficiency of prepared liposomes were monitored 
during their storage at 4ºC for twenty days. 
 
3. RESULTS AND DISCUSSION 
3.1 Polymethoxylated flavonoids and artemisinin isolation 
3.1.1 Liquid-liquid extraction 
In an attempt to separate the most abundant polymethoxylated flavonoids (PMFs) found in the 
A.annua acetone extract, the techniques of Sephadex LH-20, silica gel column chromatography and 
flash chromatography were applied. Row extract was suspended in MeOH (for final concentration 
of 100 mg/ml) and defatted with n-heptane. In order to isolate the PMFs, the extract was further 
partitioned with CH2Cl2 or EtOAc and H2O was added to enhance the partitioning and isolate more 
polar compounds. Analyses showed that the CH2Cl2 fraction had the highest content of 
polymethoxylated flavonoids and artemisinin so this method was selected as the best one. 
HPLC-DAD-ESI-MS analysis showed that minimal loss of PMFs occurred during this treatment 
(total experimental setup is visible in Figure 1). The result can be seen in Table 1, where a 
percentual comparison between raw extract and defatted extract is showed.  
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Figure 1: Flowchart of entire experiment. 
 
Compunds Total acetone 
extract 
Defatted acetone 
 extract 
 (mg/g) % (mg/g) % 
     
Eupatin 15.81±0.32 1.6 27.15±0.08 2.7±0.01 
Casticin/Chrysosplenetin 13.84±0.18 1.4 23.74±0.04 2.4 
Artemetin 0.74±0.02 0.01 1.20 0.1 
5-hydroxy-3,6,7,4’-tetramethoxyflavone 1.21±0.01 0.1 1.95±0.02 0.2 
     
Total flavonoids 31.14±0.061 3.1±0.01 54.04±0.23 5.4 
     
Table 1: Table of contents of A. annua extract. Yields of PMFs in the raw extract and defatted 
extract are reported. 
Annex I  
 
129 
 
Figure 2: HPLC-DAD chromatograms at 280 nm, with (A) total raw extract and (B) defatted total 
extract. Clearly visible is that the defatted extract is removed from more polar compounds, wich 
enhances separation and purification afterwar. (C) Standard compounds. 1: scopoletin, tr= 3.5 
min; 2: esperetin, tr= 6.05 min; 3: eupatin, tr= 6.1 min; 4: casticin/ chrysosplenetin, tr=10.1 min; 5: 
artemetin, tr= 17.3 min; 6: 5-hydroxy-3,6,7,4’-tetramethoxyflavone, tr: 21 min; 7: artemisinin (no 
uv absorption) tr =23.7.  
As reported in Figure 2 the defatted total extract, used for the different types of chromatography, 
showed the presence of different flavonoids: scopoletin, esperetin, eupatin, the isomers casticin and 
chrysosplenetin, artemetin and 5-hydroxy-3,6,7,4’-tetramethoxyflavone and artemisinin that was 
identified by HPLC-ESI-MS analysis because of the lack of UV absorption. Peaks characterization 
was carried out comparing results obtained by HPLC-DAD-ESI-MS with results of relative 
standards and with literature data.   
3.1.2 Investigated separation methods 
The first method (size exclusion chromatography) gave the poorest results, as, independently of 
the elution system, the main flavonoids were not separated an eluted together with other 
constituents, i.e. hydroxy coumarins, chlorogenic acid with its analogues. The compounds eluted in 
the following order: artemisinin, a non-identified flavonoid (later identified, when better separated 
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by flash chromatography) eluted with artemetin, scopoletin, casticin/chrysosplenetin, eupatin eluted 
all together. Therefore, an increased number of successive columns were needed in order to get 
better purities of the PMF’s, however the isomers casticin and chrysosplenetin always eluted 
together.  
Application of silica gel column chromatography increased the separation of PMFs, but was also 
unable to separate the isomers, even when combined with further silica gel or Sephadex LH-20 
column chromatographies of the fraction containing the pair of isomers. Preparation of the extract 
allow to obtain a sample suitable for both the silica gel column and the pre-column of the flash 
chromatography system. 25 g of the defatted extract was suspended in an excess of acetone and 
mixed with a minimum possible of silica gel powder (113.4g) in order to enhance the extract 
concentration in the mixture. Acetone was then evaporated leaving a homogeneus dark green 
sample powder.  
Flash chromatography showed to be the most efficient method among the three applied methods 
for the extract considered, due to the real-time detection (UV light optimum absorptions were set at 
280 and 350 nm) of the PMFs. It enables to better separate the fractions, including the isomers 
casticin and chrysosplenetin, which were the most problematic to separate especially with the others 
two open column chromatographic methods (Figure 3 and 4). The purity of the compounds of 
interest, obtained from the tested chromatographic methods were evidenced by monitoring the 
fractions with: TLC, HPLC-DAD-ESI-MS. 
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Figure 3:  Chromatograms at 280 nm of the isomers casticin and chrysosplenetin from A. annua L. 
acetone extract, obtained after fractionation using the three different chromatographic methods. 
 
Figure 4:  Chromatograms at 280 nm of eupatin from A. annua L. acetone extract, obtained after 
fractionation using the three different chromatographic methods. 
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3.1.3 Optimization of flash chromatography method 
After establishing that the chromatographic methods, such as size exclusion chromatography (SEC) 
and silica gel normal phase column chromatography were not adequate enough to separate the 
PMFs (Table 2) presents in the acetone extract of A. annua (in particular casticin /chrysosplenetin) 
further enhancement of the flash chromatography method was performed. 
Fine-tuning of the solvents gradient and flow rate was needed, until complete separation of the main 
PMFs (casticin, chrysosplenetin and eupatin) was achieved by adapting the mobile phase and the 
flow parameters with those used during the silica gel open column chromatography. For comparison 
purposes, the sample powder (previously prepared for both silica open column and flash 
chromatography) was loaded, however in minor quantity (4.4 g of sample powder containing 0.795 
g of extract) due to the capacity of the precolumn (up to 5 g, for dry samples only) available for the 
experiment.  
 
 
 
 
 
 
Table 2:  Chemical structures of main PMFs found in A. annua. 
  
 R1 R2 R3 R4 R5 R6 R7 R8 MW 
 Casticin -OCH3 -OCH3 -OH -OCH3 -OCH3 -OH -OCH3 -H 374 
 Artemetin -OCH3 -OCH3 -OH -OCH3 -OCH3 -OCH3 -OCH3 -OCH3 388 
 Chrysosplenetin -OCH3 -OCH3 -OH -OCH3 -OH -OCH3 -OCH3 -H 374 
 5-hydroxy-5,6,7,4’- 
tetramethoxyflavone 
-OCH3 -OCH3 -OCH3 -OCH3 -OH -OH -OCH3 -H 358 
 Eupatin -OCH3 -OCH3 -OH -OH -OCH3 -OH -OCH3 -H 360 
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3.1.4 Isolation by flash chromatogaphy method 
The fractions, containing the PMFs , collected automatically by the instrument, were analyzed by 
TLC and identified by HPLC-DAD-ESI-MS means, using standards when available. Flash 
chromatography method allowed the separation of six compounds (Figure 5), eluted in the 
following order: artemisinin (a sesquiterpene lactone), 5-hydroxy-3,4’,6,7-tetramethoxyflavone and 
artemetin (5-hydroxy-3,3’,4’,6,7-tetramethoxyflavone), found both in very small quantities, 
scopoletin (7-hydroxy-6-methoxycoumarin), which, in a small amount, eluted together with the 
flavonol chrysosplenetin (4’,5-dihydroxy-3,3’,6,7-tetramethoxyflavone), the isomer casticin (3’,5-
dihydroxy-3,4’,6,7-tetramethoxyflavone) and finally eupatin (3,3’,5-trihydroxy-4’,6,7-
trimethoxyflavone). The effective separation of chrysosplenetin and casticin, were confirmed by 
1
H 
NMR (Figure 6). The identification of the compound 5-hydroxy-3,4’,6,7-tetramethoxyflavone 
was possible by comparing the obtained results with literature data (Sy, 1998) : UV λmax= 336 and 
272 nm; ESI-MS: [M + H]
+
= 359 m/z (100%);  
1
H NMR (CDCl3) δ 3.88 (3H, s, 3-OCH3), δ 3.90 
(3H, s, 4’-OCH3), δ 3.93 (6H s, 6-OCH3), δ 3.97 (3H, s, 7-OCH3), δ 6.52 (1H, s, H-8), δ 7.05 [2H, 
d, (8Hz), H-3’ and H-5’], δ 8.09 [2H, d, (8 Hz), H-2’and H-6’]; δ 12.15 (1H, s, 5-OH). 
3.1.5 Cristallization and characterization of isolated compounds  
The main compounds isolated (artemisinin, chrysosplenetin, casticin and eupatin) were submitted to 
crystallization using different solvents according to their polarity, which were the following: EtOH 
for crystallizing artemisinin (acquiring a purity of 96% confirmed by ESI-MS using the artemisinin 
standard as external standard); EtOAc for crystallizing chrysosplenetin to obtain a purity of 
84,54% and the following spectral data: UV λmax: 257, 270 and 350 nm ; ESI-MS: [M + H]
+
= 375 
m/z (100%); 
1
H NMR (CDCl3) δ 3.87 (3H, s, 3-OCH3), δ 3.94 (3H, s, 6-OCH3), δ 3.98 (6H s, 7-
OCH3), δ 4.00 (3H, s, 3’-OCH3), δ 6.02 (1H, s, 4’-OH), δ 6.52 [1H, s, H-8], δ 7.07 [1H, d, (7.96 
Hz), H-5’], δ 7.68 [1H, dd (1.96 Hz e 8.3Hz), H-6’], δ 7.73 [1H, d, (1.72 Hz), H-2’]. These results 
were in accordance with literature data available for this compound (Sy, 1998). The same solvent 
(EtOAc) also used to crystallize casticin to obtain a purity of 85.42% and a spectral data of: UV 
λmax: 257, 270 and 350 nm; ESI-MS: [M + H]
+
= 375 m/z (100%); 
1
H NMR (CDCl3) δ 3.89 (3H, s, 
4’-OCH3), δ 3.95 (3H, s, 7-OCH3), δ 3.98 (6H s, 3-OCH3), δ 4.01 (3H, s, 6-OCH3), δ 5.71 (1H, s, 
3’-OH), δ 6.52 [1H, s, H-8], δ 6.99 [1H, d, (8.52 Hz), H-5’], δ 7.70 [1H, d (1.96 Hz), H-2’], δ 7.75 
[1H, dd, (2.4 e 8 Hz), H-6’]. These results were consistent with the previously published data for 
this compound  (Mesaik, 2009). MeOH was used for crystallizing eupatin, to resulting in a purity 
of 97.61% and the following spectral data was obtained: UV λmax: 258, 270 and 350 nm; ESI-MS: 
[M + H]
+
= 361 m/z (100%); 
1
H NMR (CDCl3) δ 3.80 (3H, s, 6-OCH3), δ 3.88 (3H, s, 7-OCH3), δ 
3.99 (6H s, 4’-OCH3), δ 6.80 (1H, s, 8-H), δ 7.01 [1H, d, (8.4 Hz), H-5’], δ 7.61 [1H, dd (2 e 8.42 
Hz), H-6’], δ 7.73 [1H, d, (2.4 Hz), H-2’], also in agreement with literature  data available for the 
compound (Sy, 1998). 
A 
Annex I  
 
134 
Figure 5: Chromatograms at 280 and 350 nm obtained by flash chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:
 1
H NMR spectra of casticin and chrysosplenetin compounds in CDCl3 (400 MHz).
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3.1.6 Comparison of separation methods 
Characteristics of the different isolation methods are reported on Table 3. The displayed results are 
percentual recoveries from the defatted extract. Although it seems that the differences in recovery 
are similar between the used chromatographic methods, the separation of the PMFs was most 
efficiently observed with the silica gel open column and flash chromatography. But, the separation 
of casticin and chrysosplenetin was possible only with the flash chromatographic method (Figure, 
7). 
 
 Sephadex LH-20 Silica gel Column Flash 
Chromatography 
Time High High Low 
Amount of Solvents Low High High 
Cost Low High High 
Recovery of 
Flavonoids (%) 
85.34
1 
75.02
1 
78.28
2 
Other compunds  Isolation of artemisinin Isolation of artemisinin 
and scopoletin 
(1) impossible isolation of isomers casticin and chrysosplenetin 
(2) possible isolation of  isomers casticin and chrysosplenetin 
Table 3: Comparison between different isolation methods. 
 
 
Figure 7: Chromatograms of the main polymethoxyflavonoids from A. annua L. acetone extract 
obtained from flash chromatography, after crystallization.  
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3.2 Transferrin conjugated liposomes for artemisinin delivery to cancer cells: preliminary 
results. 
The high specificity of endocytic uptake of transferrin (Tf) by the transferrin receptor (TfR) has 
made it a subject of interest for targeted drug delivery. TfR-targeted drug conjugates can be 
delivered across epithelial barriers or accumulated in proliferating tissues (Widera, 2003).   
Liposomes have been used as vehicles for drug delivery because of their biocompatibility and the 
possibility to incorporate both water-soluble and hydrophobic materials (Torchilin, 2000). They 
received much attention as carrier systems for advanced drug delivery in the context of anticancer 
therapy (Shimizu, 2003). In general, formation of ligand–liposome-complexes should be simple, 
fast, efficient, reproducible and yield stable, non-toxic bonds. The biological properties of the 
ligands (i.e. target recognition and binding efficiency) should not be substantially altered and the 
drug loading efficiency and drug release rates of the vesicle should not be negatively affected. 
Lastly, the ligand targeted liposomes should be stabile and their circulation half-lives should be 
long enough to allow them to reach and interact with the target cells.  
A particularly useful protein– liposome coupling procedure involves the covalent modification of 
functional groups of proteins using polyethylene glycol (PEG)-linked lipid residues (Bendas, 1997). 
A bond between free amino groups of the protein and carboxylic groups of the linker (DSPE-
PEG2000-COOH) is formed in the presence of a water-soluble carbodiimide (Figure 8). The method 
uses sulpho-N-hydroxysuccinimide (S-NHS) in addition to N-(3-dimethylaminopropyl)-N'- 
ethylcarbodiimide hydrochloride (EDC). S-NHS is a water-soluble analogue to NHS which is used 
to modify carboxyl groups to amine-reactive NHS-esters. This is accomplished by mixing the NHS 
with a carboxyl containing molecule and a dehydrating agent, EDC, which reacts with the carboxyl 
group first and forms an amine-reactive intermediate, an O-acylisourea.  
 
 
 
 
 
 
 
 
 
Figure 8: Coupling reaction of transferrin to the surface of liposomes using DSPE-PEG2000-COOH 
as linker lipid (Anabousi, 2005).
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3.2.1 Characterization of liposomes 
In the present study Tf-coupled liposomes for artemisinin delivery have been developed; the 
physicochemical characterization and drug-loading parameters of formulation are summarized in 
Table 4. A good value of transferrin coupling efficiency  (46,71 µg/µmol lipids) has been obtained. 
It can be seen from transmission electron microscopy (TEM) that liposomes were spherical and the 
size correlated well with the results of the laser diffraction particle size (Figure 9). 
Table 4: Size, polydispersity index (P.I.), and encapsulation efficiency of L-Tf: empty liposomes 
conjugated with transferrin and L-Tf-A: artemisinin loaded liposomes conjugated with transferrin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: TEM images revealing shape, structure, and sizes of transferrin conjugated liposomes 
loaded with artemisinin. 
 
3.2.2 Stability studies 
Chemical and physical stability were checked within 20 days (Figure 10); vescicles were stable with 
a leakage of drug of 20% after 15 days; we can observe at the same time slightly increasing in size 
and P.I. values. 
Formulation Mean size  
(nm) 
P.I EE 
 (%) 
L-Tf 175.9±1 0.35  - 
L-Tf-A 164.2±5 0.30 55 
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Figure 10: Chemical (A) and physical (B; C) stability of transferrin conjugated liposomes loaded 
with artemisinin at storage conditions (20 days, 4°C). 
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4. CONCLUSIONS 
This work reports the comparison of three separation methods: Sephadex LH-20, silica gel column 
chromatography and flash chromatography. Artemisia annua acetone extract was first pretreated, 
using liquid/liquid extraction and after the compounds of interest were separated with the previous 
mentioned methods. The latter one has been proven to be the most convenient method for the 
separation of polymethoxylated flavonoids. The results showed that artemisinin and the main 
polymethoxylated flavonoids were well separated with silica gel column and flash chromatography 
methods, however the pair of isomers chrysosplenetin and casticin was only separated by flash 
chromatography. Followed by a standard crystallization method, using EtOH for artemisinin, 
MeOH for eupatin and EtOAc for both casticin and chrysosplenetin, the isolated compounds were 
better purified (purities ranged between 85-98%).  
Flash chromatographic method resulted the most rapid and efficient way for separating 
polymethoxylated flavonoids and artemisinin. This method was a little bit more expensive than the 
other two chromatographic methods but it compensates drastically for time. Especially converted to 
industrial scale, when the applied solvents can be recycled, it promises to be an efficient 
methodology; price of Sephadex-LH 20 and time required for this method, makes it infeasible in 
this scale. In conclusion Artemisia annua is proven to be a valuable source of polymethoxylated 
flavonoids and artemisinin and flash chromatography demonstrated to be a rapid and reproducible 
technique for the isolation of these compounds, and could make them available for further purposes, 
such as anticancer activities.  
The second part of our work was focused on the development of a nanocarrier for artemisinin 
delivery to cancer cells to improve its activity and selectivity. Iron content is higher in tumor cells 
(Shterman, 1991) than in normal cells making them more susceptible to artemisinin derivatives. The 
susceptibility of tumor cells to artemisinins can further be enhanced by the addition of transferrin or 
ferrus iron (Moore, 1995; Efferth, 2004). Active targeting of therapeutic drugs associated with 
nanocarrier is achieved by conjugated a cell-specific ligand at the surface of the carrier, thereby 
allowing a preferential accumulation of the drug in the target cell or tissue. This approach may be 
succesfull when the receptor for surface-bound ligands are expressed uniquely in diseases cells or if 
their expression is differentially higher in disease cells as compared to normal ones. It is the case of 
our target TfR overexpressed in several tumoral tissues. Human Tf has been previously used for this 
purpose because of its ability to deliver liposomes into the intracellular compartment through 
receptor-mediated endocytosis (Fonseca, 2005). The formulation developed and loaded with 
isolated artemisinin has proper physical characteristics as drug carrier for parental administration in 
terms of particle size, polydispersity, encapsulation efficacy. Further investigation and optimization 
of this formulation would be best addressed through in vitro experimentation. 
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1. INTRODUCTION 
Leukemic diseases are a heterogeneous group of malignant diseases, some of which have a poor 
prognosis. Natural compounds are of considerable therapeutic interest for these tumors (Efferth, 
2002). The search for anticancer agents with improved pharmacological features continues to be an 
important aspect for the discovery and development of novel therapeutic strategies. The huge 
structural diversity of natural compounds derived from plants, marine flora and microorganisms can 
serve as “lead” compounds for semi-synthetic derivatization and improvement of their therapeutic 
potential (Gordaliza, 2007).  
As a starting point, the present study investigated the cytotoxic activity of 15 polyphenolic plant 
constituents belonging to different chemical classes, including flavonoids, phenylpropanoids, 
curcuminoids, catechins, and anthranoids. The rationale was to identify lead compounds with 
cytotoxic activity towards cancer cells. Polyphenols constitute one of the largest and ubiquitous 
groups of phytochemicals having a primary function to protect plants from photosynthetic stress, 
reactive oxygen species, and consumption by herbivores. Polyphenols are also present in large 
amounts in many vegetables and are thought to play a major role for health (Hounsome, 2008; 
Barnes, 2008; Gosh, 2009; McKay, 2011). Recently, a lower incidence of cancer in certain 
populations has been demonstrated to be related to the consumption of certain nutrients, and 
especially polyphenol-rich diets (Sporn, 2002). For this reason, there is an increasing interest using 
polyphenols as chemopreventive agents. This may be a promising approach aiming to reduce 
cancer-associated morbidity and mortality by delaying the process of carcinogenesis (Yang, 2001; 
Sing, 2009; Cui, 2009; Singh, 2010). 
Polyphenols exert their anticancer activity not only by quenching the generation of reactive oxygen 
species and thereby protecting critical cellular targets (i.e., DNA, proteins, lipids) from oxidative 
insult (Rafter, 2002; Potter, 1997; Roy, 2003). Their anticancer activity is also due to their 
interference with intracellular signaling pathways regulating proliferation, induction of apoptosis, 
and response to oxidative stress (Kong, 2001; Park, 2003; Loo, 2003; Heber, 2002). Among the 
investigated polyphenols, resveratrol has been shown to induce apoptotic cell death in HL60 human 
leukemia cells, but not in normal peripheral blood lymphocytes (Clement, 1998). Quercetin reduces 
cell proliferation, causes cell cycle arrest in the G0/G1 phase (Yoshida, 1992; Yoshida, 1990), the 
G2/M-phase (Koide, 1997; Choi, 2001) or the S-phase (Richter, 1999), and induces caspase-3 
activity and apoptosis (Ritcher, 1999; Liesveld, 2003; Wang, 1999). Curcumin has anti-tumor 
activity in a variety of cell lines from solid tumors and leukemia in vitro as well as in animal tumor 
models (Duvoix, 2005). Ellagic acid causes G0/G1phase arrest, inhibition of proliferation, and 
induction of apoptosis (Narayanan, 1999; 2001). Epigallocatechin gallate induces internucleosomal 
DNA fragmentation in human epidermoid carcinoma cells, human carcinoma keratinocytes, human 
prostate carcinoma cells, mouse lymphoma cells, but not in normal human epidermal keratinocytes 
(Ahmad, 1997). The antitumor activity of other pholyphenols such as verbascoside, hypericin, 
pseudohypericin, and the novel constituents kaempferol-3-O-(2’’,6’’-di-E-p-coumaroyl)-β-
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glucopyranoside or kaempferol-3-O-(3’’,4’’-diacetyl-2’’,6’’-di-E-p-coumaroyl)- β-glucopyranoside 
has not been investigated yet.  
The multiple effects of flavonoids on gene regulation, cell proliferation and apoptosis in leukemia 
cells have recently been reviewed (Strissel, 2005). Matsui et al. (Matsui, 2005) demonstrated that 
six individual flavonoids, flavone, luteolin, apigenin, genistein, quercetin and fistein induced 
apoptosis in leukemia and lymphoma cell lines in a dose-dependent manner by disruption of 
mitochondrial membranes and activation of caspase-3.  
Considering the growing interest in this field, a doxorubicin-sensitive acute T-lymphoblastic 
leukemia cell line (CCRF-CEM) and its multidrug-resistant subline (CEM/ADR5000) were used to 
evaluate the activity of 15 polyphenolic constituents derived from medicinal plant. Casticin was the 
most potent compound. To get insight into possible molecular modes of action, we performed 
microarray-based analyses to identify genes which are differentially regulated in treated cells 
compared to untreated controls.    
 
2. MATERIALS AND METHODS 
 
2.1 Plant Material 
Fructus of Vitex agnus-castus (Verbenaceae) provided by Pierre Fabre (Pierre Fabre Laboratories, 
Boulogne, France) was used for the preparation of extract and the isolation procedures.  
2.2 Polyphenols 
Curcumin, epigallocatechin-3-gallate, silymarin, were purchased from Extrasynthese (Genay, 
France). The following compounds were isolated from plants as previously described: hypericin and 
pseudohypericin were isolated from Hypericum perforatum L. (Karioti, 2009a), rosmarinic acid and 
salvianolic acid B were isolated from Salvia miltiorrhiza (Wang, 2009), bergenin from Ardisia 
crenata, kaempferol-3-O-(2’’,6’’-di-E-p-coumaroyl)-β-glucopyranoside, kaempferol-3-O-(3’’,4’’-
diacetyl-2’’,6’’-di-E-p-coumaroyl)-β-glucopyranoside, tiliroside and ellagic acid, were isolated 
from Quercus ilex (Karioti 2010; Karioti 2009b respect), oleuropein was isolated from Olea 
europaea (Karioti, 2006), verbascoside was isolated from Lippia alba (Timoteo, 2008), and casticin 
was isolated from the fruits of Vitex agnus castus L (Figure 1; Table1). 
In brief, fruits of Vitex agnus castus L. (2 kg) were partially grounded and defatted with petroleum 
ether and exhaustively extracted with dichloromethane. The crude dichloromethane extract was 
partitioned with cyclohexane and MeOH (1:1) and the polar fraction was subsequently purified over 
Sephadex LH-20 column alternating between lipophilic (cyclohexane:CH2Cl2:MeOH, 7:4:1) and 
polar solvent systems (MeOH:H2O, 90:10-70:30). The chemical structure of casticin was 
determined by combining the NMR and HPLC/DAD/MS data and by comparing its spectroscopic 
data with those reported in the literature (Han, 2007). Similarly, Ardisia crenata polar extract 
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containing bergenin (17%) and saponins was subjected to successive column chromatography over 
Sephadex LH-20 using polar mixtures of MeOH:H2O 50:50 to give pure bergenin (purity > 98, 
checked by NMR and HPLC-DAD-MS). 
2.3 Compound isolation and structure elucidation 
1
H NMR spectra was recorded in CD3OD on Bruker DRX-400 instrument at 295 K. Chemical shifts 
are given in parts per million (ppm) and were referenced to the solvent signals at 3.31 ppm for 
CD3OD. The HPLC analyses were performed using a HP 1100 Liquid Chromatograph (Agilent 
Technologies, PaloAlto, CA, USA) equipped with a HP 1040 diode-array detector (DAD), an 
automatic injector, an auto sampler and a column oven and managed by a HP 9000 workstation 
(Agilent Technologies, Palo Alto, CA, USA). The HPLC system was interfaced with a HP 1100 
MSD API electrospray (Agilent Technologies, Palo Alto, CA, USA). The interface geometry, with 
an orthogonal position of the nebulizer with respect to the capillary inlet, allowed the use of 
analytical conditions similar to those of HPLC-DAD analysis. Mass spectrometry operating 
conditions were optimized in order to achieve maximum sensitivity values: gas temperature 350ºC 
at a flow rate of 10 l/min, nebulizer pressure 30 psi, quadrupole temperature 30ºC, and capillary 
voltage 3500 V. Full scan spectra from m/z 100 to 800 in the positive-ion mode were obtained (scan 
time 1s). Separations were performed on a reversed phase column Purospher® Star RP-18, namely 
Hibar® Prepacked column RT (250×4.6 mm) with particle size 5 mm (Merck, Darmstadt, 
Germany). The eluents were A: water adjusted to pH 3.2 by formic acid; and B: acetonitrile. The 
mobile phase was isocratic using 50% A and 50% B for 15 min, following by gradient from 50% to 
100% B in 5 min, at a flow rate of 1 mL/min. The system was operated with oven temperature at 
26ºC; the injection volume was 20 µl. UV-VIS spectra between 210 and 350 nm, with a peak 
threshold of 0.1 mAu, were recorder; chromatograms were acquired at 280 nm for casticin. Column 
chromatography (CC) was carried out on a Sephadex LH-20 (Pharmacia). TLC: Merk silica gel 60 
F254 (Art. 5554). Detection: UV-light, spray reagent (vanillin-H2SO4 on silica gel). All the solvents 
used for the extraction and HPLC analysis (MeOH, cyclohexane, dichloromethane, and acetonitrile) 
were HPLC grade from Merck (Darmstadt, Germany); 85% formic acid was provided by Carlo 
Erba (Milan, Italy). Water was purified using a Milli-Qplus system (Milford, MA, USA). 
2.4 Cell lines 
A drug-sensitive acute T-lymphoblastic leukemia cell line (CCRF-CEM) and its multidrug resistant 
subline (CEM/ADR5000) were used in XTT assay to evaluate the activity of the compounds. 
Human CCRF-CEM leukemia cells were maintained in RPMI-1640 (Invitrogen) supplemented with 
10% FBS, antibiotics (1% of a 10,000 U/ml Penicillin G and 10 mg/ml Streptomycin), in a 
humidified 7% CO2 atmosphere at 37ºC. Cells were passaged twice weekly. All experiments were 
done with cells in the logarithmic growth phase. The establishment of drug-resistant subline has 
been previously described (Kimmig, 1990). Drug-resistant CEM-ADR5000 cells were maintained 
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in the absence of drug and resistance was stabilized by treatment for one day every week with 
doxorubicin (5000 ng/ml). CEM/ADR5000 cells specifically over-express P-
glycoprotein/MDR1/ABCB1, but none of the other resistance-related ATP-binding cassette (ABC) 
transporters (Efferth, 2003; Gillet, 2004). The cross-resistance profile of CEM/ADR5000 cells to 
established anti-cancer drugs and a panel of natural products has been previously published 
(Kimmig, 1990; Efferth, 2008).  
2.5 XTT Assay 
The cytotoxicity of compounds was determined by means of the Cell Proliferation Kit II (Roche 
Diagnostics, Mannheim, Germany). This test is based on the cleavage of the yellow 2,3-bis[2-
methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilideinner salt (XTT) by ubiquitous 
dehydrogenases leading to the formation of an orange formazan dye (Scudiero, 1988).  The amount 
of dye is commensurate to the number of metabolic active cells. Fresh stock solutions of each 
compound were prepared in DMSO or H2O at a concentration of 100 mM. A dilution series ranging 
from 10
-4 
M to 10
-9 
M was prepared using RPMI medium to perform the XTT test. Cells were 
diluted to a final concentration of 1×10
5
 cells/mL, and 100 µl of the cell suspension were sowed 
into the wells of a 96-well culture plate (Costar, Corning, USA). Marginal wells were filled with 
100 µl of pure medium, in order to minimize effects of evaporation. Besides, wells filled with 
medium were required to determine the background absorbance caused by non metabolized XTT. A 
row of wells containing cells was left untreated, and another row of wells containing cells was 
treated with 1 µl of DMSO or H2O. This served as solvent control. The other rows of wells 
containing cells were supplemented with different concentrations of compound. Each concentration 
was tested in at least two independent plates containing different batches of cells. After incubation 
for 72h with compounds at 37ºC, 5% CO2 in humidified atmosphere, XTT reagent was freshly 
prepared and added to each well as specified by the manufacturer: XTT-labeling reagent and 
electron-coupling reagent were mixed in a ratio of 50:1, and 50 µl of this mixture were added to 
each well of the 96-well plate. The plates were incubated for about 6 h at 37ºC, 5% CO2 in 
humidified atmosphere and read out after incubation. Quantification of cell cytotoxicity was 
performed in an ELISA plate reader (Bio-Rad, Munich, Germany) at 490 nm with a reference 
wavelength of 655 nm. Absorbance values at both wavelengths were subtracted. The cytotoxic 
effect of the treatment was determined as percentage of viability and compared to untreated cells 
(Konkimalla, 2010). The toxicity of compounds was determined by means of the formula: 
Cell viability (%) = (Absorbance of sample cells/Absorbance of untreated cells) × 100 
All in vitro experiments were carried out on two microplates with six parallel wells. All values are 
expressed as the mean ± SD of two independent experiments with each six-fold parallel 
measurements. 
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2.6 RNA isolation and analysis 
Total RNA was isolated using the RNeasy Kit (Qiagen, Hamburg, Germany) according to the 
manufacturer's instructions. The quality of total RNA was checked by gel analysis using the total 
RNA Nano chip assay on an Agilent 2100 Bioanalyzer (Agilent Technologies GmbH, Berlin, 
Germany). Only samples with RNA index values greater than 8.5 were selected for expression 
profiling. RNA concentrations were determined using the NanoDrop spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). 
2.7 Probe labeling and Illumina Sentrix Bead Chip Array Hybridization 
Biotin-labeled cRNA samples for hybridization on Illumina Human Sentrix-8 BeadChip arrays 
(Illumina, Inc.) were prepared according to Illumina's recommended sample labeling procedure 
based on the modified Eberwine protocol (Eberwine, 1992). In brief, 250 ng total RNA was used 
for complementary DNA (cDNA) synthesis, followed by an amplification/labeling step (in vitro 
transcription) to synthesize biotin-labeled cRNA according to the MessageAmp II aRNA 
Amplification kit (Ambion, Inc., Austin, TX). Biotin-16-UTP was purchased from Roche Applied 
Science, Penzberg, Germany. The cRNA was column purified according to TotalPrep RNA 
Amplification Kit, and eluted in 60 µl of water. Quality of cRNA was controlled using the RNA 
Nano Chip Assay on an Agilent 2100 Bioanalyzer and spectrophotometrically quantified 
(NanoDrop).  
Hybridization with containing 19.730 genes per microarray was performed as previously described 
(Kimmig, 1990). 
2.8 Scanning and data analysis 
Microarray scanning was performed using a Beadstation array scanner, and the setting was adjusted 
to a scaling factor of 1 and PMT settings at 430. Data extraction was individually done for all beads, 
and outliers were removed, if median absolute deviations (MAD) were above 2.5. All remaining 
data points were used for calculation of the mean average signal of a sample. Standard deviations 
were calculated of all samples. 
Data analysis was done by normalization of signals using the quantile normalization algorithm 
without background subtraction. Differentially regulated genes were defined by calculating the 
standard deviation differences of a given sample in one-by-one comparisons of samples or groups. 
Genes were further filtered using Chipster software (http://chipster.csc.fi/) by discarding genes with 
a P-value lower than 0.05 and having a differential expression above one time of standard deviaton. 
The final set of filtered genes was analyzed using Ingenuity Pathway Analysis 
(http://www.ingenuity.com/) to identify affected networks of genes and pathways.  
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Figure 1: Chemical structures of the compounds investigated 
 
 
3. RESULTS 
 
3.1 Isolation of polyphenols 
All polyphenols used in the present investigation were from commercial sources or isolated in our 
laboratory during previous projects (see Material and Methods) (Table 1). Casticin was isolated for 
the first time in the course of the present study. The presence of casticin was evidenced by 
monitoring of the fractions by thin layer chromatography. The casticin fraction was analyzed by 
NMR spectroscopy (
1
H NMR) and HPLC-DAD-ESI-MS analyses (Figure 2A and 2B) and data 
were compared with those reported in the literature (Han, 2007). HPLC analyses indicated that 
casticin has a purity of 97% based on the peak area percent (Figures 2C).  
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Figure 2A: 
1
H NMR spectra of casticin isolated from Vitex agnus castus. 
 
Figure 2B: HPLC-ESI-MS and 2C: HPLC-DAD chromatograms of casticin isolated from Vitex 
agnus castus. 
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MW 
 
Purity 
 
Medicinal plant of 
origin 
Commercial Compounds    
Curcumin 368 ≥ 98% Curcuma longa 
Epigallocatechin-3-gallate 458 ≥ 98% Camellia sinensis 
Silybin (Silymarin) 482 _ Silybum marianum 
Compounds isolated in house    
Bergenin 328 ≥ 98% Ardisia crenata 
Casticin 374 ≥ 98% Vitex agnus castus 
Ellagic acid 302 ≥ 98% Quercus ilex 
Hypericin 504 ≥ 98% Hypericum 
perforatum 
Kaempferol-3-O-(2’’,6’’-di-E-p-coumaroyl)-
glucopyranoside 
740 ≥ 98% Quercus ilex 
Kaempferol-3-O-(3,4-diacetyl-2,6-di-E-p-coumaroyl)-
glucopyranoside 
824 ≥ 98% Quercus ilex 
Oleuropein 540 ≥ 98% Olea europaea 
Pseudo-hypericin 522 ≥ 98% Hypericum 
perforatum 
Rosmarinic acid 360 ≥ 98% Salvia miltiorrhiza 
Salvianolic acid B 718 ≥ 98% Salvia miltiorrhiza 
Tiliroside 594 ≥ 98% Quercus ilex 
Verbascoside 624 ≥ 98% Lippia alba 
 
Table 1: Phytochemical compounds and their plant origins. 
 
3.2 Cytotoxicity of phytochemicals toward sensitive and multidrug-resistant leukemia cells 
The cytotoxicity of casticin has been determined towards wild-type CCRF-CEM leukemia cells and 
a multidrug-resistant subline thereof, CEM/ADR5000. For comparison, 14 other phytochemicals 
have been tested in these two cell lines. The IC50 values calculated from dose response curves are 
shown in Table 2. The phytochemicals most active towards CCRF-CEM cells were casticin, 
hypericin, and kaempferol-3-O-(3’’,4’’-diacetyl-2’’,6’’-di-E-pcoumaroyl)-glucopyranoside. These 
compounds were tested in a multidrug-resistant subline of CCRF CEM, CEM/ADR5000. Of them, 
casticin had the lowest IC50 value for both cell lines. CEM/ADR5000 exhibited a low degree of 
cross-resistance towards casticin (1.57-fold). No or only weak cross-resistance was observed 
towards pseudo-hypericin, hypericin, oleuropein, verbascoside and kaempferol-3-O-(3’’,4’’-
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diacetyl-2’’,6’’-di-E-p-coumaroyl)-β glucopyranoside (0.84-to 1.95-fold). CEM/ADR5000 
exhibited a higher degree of cross-resistance towards curcumin (16.98-fold).  
 
Compound CCRF-CEM 
(IC50) 
CEM-ADR5000 
(IC50) 
Relative 
resistance*
 
Bergenin Inactive Inactive - 
Casticin 0.28±0.02 μM 0.44±0.17 μM 1.57 
Curcumin 3.74±2.26 μM 63.50 μM 16.98 
Ellagic acid 164.10±30.69 μM Inactive - 
Epigallocatechin-3-gallate 16.04±1.56 μM Inactive - 
Hypericin 1.52±0.23 μM 1.34±0.11 μM 0.88 
Kaempferol-3-O-(2’’,6’’-di-E-p-coumaroyl)-
glucopyranoside 
57.43±22.75 μM 111.92±19.49 μM 1.95 
Kaempferol-3-O-(3,4-diacetyl-2,6-di-E-p-
coumaroyl)-glucopyranoside 
2.15±0.37 μM Inactive - 
Oleuropein 66.14±15.75 μM 70.05±1.30 μM 1.06 
Pseudo-hypericin 12.14±5.10 μM 11.99±4.8 μM 0.99 
Rosmarinic acid 80.95±15.97 μM Inactive - 
Salvianolic acid B Inactive Inactive - 
Silymarin 68.12±16.33 μM Inactive - 
Tiliroside Inactive Inactive - 
Verbascoside 97.27±3.65 μM 81.90±23.84 μM 0.84 
    
Table 2: 50% inhibition concentration (IC50) values (expressed as the mean±SD of two independent 
experiments each with six-fold determination) and relative resistance to natural compounds in 
CCRF-CEM cells and multidrug-resistant CEM/ADR5000 cells as determined by the XTT test. The 
IC50 values were calculated from dose-response curves using GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA). *Relative resistance was calculated by dividing the IC50 of CCRF-
CEM cells by the IC50 of CEM/ADR5000 cells. 
 
3.3 Differential gene expression in casticin-treated and untreated cells 
The effect of casticin treatment on gene expression was determined by microarray-based mRNA 
hybridization. CCRF-CEM cells were treated with the IC50 dose of casticin (0.28 µM) for 24 or 72h 
or left untreated.  
A total of 186 genes were up-regulated and 302 genes were down-regulated upon treatment for 24 h 
compared to untreated cells. After 72h treatment, 219 genes were up- and 72 genes down-regulated. 
In order to further analyze the molecular modes of action of casticin, we performed a signaling 
pathway analysis by means of the Ingenuity Pathway Analysis software. The most prominent 
functional groups of genes differentially regulated upon casticin treatment for 24 h (p<0.05) were 
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those involved in drug metabolism, lipid metabolism, small molecule biochemistry, and cell cycle 
(Figure 3A). Treatment of CCRF-CEM cells for 72 h affected genes involved in cell cycle, cellular 
assembly and organization, DNA replication and repair as well as cell death (Figure 3B). As a next 
step, we asked whether these genes from diverse functional classes act independently or whether 
they act together beyond the constraints of "canonical" pathways in a concerted manner after 
casticin challenge. For this reason, we built dynamic network analyses using the differentially 
regulated genes. As shown in Figure 4, specific pathways of interacting genes appeared after 
casticin treatment. A specific molecular network with a connection to cell death and cellular growth 
and proliferation was determined in CCRF-CEM cells treated for 24 h with casticin (Figure 4A). A 
comparable molecular network related to cellular growth and proliferation was identified in CCRF-
CEM cells after 72 h treatment with casticin (Figure 4B). Interestingly, both networks were related 
to the same cellular regulators, i.e., NFKB, p38MAPK, histones H3 or H4, and FSH, indicating 
importing functions for the activity of casticin in CCRF-CEM cells.  
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Figure 3: mRNA-based microarray analyses of CCRF-CEM cells treated with casticin. Microarray 
hybridizations were performed using Illumina Sentrix BeadChip arrays (see Material and 
Methods). Identification of functional groups of genes regulated upon casticin treatment for 24 h 
(A) and 72 h (B) in CEM-CCRF cells. Gene expressions of cells treated with 50% inhibition 
concentration of casticin were compared to those in untreated cells. The evaluation of differentially 
expressed genes was performed using the Ingenuity Pathway Analysis software, version 5.5.
Annex II  
 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Signaling network of CCRF-CEM leukemia cells treated with casticin (50% inhibition 
concentration) for 24 h (A) or 72 h (B). 
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4. DISCUSSION 
In the present study, casticin was the most cytotoxic polyphenol towards CCRF-CEM leukemia 
cells among a group of 15 polyphenols. Casticin is an unusual polymethoxy-flavonoid bearing a 
methoxyl moiety at C-3 of the C-ring, which is an essential structure activity requirement of 
flavones for cytotoxicity (Beutler, 1998). The presence of this methoxyl group at C-3 may explain 
why casticin was more cytotoxic than the other polyphenols investigated by us. 
Polymethoxyflavones, bearing two or more methoxy groups on their basic benzo-γ-pyrone skeleton 
with a carbonyl group at the C4 position, are found in a limited number of plant families. 
Polymethoxyflavones structurally related to casticin display chemoprotective effects by inhibiting 
cancer cell growth, induction of apoptosis, and blocking metastasis (Li, 2009). The rate of 
methylation of polyphenols in chemoprevention is not fully understood. The enhanced permeability 
of cellular membranes to polymethoxyflavones due to their lipophilic nature may lead to enhanced 
cellular absorption and bioactivity. In addition, methylation may increase the oral bioavailability of 
these compounds. In the past, polymethoxyflavones raised only modest interest for 
chemoprevention because of their lack of antioxidant properties, which was suggested as a main 
mechanism of action. However, recent findings point to signal transduction pathways as being the 
main targets for flavonoids (Williams, 2004).  
Polyphenols may modulate various targets either by direct interaction or by modulation of gene 
expression. To gain insight into the molecular networks and pathways related to the cytotoxicity of 
casticin towards cancer cells, we performed mRNA-based microarray analysis. Upon treatment of 
CCRF-CEM cells with casticin, several genes that form a network related to the transcription factor 
NF-κB were differentially expressed. Hence, casticin may act in part by affecting NF-κB signaling. 
Casticin has been described to inhibit NF-κB and many other flavonoids are also well known NF-
κB inhibitors (Nam, 2006; Gillet, 2004). NFκB plays a major role in regulating immune response, 
cell proliferation, and apoptosis. Seven related proteins (NF-κB1 and NF-κB2, each with two 
alternatively spliced forms, and REL-A, REL-B and c-REL) can form dimers, which are able to 
bind specific DNA motifs in the promoters of target genes (Nam, 2006; Gilmore, 2006; Brasier, 
2006). These heterodimers can activate the transcription of about 200 target genes (Perkins, 2007). 
Inactive NF-κB1 or NF-κB2 proteins are complexed with IκBα (inhibitory κB) proteins in the 
cytosol. Phosphorylation of IκBα by IκBα kinase (IKK) leads to IκB degradation and translocation 
of NF-κB1 and NF-κB2 into the nucleus. Casticin demonstrated anti-inflammatory effects in vivo 
(Kobayakawa, 2004) confirming the use of plants from the genus Vitex for the treatment of 
inflammation in European, Asian and Chinese traditional medicines. In addition, casticin inhibited 
leukemia and breast cancer growth in vitro (Wang, 2005; Haidara, 2006). The results of our 
microarray analysis testify to NF κB as being involved in the underlying mechanism of casticin 
against cancer cells. 
p38MAPK is another protein in the network affected by casticin treatment of CCRF-CEM cells. 
MAPKs form signaling cascades regulating important cellular functions such as cell growth, 
differentiation and apoptosis (Vakifahmetoglu, 2008 ;Pearson, 2001). They are activated by stress 
Annex II  
 
159 
stimuli including cancer therapy (Vega, 2004). No effect on p38MAPK signaling by casticin has yet 
been described, but p38MAPK inhibition is known for other polyphenols (Choi, 2008; Li, 2009; 
Adhikary, 2010; Ho, 2010). p38MAPK is known to act upstream of NF-κB and to activate NF-κB 
(Itatsu, 2009) indicating that the effect of casticin on both these signaling molecules may contribute 
to its cytotoxic properties. Interestingly, another polyphenol, furosin, has been reported to suppress 
RANKL-induced osteoclast differentiation and function through inhibition of MAPK activation 
(Park, 2004). Together with our results concerning casticin, this may speak for a more general role 
of polyphenols affecting RANKL, NF-κB, and MAPK signaling pathways.  
Casticin treatment led to differential expression of a network of genes with different functions, 
including histones. Histones are constituents of nuclear chromatin and organize DNA condensation 
during meiotic and mitotic chromosome formation. The histones H3 and H4, which appeared in our 
casticin-specific genetic network are core histones whose epigenetic modifications (e.g. 
methylation, acetylation, phosphorylation SUMOylation, and ubiquitinylation) play a role in gene 
regulation (Rosenfeld, 2009). While casticin is not yet known to affect histones, the role of 
flavonoids in chromatin remodeling during inflammatory processes is well described (Rahman, 
2006; Gilbert, 2010; Rahman, 2010). Epigenetic modification by flavonoids may represent an 
attractive novel treatment strategy for cancer, and as such deserves further exploration.  
In our microarray-based network, another set of genes centered on FSH. In both females and males, 
FSH regulates the maturation of germ cells, and the development, growth and pubertal maturation 
of the organism (Dickerson, 2008). Interestingly, endothelia of tumor blood vessels frequently 
reveal elevated FSH receptor levels, and FSH seems to contribute to neoangiogenesis in tumors by 
vascular endothelial growth factor-dependent and independent pathways (Radu, 2010). Hence, 
inhibition of FSH signaling may represent a strategy for antiangiogenic cancer therapy. Our finding 
that casticin affected FSH-associated genes in the signaling network may be taken as a hint that 
casticin might inhibit tumor angiogenesis. This speculation merits further analysis.  
In conclusion, the cytotoxicity of casticin towards sensitive and multidrug-resistant leukemia cells 
was associated with multiple effects on different signal transduction pathways. A general feature of 
natural products is their ability to act on multiple targets and pathways rather than one single target 
(Efferth, 2011). This plays a major role in preventing the development of resistance, which has been 
an important selection advantage during the evolution of life. In the case of casticin, this feature 
might be explained in future therapy of cancers. 
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